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ABSTRACT 
Synthetic steroids have potential application in pharmacology. These 
steroids possess antitubercular, antitumour, anti-inflammatory, 
antineoplastic, immunosuppressive and antimicrobial activities. In the 
present study six synthetic steroidal hormones were taken to evaluate 
their cytogenetic effects on human lymphocyte chromosomes in vitro. 
All the synthetic steroids used in the present study were sex hormones 
two each from estrogens, progestins and androgens. 
The sex hormones are used widely in human medicine for a large 
variety of conditions, apart from their uses as oral contraceptive agents. 
They are used in the treatment of dysmenorrhoea, endometriosis, 
dysfunctional uterine bleeding, as replacement therapy in patients with 
various hormonal disbalances, in gonadal dysgenesis and in women with 
symptoms of climacteric. They are also used in the prevention of 
postmenopausal osteoporosis and in the treatment of advanced breast 
and endometrial carcinoma. In obstetric practice progestins are used in 
the management of threatened abortion and to prevent premature labour. 
And local estrogens are used successfully to 'prime' the unripe cervix 
to induction of labour. Estrogens are also used to develop secondary 
female sex characteristics in trans-sexual males and androgens to 
suppress these characteristics in trans-sexual females. Androgens are 
used in the treatment of male hypogonadism, in the treatment of 
symptoms of climacteric and in advanced mammary tumours in women. 
Certain synthetic androgens are also used to induce ovulation in 
anovulatory women and also in oligospermic males. The use of androgens 
to improve athletic performance is well known. Apart from the above 
described applications, these synthetic steroids are used in large number of 
other conditions. 
Cytogenetic studies were carried out to evaluate the genotoxic effects 
of these synthetic steroids on human system. The genotoxic effects of 
steroids cannot be assessed on bacterial system because specific receptor 
molecules needed by tiie steroids to perform their action are absent in 
bacteria. Therefore, cytogenetic tests are more appropriate parameters for 
evaluating the genotoxic effects of steroids. Human peripheral blood 
lymphocytes were used for this purpose because of the ease of obtaining 
blood samples, in contrast to other human cell populations (e.g. bone marrow 
cells), and because these cells are extremely sensitive indicators of the in 
vivo and in vitro induced chromosomal changes (structural and numerical). 
It is a single system that provides us with a large number of dividing cells. 
These are easily cultured to yield large number of mitotic figures for 
chromosome analysis. 
The parameters used in the present study included chromosomal 
aberrations, sister chromatid exchange analysis and cell growth kinetics assay 
in the absence as well as in the presence of exogenous metabolic activation 
system (S^ mix). The students't' test (paired) was applied for chromosomal 
aberrations and sister chromatid exchanges. The 2x3 chi-square test was used 
for cell growth kinetics studies. The level of significance was compared at 
P<0.05 for all parameters. Lymphocytes were exposed to all drugs for three 
different durations (i.e. 24, 48 and 72 h.) and for three different dose 
concentrations. The synthetic steroids were used with a view to study the 
following objectives: 
(1) To study the in vitro effects of the steroids on human lymphocyte 
culturing system. 
(2) To study the toxic effects of the steroids on human lymphocyte 
chromosomes. 
(3) Evaluation of the chromosome damage in parallel in the presence 
of metabolic activation (S^ mix). 
(4) To study the effects of the steroids on the frequency of sister 
chromatid exchange (SCE). 
(5) To find the frequency of SCEs when compared in the presence of 
Sg mix, and finally, 
(6) To study the effects of the steroids on cell growth kinetics in the 
presence as well as in the absence of S^  mix. 
Out of the six synthetic steroids studied, three were found to have 
harmful effects on human peripheral lymphocyte chromosomes. Both 
the estrogens i.e. mestranol and quinestrol were found to be genotoxic. 
Among progestins, norgestrel was found to be genotoxic whereas, 
norethindrone was not having any harmful effect on the chromosomes. 
Both the androgens i.e. danazol and oxymetholone also did not show any 
harmful effect on the chromosomes. 
Mestranol was found to be associated with increase in the incidence 
of chromosomal aberration. At 10 ng/ml dose concentration the drug 
did not show any significant result, but at 25 jig/ml concentration highly 
significant increase in chromosomal aberration was noted at all exposure 
durations (i.e. 18.00%, 22.00% and 27.00% respectively at 24, 48 and 
72 h of incubations). At the highest dose of concentration i.e. 50 |ig/ml, 
an interesting result was obtained. A steep decline in chromosomal 
aberrations and aberrant metaphases were observed. This can be attributed 
to the toxic effect of the drug on the mitotic index at this concentration. 
In the presence of metabolic activation the drug induced significant level 
of chromosomal aberration at 25 i^g/ml concentration only (i.e. 29.50%). 
Similar trend was noted for this drug in the sister chromatid exchange 
analysis in the absence as well as in the presence of metabolic activation 
i.e. highly significant increase in sister chromatid exchange frequency 
occurred in both cases at 25 [ig/ml of dose concentration only (5.04 ± 
0.224 and 5.38±0.180 respectively). The result of cell growth kinetics 
study was again similar for mestranol. The replication indices were found 
significant only at 25 jig/ml of dose concentration in the absence as 
well as in the presence of metabolic activation (1.43 and 1.46 
respectively). 
Another estrogen quinestrol was also found to be genotoxic. 
Quinestrol did not increase chromosomal aberration frequency at 10 
)ig/ml of dose concentration. But at 25 ng/ml concentration the drug 
was found to increase aberrant metaphases as well as chromosomal 
aberration frequency at all treatment durations (i.e. 18.66%, 22.67% 
and 39.66% respectively at 24, 48 and 72 h). At 50 i^g/ml concentration 
the aberration frequency first increased i.e. at 24 h duration (33.67%) 
but decreased later on with the increase in exposure duration (6.00% 
and 4.33% respectively at 48 and 72). This interesting result may be 
attributed to cell death at the highest concentration and for longer 
exposure duration. In the presence of metabolic activation experiment, 
a dose time relationship was observed and the aberration frequency 
increased with increase in dose concentration. All the values obtained 
were significant. Quinestrol increased the SCE frequency, significantly 
both in the absence as well as in the presence of metabolic activation, 
only at 25 and 50 (ig/ml of dose concentration. A dose time relationship 
was observed and maximum value of SCE frequency was observed at 50 
|ag/ml concentration in both cases (4.28±0.090 and 4.68±0.100 
respectively). Cell growth kinetics study for quinestrol also reveals a 
similar trend. The replication indices at 25 and 50 i^ g/ml concentration 
were found significant both in the absence (1.46 and 1.40 respectively) 
as well as in the presence (1.46 and 1.43 respectively) of metabolic 
activation. 
Norethindrone, a progestin, was not found to cause harmful effects 
on human lymphocyte chromosomes. The drug did not induce significant 
level of chromosomal aberration in human lymphocytes at any dose 
concentration (20, 40 and 75 fxg/ml) and any treatment duration in the 
absence as well as in the presence of metabolic activation system. 
Another progestin, norgestrel, was found to be effective in 
increasing chromosomal aberration frequency as well as aberrant 
metaphases. A dose time relationship was observed. The drug was not 
effective at 10 ng/ml concentration at any treatment duration. At 25 and 
50 fig/ml of dose concentration the drug enhanced significant level of 
chromosomal aberration frequency at all durations. The values obtained 
were 19.00%, 26.33% and 50.33% respectively at 25 ^g/ml of 
concentration, and 22.00%, 28.00% and 54.66% respectively at 50 |ig/ml 
of concentration. In the presence of metabolic activation the values 
obtained for this drug were significantly high at all concentrations 
(9.50%, 22.50% and 41.00% respectively). Norgestrel enhanced SCE 
frequency significantly both in the absence as well as in the presence of 
S, mix at 25 and 50 )ig/ml of concentrations only. The value observed in 
the absence of S^  mix were 2.98±0.104 and 4.44±0.086 respectively. In 
the presence of S^  mix the values were 3.34±0.120 and 5.22±0.136 
respectively. Similar results were observed for cell growth kinetics study 
also . Signiflcant values were obtained at 25 and 50 ng/ml of dose 
concentration only. Replication indices observed were 1.52 and 1.47 
respectively in the absence of S^  mix. In the presence of S^  mix the 
replication indices were 1.44 and 1.46 respectively. 
Both the synthetic androgens, i.e. danazol and oxymetholone, 
evaluated for their cytogenetic effects in the present study were found 
to be non-genotoxic. The drugs neither induce significant level of 
chromosomal aberrations, aberrant metaphases and sister chromatid 
exchanges nor they affect the mitotic index, either in the absence or in 
the presence of metabolic activation system. 
The overall conclusion that emerges from the results of present 
investigation reveals that both the estrogens (i.e. mestranol and 
quinestrol) and one progestin (i.e. norgestrel) seem to be potent 
mutagens and they are well associated with clastogenic effects in the 
presence as well as in the absence of metabolic activation system. 
Various structural and numerical chromosomal changes were observed 
when the lymphocytes were treated with estrogens and the progestin 
'norgestrel'. It was concluded that the use of synthetic steroidal drugs 
particularly those drugs which are used as oral contraceptives is 
associated with a significant increase in the incidence of chromosome 
abnormalities per cell, besides an increase in the number of abnormal 
cells, and gene mutation which is exhibited as SCE. It is established that 
there is an apparent relationship of chromosome abnormalities, sister 
chromatid exchanges and cell proliferation inhibiting effect with 
mutagenesis, carcinogenesis and teratogenesis. 
The phenotypic expression of genetic damage in the drug user, either 
as visible chromosomal aberrations or the point mutations, is dependent 
on the developmental time when the damage occurs (i.e. pre- or post-
natal life) and the type of cell in which the damage occurs (i.e. somatic 
or germinal). Such damage in somatic cells of the developing embryo 
can lead to malformations and abortions in extreme cases. Any mutational 
effect on adult somatic cells could lead to cancer, and genetic damage 
in germ cells of the person taking these drugs would only be manifested 
in his or her offspring leading to teratogenesis or carcinogenesis. 
It is suggested that such type of genetic damage might have occurred 
due to the ability of these steroids to generate free oxygen radicals in 
the lymphocytes. 
It is, therefore, advisable to be careful of the potential hazards of 
these drugs to which we are continuously exposed day in and day out in 
modern life. This demands the lowest possible use of effective and 
acceptable doses of these drugs so as to minimize any potential risk. 
Otherwise, they may become capable of attacking the genetic material 
directly in their unmetabolized or the metabolized state. 
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INTRODUCTION 
In many ways chemicals are a basic factor in the well-being and 
effective functioning of the present day societies. The quality of life at 
both the social and individual levels would be severely restricted if we 
had to live without petroleum products, plastics, synthetic drugs, 
synthetic textiles and man-made mineral fibres or without the synthetic 
materials needed to produce modern electronic devices. 
As in the case of drugs, the use of other chemicals implies not 
only the desired benefits but also adverse effects. We are compelled to 
compromise between costs and benefits. When the desired and the 
adverse effects of the use of chemicals are weighed, it is pertinent to 
ask whether we really need all the two thousand new chemicals 
synthesized annually and whether all the 60,000 to 70,000 chemicals 
used daily in industrialized societies are truly essential? It is wondering 
how long our ecosystem can survive and how long the biosystem, man 
included, can tolerate the doubling of the consumption of chemicals that 
occurs every seven years (IARC, 1984). 
In fact, humanity is faced today with growing problems of 
'chemicalization', and questions of weighing risks and benefits have 
become more and more relevant. This is because all societies have 
become increasingly dependent on chemicals. Severe and system-wide 
damage to the ecosystem has been recognized, such as damage due to 
acid rain, the pollution of soil and water and increasing rates of certain 
types of cancer and allergies. 
Appropriate toxicity testing has been done only for about 10% of 
the chemicals used daily and in the work environment only 1% of the 
chemicals used daily have exposure limits. And these are the chemical 
carcinogens which are most long-acting chemicals to which human 
population will be exposed for longtime in the future (lARC 1984). 
The extent to which human somatic and germinal mutation 
frequencies may be increased by exposure to ionizing radiation and to 
the variety of chemicals that characterize modem societies has been a 
matter of concern in recent years. Somatic mutations, either genetic or 
chromosomal, are not transmitted to the offspring of an exposed 
individual. However, increase in the frequency of these mutations may 
contribute to an increase in the frequency of acquired disorders, for 
example, cancer. Increase in the frequency of germinal mutations, genetic 
or chromosomal, are likely to contribute to inherited defects in the 
offspring of individuals exposed to mutagenic agents (WHO 1985). 
The history of chemical mutagenesis goes back to 1962. The first 
chemical mutagen discovered was mustard gas or sulfur mustard [D-
(2chloroethyl) sulfide], when C.Auerbach and her associates first 
discovered the mutagenic effects of mustard gas and related compounds 
used during world war II. Hundreds of chemicals are now known to have 
from slight to very large mutagenic effects. 
Increasing evidence indicates that most neoplastic conditions arise 
from interaction between external factors and a predisposing genotypic/ 
phenotypic susceptibility, that may be attributed to, e.g., increased 
susceptibility of target cells to transformation, inability to repair certain 
kinds of DNA damage or reduced capacity to destroy malignant cells. 
Much progress has been made in our understanding of the relationship 
to cancer development of such predisposing host factors and 
environmental carcinogens. However, one basic mechanism that remains 
to be elucidated is the role played by chromosomal aberrations in the 
causation and/or evolution of neoplasia, especially the influence of 
external factors on the karyotypic pattern of tumour cells. 
MECHANISM OF ACTION OF THE CARCINOGENIC/ 
MUTAGENIC CHEMICAL AGENTS: 
Chemical mutagens are divided into two classes: 
(1) The first class comprises those mutagens which are mutagenic to 
both replicating and non-replicating DNA. For example, nitrous acid and 
alkylating agents (a large class of chemical mutagens that transfer alkyl 
groups i.e. CH3-.CH3 CH^-, etc. to the bases in DNA). 
(2) The another class contains those mutagens which are mutagenic 
only to replicating DNA. For example, includes the acridine dyes, which 
bind to DNA and increase the probability of mistakes during replication. 
And base analogs which are purines and pyrimidines with structures 
similar to the normal bases of DNA. The base analogs must be 
incorporated into DNA chains in the place of normal bases during 
replication to exert their mutagenic effects. 
Mechanism of action of different well known highly potent 
mutagens are as follows : 
1. Base Analo£s : The base analogs are mutagens which have 
structures sufficiently similar to the normal bases so that they are 
metabolized and incorporated into DNA during replication, but 
sufficiently different such that they increase the frequency of mispairing 
of bases and thus mutation. Examples are 5-bromouracil and 2-
aminopurine. 
(a) 5-bromouracil: The pyrimidine 5-bromouracil is a thymidine analog, 
which exists in two forms, keto and enol forms respectively. If 5-
bromouracil is present in its less frequent enol form as a nucleoside 
triphosphate at the time of its incorporation into a nascent strand of 
DNA, it will be incorporated opposite guanine in the template strand 
and cause a GC->AT transition. However, on the other hand, 5-
bromouracil may also be incorporated in its more frequent keto form 
opposite adenine (in place of thymine) and undergoes a tautomeric shift 
to its enol form during a subsequent replication, it will cause an AT->GC 
transition. Thus 5-bromouracil induces transitions in both directions, 
AT<^GC. 
(b) 2-aminopurine: This purine base analog induces mutations in a 
similar manner as described above. 
2. Nitrous Acid; Nitrous acid (HNO^) is a very potent mutagen that acts 
directly on either replicating or nonreplicating DNA by oxidative 
deamination of the bases that contain amino groups-adenine, guanine and 
cytosine. Conversion of the amino groups to keto groups changes the 
hydrogen-bonding potential of the bases. And thus by nitrous acid 
transitions may be induced in both directions AT«GC. 
3. Acridines; The acridine dyes such as proflavin, acridine orange, and 
a whole series of compounds called ICR-170, ICR-190 etc., are very 
powerful mutagens that induce frameshift mutations. The ICR compoimds 
have acridine moieties with various side chains, often alkylating agents. 
The positively charged acridines intercalate or "sandwich themselves" 
between the stacked base pairs in DNA and cause small additions and 
deletions usually of a single base-pair, result in reading frameshifts for 
the portion of the gene distal to the mutation. 
4. Alkylating and Hvdroxvlating Agents; Alkylating agents such as 
nitrogen and sulfur mustards, methyl and ethyl methane-sulfonate (MMS 
and EMS), nitrosoguanidine (NTG), and many others have several effects 
on DNA. One major mechanism of mutagenesis by alkylating agents 
involves the transfer of methyl or ethyl groups to the bases such that 
their base-pairing potentials are altered and transitions result. For 
example, ethylation at the 7-N position and at the 6-0 position are 
believed to be the two effects of EMS. 7-Ethylguanine is then believed 
to base-pair with thymine. Other base alkylation products are believed 
to somehow "activate" repair processes in much the same way as thymine 
dimers do. The occasional errors occurring in these repair processes 
may lead to transversions and frameshift mutations in addition to 
transitions. Finally some alkylating agents, particularly difunctional 
alkylating agents (those with two reactive alkyl groups), cross-link DNA 
strands and/or molecules and induce chromosome breaks and the various 
kinds of chromosomal aberrations found correlated with breaks. 
Nitrosoguanidine (NTG), one of the most potent chemical mutagens 
known, has been found to induce clusters of closely linked mutations in 
the segment of the chromosome which is replicating during the mutagenic 
treatment. Mutants isolated after NTG treatment often carry multiple, 
closely linked mutations. 
The hydroxylating agent hydroxylamine, NH^OH, in contrast to many 
of the alkylating agents, has a very specific mutagenic effect. It induces 
only GC->^AT t rans i t ions . Although the exact mechanism of 
hydroxylamine mutagenesis is still somewhat uncertain, it apparently 
acts by hydroxylating the amino group of cytosine. The resulting 
hydroxylaminocytosine can base-pair with adenine to produce the 
observed GC->AT transitions. 
It is also assumed that some DN A damaging agents are carcinogenic 
because they induce mutations. These damages lead to heritable changes 
in the methylation of cytosine in DNA. Considerable evidence exists to 
show that gene expression in mammalian cells is in part controlled by 
methylation of specific DNA sequences (Robin 1987). 
Most chemical carcinogens and alkylating or acetylating agents 
(electrophilic reagents) produce such compounds following metabolism 
in the body. This means that they have electron deficient centre and will 
combine with electron rich centres within the cell. Reaction with DNA 
is the most important process in the initiation of mutagenesis and 
carcinogenesis, although reaction with certain amino acids in proteins 
will also occur (Farmer 1982). 
CORRELATION OF MUTAGENESIS AND CARCINOGENESIS; 
For many years it has been recognized that most of the strong 
mutagenic agents, such as ionizing radiations, ultraviolet light, and 
chemicals are also carcinogenic, i.e. induce cancers. In recent years, 
sensitive techniques have been developed to test chemicals and other 
agents for mutagenicity and carcinogenicity. There are several techniques 
for testing a chemical for its mutagenicity and carcinogenicity. But the 
most sensitive technique is the Ames' Salmonella mutagenicity test 
(Ames et al., 1975). Over a period of several years, hundreds of different 
chemicals were tested by B.N. Ames and his colleagues. They observed 
greater than 90% correlation between the mutagenicity and 
carcinogenicity of the substances tested. Initially several potent 
carcinogens were found to be non-mutagenic to the tester strains. 
Subsequently, many of these carcinogens, although non-mutagenic per 
se, were found to be metabolized to strong mutagenic derivatives in 
eukaryotic cells. Further, rat liver microsomal fraction was added to the 
Ames' microbial mutagenicity tests to detect the mutagenicity of 
metabolic derivatives of substances being tested. Several chemicals 
which were not mutagenic and carcinogenic by themselves were found 
to be mutagenic and carcinogenic after being metabolized. For example, 
nitrates are not mutagenic or carcinogenic by themselves, but they are 
converted by a series of enzyme catalyzed reactions to nitrosamines, 
which are highly mutagenic or carcinogenic. Activation was not always 
required for a chemical to be a mutagen and subsequently carcinogen. 
Geneticists generally concur on the idea that there is a strong 
correlation between mutagenicity and carcinogenicity which was later 
on proved by Ames and his colleagues. Now there is a general 
consideration that cancer is caused by somatic mutations. This theory 
has received strong support from the discovery of cellular oncogenes 
(cancer-causing genes) and the demonstration that oncogene responsible 
for human bladder carcinoma resulted from a single base-pair change in 
its normal cellular counterpart (Reddy et al., 1984). 
All cancers exhibit a loss of the normal control of cell division 
that result in the tumour formation. Cell division is undoubtedly, atleast 
in part under genetic control. Thus, mutation in a gene involved in the 
control of cell division, like a mutation in any other gene, can cause a 
loss of function and thus a loss of the normal control of cell division. 
Thus, nowadays the key question is not that whether there is relation 
between mutagenicity and carcinogenicity, but the question is that what 
proportion of human cancers are caused by somatic mutations (Barbacid, 
1986). 
It has been found that the products of various protooncogenes play 
central role in the control of cell division. Oncogenes from human 
cancer cells have been cloned and characterized, they are frequently 
found to be derivatives of c-ras protooncogenes. The genomes of all 
vertebrates contain three distinct, but closely related protooncogenes 
called as ras protooncogenes. These are C-H-ras, C-K-ras and N-ras 
(Barbacid, 1987). The first cellular oncogene to be characterized in detail 
was derived from a human bladder carcinoma called EJ. When the cellular 
oncogene present in these EJ bladder tumour cells was cloned and 
sequenced, it was found to be a derivative of the C-H-ras protooncogene. 
Surprisingly, the oncogenicity of the EJ C-H-ras mutant gene was found 
to result from a single base-pair substitution, that is GC->TA 
transversion. Subsequent to the characterization of the C-H-ras oncogene 
present in the EJ human bladder carcinoma line, oncogenic variants of 
the three c-ras protooncogenes have been detected and characterized in 
a large number of different mammalian cancer cell lines (Bishop, 1982). 
All the mutations that conferred oncogenicity on the ras genes involved 
one or more of three codons: codons number 12, 59 and 61 (Barbacid, 
1987). 
CORRELATION OF MUTAGENESIS AND CARCINOGENESIS 
WITH CHROMOSOMAL ABERRATIONS: 
Chromosomal damage indicates a biological effect on the genome. 
It is generally believed that increased rates of chromosomal aberration 
in a population may indicate an increased cancer risk for the group. The 
suggestion that increased rates of chromosomal aberrations might, 
somehow, favour the occurrence of cancer is supported by the observation 
that among subjects with congenital diseases like Fanconi's anaemia and 
Blooms' syndrome, both characterized by the presence of abnormally 
high rates of chromosomal breakage and rearrangement, there is an 
increased incidence of leukemia and neoplasm (German, 1972). Cigarette 
smoke, which is a potent carcinogen, has clastogenic effects in 
lymphocyte cultures (Vijayalaxmi and Evans, 1982). Ionizing radiations 
and benzene, which are both leukaemogenic, induces chromosome 
damage in rat bone marrow cells (Fomi et al., 1971a,b). A correlation 
between the prevalence of chromosomal aberration in lymphocytes and 
cytological abnormalities in the specific target tissue (i.e., bronchial 
cells) has been demonstrated in uranium miners, a population at high 
risk for lung cancer (Brandom et al., 1978). Increased proportions of 
chromosomal aberrations have been found in the survivors of Hiroshima 
and Nagasaki (Archer et al., 1981). Chromosomal aberrations are 
generally accepted as indicators of a mutagenic and, therefore, a 
potentially malignant event and have been described in more than 5000 
cases of various malignant disorders (Mitelman, 1983a). The aberrations 
are strictly non-random within each group of tumours. This has been 
demonstrated for all types of cancer and lukaemia, in experimental 
animals and in humans, where the number of subjects studied has been 
sufficient to draw conclusions (Mitelman and Levan 1981). Consistent 
specific aberrations have been discovered in an increasing number of 
tumour types, the most characteristic aberrations are summarized in 
Table 1. Cancer-associated nom^andom and specific aberrations are 
convincing evidence for the fundamental role of chromosomal change 
in the initiation of the malignant process (Yunis, 1983; Mitelman, 1994). 
Table 1. Specific chromosome aberrations in human neoplasia. 
Tumour type Chromosome References 
Myeloproliferative 
disorders 
Chronic myeloid 
leukaemia t(9;22)(q34;qll) Nowell and Hungerford 
(1960) 
Acute myeloid 
leukaemia t(8;21)(q22;q22) 
Acute promyelocytic t(15;17)(q22;q21) 
leukaemia 
Acute monocytic t(9;ll)(p22;q23) 
leukaemia 
Refractory anaemia del(5)(q 12q31) 
Polycythemia vera del(20)(q 11) 
Lymphoproliferative 
disorders 
Burkitt's lymphoma t(8;14)(q24;q32) 
(1972) 
Acute lymphocytic t(9;22)(q34;qll) 
Workshop 
leukaemia t(4;ll)((q21;q23) 
Leukaemia 
t(8;14)(q24;q32) 
Chronic lymphocytic+12 
leukaemia 
Solid tumours 
Meningioma -22 
and 
Cervical carcinoma 
Ovarian carcinoma 
Neuroblastoma 
Gilbert 
?lq 
t(6;14)(q21;q24) 
del(l)(p32) 
Pleomorphic adenoma t(3;8)(p21 ;q 12) 
Small-cell lung del(3)(pl4-23) 
carcinoma 
Seminoma i(12p) 
Rowley (1973) 
Rowley et al. (1977) 
Beiger etal. (1982), 
Hagemeijer et al. (1982) 
Sokaletal. (1975) 
Reeves et al. (1972) 
Manolov and Manolova 
Zech et al. (1976) 
Third International 
on Chromosomes in 
(1981) 
G&hnon etal. (1980), 
Morita et al. (1981) 
Mark et al. (1972), Zankl 
Zang(1972) 
Atkin and Baker (1979) 
Wakeeta l . (1980) 
Brodeur et al. (1981), 
et al. (1982) 
Mark etal. (1982) 
Whang-Peng et al. (1982) 
Atkin and Baker (1982) 
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Ewing's sarcoma t( 11 ;22)(q24;ql2) Aurias e/o/. (1983), 
Turc-Carel et al. (1983) 
Malignant melanoma der(6)(q21q23) Trent e/a/. (1983), 
Becher er a/. (1983) 
Nasopharyngeal der(3)(q25q27) Mitelman (1983) 
carcinoma 
A survey of the distribution of cancer-associated aberrations shows 
that only a few of the specific marker chromosomes are pathognomonic 
for a particular malignant disorder (Mitelman 1981, 1983b). Two 
characteristic observations deserve special mention here: the 14q+ 
marker chromosome produced by the t (8; 14) (q24:q32) and the 
reciprocal translocation t(15;17) (q22; q21), each being limited to just 
one cell type, the B-cell lymphocyte and the promyelocyte, respectively. 
Although all the other types of specific marker chromosomes are usually 
much more frequent in one or even two disorders they may 
characteristically, be found in several other tumour types also. Thus, it 
was concluded from the above study that there is little or no target-cell 
specificity with the specific chromosomal aberrations in neoplastic 
disorders. 
The aberrations that are involved, preferentially, in different tumour 
types tend to cluster to certain chromosome types. Thus, some 
chromosomes, e.g. Nos. 1, 8 and 14 seem to be particularly prone to 
aberrations during malignant development, whereas others, such as 
chromosomes 2,4,10,18,19, X and Y, show no selective involvement 
(Mitelman and Levan, 1981; Mitelman, 1983b). The studies also indicated 
that certain specific karyotypic aberrations, in particular monosomy 5 
(-5), deletions of the long arm of chromosome 5(5q"), monosomy 7(-7) 
and deletions of the long arm of chromosome 7(7q"), were more frequent 
in patients with previous occupational exposure to chemical solvents, 
insecticides and/or petroleum products or their combustion residues. 
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One interpretation of this is that the chromosomes most often affected 
carry genetic material which is important to the regulation of cell 
proliferation and/or differentiation, and which needs to be manipulated 
in the process of malignant transformation. It is, certainly, striking that 
the locations of all oncogenes that have been mapped to specific 
chromosomal regions so far, agree with the break points of characteristic 
cancer associated chromosomal aberrations (Rowley, 1983). These 
studies were further confirmed by Mitelman et al. (1981) and Golomb 
et al. (1982). 
Translocations and deletions or deficiencies involving specific 
chromosomes and, more importantly, often break points at the same 
positions on these chromosomes has been observed in certain types of 
cancer cells. Philadelphia chromosome, an altered chromosome 22 that 
has lost a large segment of its long arm has been found in various studies 
in upto 90% of the patients suffering from a specific type of cancer 
called chronic myelogenous leukemia (Klein, 1982). 
Now that the chromosomal locations of several human cellular 
protooncogenes have been determined, a striking correlation is evident 
between their locations and chromosomal break points of translocations 
and deficiencies observed in specific types of cancer cells (Yunis, 1983; 
Rowley, 1983). These results have led to speculations that the observed 
chromosome breaks and rearrangements may have caused altered 
expression of protooncogenes or other important regulatory genes 
present in the vicinity of the break points. 
The Philadelphia chromosome was shown to have been produced 
by a reciprocal translocation involving the ends of the long arms of 
chromosomes 9 and 22. The break points on chromosome 9 that give 
rise to these translocations occur very close to the c-abl protooncogene, 
and the exchange transfers the c-abl gene to chromosome 22 (Klein, 
1982). 
Another type of cancer that is consistently (>80%) associated with 
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specific kind of translocation is Burkitt's lymphoma, a cancer of the 
antibody producing B-lymphocytes. The translocations observed in B 
cells of patients with Burkitt's lymphoma invariably involve chromosome 
8 and one of the three chromosomes (2, 14 and 22) that carry genes 
encoding antibody chains. The most common sites of the chromosome 
breaks that give rise to the translocations between chromosome 8 and 
14 in Burkitt's lymphoma cells are in bands q24 and q32, respectively 
(Kaiser-McCaw et al., 1977; Dalla-Favera, 1982). The c-myc 
protooncogene is located in band q24 on chromosome 8, and c-myc is 
transferred adjacent to the heavy chain antibody genes on chromosome 
14 by the translocation events. Other chromosomal translocation events 
have been detected with high frequencies in other types of cancer cells 
as well, although none with as high an incidence as the translocations 
associated with chronic myelogenous leukemia and Burkitt's lymphoma 
(Le Beau and Rowley, 1986; Kaiser-McCaw et al., 1977; Dalla-Faveva, 
1982;Rabbitts, 1985). 
Other types of chromosomal changes present in cancerous cells 
are "double minutes" (DMs) and "homogenously staining regions" (HSRs). 
The double-minute chromosomes are super numerary chromosomes that 
contain the amplified gene and adjacent chromosomal DNA on 
extrachromosomal circular molecules of DNA. They contain the circular 
molecules of DNA packaged in nucleosomes and chromatin fibres just 
like normal chromosomes. The same unit of gene that is present in DMs 
is often present as the tandemly repeated one within the HSR regions 
of chromosomes containing amplified genes. 
DNA Damage : Damage to DNA is likely to be a major cause of cancer 
and other diseases (Haitt et al., 1977; Ames, 1971). There is an evidence 
which supports that carcinogens and radiations are likely to induce 
majority of human cancers and other genetic defects by way of damage 
to DNA (McCann et al., 1975). Defined precisely, DNA damage is an 
alteration that constitute a stumbling block for the replication machinery 
and hence hampers the replication of DNA, endangering the survival of 
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the cell (Davoret, 1979). 
The correlation between radiation-induced damage and cancer has 
long been apparent to the radiation biologists but through molecular 
evidence, it has been found that DN A damage is a direct cause of cancer. 
The evidence comes from patients suffering from Xeroderma 
pigmentosum (Morgan et ai, 1996). With certain eukaryotic cells, the 
consequences of DNA damage can also be assessed by cytogenetic 
analysis. The human disorders/irox/a telangiectasia. Bloom's syndrome 
and Fanconi's anaemia are genetic diseases characterized by an increased 
susceptibility to cancer (Walker et al., 1985). 
Most chemical carcinogens become electrophilic through an 
enzymatic activation process, or are electrophilic reagents which react 
with DNA, RNA and proteins (Miller and Miller 1974). They cause DNA 
damage and induce various mechanisms of repair. Therefore , 
determination of DNA repair has been suggested to p red ic t 
carcinogenicity. Combes (1983) studied the efficacy of DNA repair 
assays in predicting genotoxicity in bacteria; a review of the literature 
showed good correlation between DNA repair and mutagenicity in 
bacterial systems. 
DNA Repair : DNA is the primary carrier of genetic information and 
the structural integrity of DNA is a prerequisite for gene expression. It 
is a known fact that primary structure of DNA is of a dynamic nature and 
subject to a constant change. All ionizing and UV-radiations as w ell as 
multitudes of other chemical agents upset the genetic and metabolic 
machinery of the living system. The living systems have, therefore, 
evolved repair processes to maintain structural and functional fidelit>' 
of DNA against a large range of insults (Friedberg 1985). The molecular 
mechanism involved in repair of damaged portions of DNA and their 
restriction into functionally intact informational units is fundamental 
to the maintenance of the functional integrity. Defective DNA repair 
could cause an accumulation of lesions or mutations which might either 
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be lethal or lead to an altered phenotype, or cause neoplastic 
transformation. Repair at the cellular and macromolecular level is 
multiple in its form and varies as a function of species, tissues and stage 
of the cell cycle (Hart et al., 1979). 
An indication of the importance of keeping mutation, both somatic 
and germline, at a tolerable level is the multiplicity of repair mechanisms 
in organisms ranging from bacteria to humans. Mechanisms for the repair 
of damaged DNA are probably universal. Escherichia coli, for example, 
possesses at least four different mechanisms for the repair of DNA 
containing thymine dimers: (1) photoreactivation, (2) excision repair, 
(3) post replication recombination repair, and (4) Inducible error-prone 
"SOS" repair. 
DNA repair in in vitro system can follow atleast two major pathways. 
Various mechanisms are implicated in the repair process which eithei 
brings about reversion of lesions or excision of lesions. The reversion 
of lesions may be carried out by photoreactivating enzymes which can 
remove pyrimidine dimers generated by UV light (Sutherland et al., 
1975) or by certain enzymes like insertases and alkyltransferases (Livnen 
etai, 1979; Deutsch and Linn, 1979;Newbold e/a/., 1980; Pegge/a/.. 
1982; Harris et al., 1983; Yarosh et al., 1983). The excision repair has 
been described in variety of mammalian cells (Hart and Setlow, 1974). 
This may be carried out either by base-excision repair (Shaper and 
Grossman, 1980) or Nucleotide excision repair mechanism (Lindahl, 
1982). However, even after replication the DNA lesions can be repaired 
by post replication repair mechanism as was demonstrated by Rupp and 
Howard - Flandar (1968) in E. coli. 
MUTAGENICITY/CARCINOGENICITY TEST SYSTEMS 
In recent years, sensitive techniques have been developed to test 
chemicals and other agents for mutagenicity and carcinogenicity. 
Carcinogenicity tests are usually done with rodents, and more frequently 
with newborn mice. These studies involve feeding or injecting the 
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substance being tested and subsequent examination of the animal for 
tumour formation. The mutagenicity tests have often been done in similar 
fashion. However, because mutation is a low frequency event and because 
maintaining large populations of animals such as mice is an expensive 
undertaking, such animal tests have usually been quite insensitive, that 
is, low levels of mutagenicity would have seldom been detected. 
Long term tests are expensive and time consuming. There is another 
problem of predicting whether humans will respond to the carcinogen in 
the same way as do the animals (Farmer 1982). There are several instances 
in which only one species like mouse was found to respond to the test 
and the rats did not. Then, how can we extrapolate the risk from rodents 
to humans, a very dissimilar long-lived species. Opposite was also found 
in which a chemical was found to be carcinogenic by epidemiological 
studies but was non-carcinogenic in rodents (Ames et al., 1987). 
Short term tests (STTs) for genotoxic chemicals were originally 
developed to study mechanisms of chemically induced DNA damage and 
to assess the potential genetic hazard of chemicals to humans. In the 
following, better known short-term tests are listed. (Table 2). The number 
of tests has increased, considerably, because of accumulating evidence 
in support of the somatic mutation theory of carcinogens (Strauss, 1981; 
Crawford, 1985; Ames e/a/., 1987) and because of reports that say many 
rodent carcinogens in vitro are genotoxic in short term tests (Ames 
1979). The in vitro short-term tests have the advantage that they can be 
conducted relatively quickly and inexpensively compared to long term 
carcinogenicity assays with rodents and do not involve testing in animals. 
Early studies on the concordance between results from in vitro short 
term tests and rodent carcinogenicity tests were highly encouraging 
(Durston et al., 1973; Sugimura el al., 1976). 
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Table ! : Methods for the assessment of mutagenicity and 
carcinogenicity (From annexures V and VIII of Council 
Directives 79/831/EEC). 
Tests for gene mutations : 
Salmonella typhimurium reverse mutation assays 
E. coli reverse mutation assay 
Gene mutation in Saccharomyces cerevisiae 
In vitro mammalian cell gene mutation 
Sex-linked recessive lethal test in Drosophila melanogaster 
Mouse spot test 
Test for chromosome mutations : 
Mitotic aneuploidy, Saccharomyces cerevisiae 
In vitro mammalian cytogenetic test 
In vivo mammalian bone marrow cytogenetic test 
Micronucleus test 
Mammalian germ cell cytogenetics 
Mouse heritable translocation 
Rodent dominant lethal tests 
Indicator tests for DNA effects : 
Mitotic recombination, Saccharomyces cerevisiae 
DNA damage and repair, unscheduled DNA synthesis 
Sister chromatid exchange in vitro 
Other indicator tests for carcinogenic potential : 
In vitro mammalian cell transformation test 
Wide use of short term tests (STTs) for detecting mutagen (Ames, 
1979) and a number of animal cancer tests of plant substances have 
contributed to the identification of many natural mutagens and 
carcinogens in the human diet (Kapadia, 1982). There is a range of 
application in which STTs have been used successively from the 
identification of mutagenic fractions in complex mixtures such as 
cooked meat (Hatch et ai, 1984; Sagimura, 1985) or air pollutants to 
the early identification of genotoxicity in the development of new 
chemical products (Tassignon, 1985). 
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AMES TESTING SYSTEM ; 
B. Ames and his associates (1975) have developed very sensitive 
techniques by which large number of chemicals and other agents can be 
screened for mutagenicity. Their procedures are rapid and inexpensive. 
Ames' procedures involve the use of specially constructed strains of 
Salmonella typhimurium (a bacterium) that carry auxotrophic mutations 
of various types: transitions, transversions, and frame shifts. The 
reversion of these auxotrophic mutants to prototrophy, ei ther 
spontaneous or induced with various agents, can easily be monitored by 
placing a known number of mutant cells in a petriplate containing medium 
supplemented with a trace of the growth factor required by the auxotroph 
(enough to support a few cell divisions, but not enough to allow the 
formation of visible colonif^s) and counting the number of colonies 
produced by p'-ototrophic reverlarts after an appropriate period of 
incubation. The frequency of reversion induced by a particular substance 
can be compared directly with the spontaneous reversion frequency to 
obtain an estimate of its mutagenicity. Its ability to induce different types 
of mutations can be assessed by using a set of test strains that carry 
different types of mutations - one strain with a transition, one with a 
frame shift mutation, and so forth. 
The genotoxic effects of steroids can not be assessed on bacterial 
systems because specific receptor molecules needed by the steroids to 
perform their action are absent in bacteria. Therefore, cytogenetic tests 
are more appropriate parameters for evaluating the genotoxic effects of 
steroids. 
CYTOGENETIC STUDIES FOR THE ASSESSMENT OF 
MUTAGENICITY; 
The birth of Human Cytogenetics as a discipline in its own right 
can be said to have taken place around 40 years ago It emerged directly 
as a consequence of the development of techniques that enabled us to 
clearly visualise chromosomes in human somatic cells and the 
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demonstrations, using these techniques, that a number of congenital 
abnormalities in man, e.g. Down's syndrome, Kleinefelter's syndrome, 
etc., were a consequence of inherited constitutional chromosomal 
anomalies. The emergence of the discipline was very much facilitated 
by these facts: (i) that human peripheral blood T lymphocytes could be 
readily stimualted to undergo mitosis in short term culture; (ii) that these 
cells were easily available in large quantity from a few drops of blood 
obtainable from virtually any individual; and (iii) that stimulated 
lymphocytes were ideal cells from the point of view of producing well 
spread metaphase chromosomes. Modem cytogenetics, of course, is not 
confined to the study of human chromosomes in lymphocytes and a wide 
variety of cells have been subjected to analysis and particularly so in 
the case of studies on human carcinogenesis. 
The techniques of cell culture enable us to expose normal human 
reVis in ^ntro to mutagens and carcinogens and allow us to study the 
consequences of such exposure on chromosome structure and behaviour 
in these cells. 
Chromosomal aberrations: 
The most well-developed method for biomonitoring of genotoxic 
exposure is the measurement of chromosomal aberrations in human 
lymphocytes (Lohman et al, 1984). This method was used in studies of 
the biological effects in humans of exposure to a known mutagen, such 
as ionizing radiations (Bender and Gooch, 1962; Buckton et al., 1962). 
The experience gained in radiation cytogenetics was subsequently applied 
to assess possible genetic damage from exposure to chemicals known 
or suspected to be carcinogenic in man (Fomi, 1979). The evaluation of 
the cytogenetic effects of chemicals is more complex than that of 
ionizing radiations, due to the different mechanisms by which different 
chemicals induce chromosomal aberrations (Wolff, 1982). Induced 
chromosome aberrations in human lymphocytes were well-developed by 
the mid-1970s (Evans and O'Riordan, 1975) . Recommended 
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methodology, classification and scoring of structural aberrations and 
statistical methods have been described (Evans, 1982; Fomi, 1979). 
Chromosome aberrations consist of breakage and rearrangement of 
chromosomes visualized in the metaphase plate. While some types of 
aberrations are easily scored (acentric fragments, dicentrics, rings), 
other types, like reciprocal translocations and pericentric inversions, 
are evident in conventional preparations only when they give rise to 
grossly abnormal chromosomes, with peculiar arm ratios (Fomi, 1984). 
Chromosome aberrations are most sensitive to agents that can directly 
break DNA duplex. However, since most chemical mutagens which cause 
chromatid type damage are 'S' phase dependent, the highest yield of 
aberration is likely to be seen in the first division of the metaphases. 
Most chemicals undergo metabolic conversion in vivo into the ultimate 
reactant, the in vivo and in vitro results of chromosomal aberration tests 
are directly not comparable (Evans, 1982). Therefore, rat Hver metabolic 
activation system (S^ mix) is used in in vitro culture to compare the in 
vivo observations. 
Sister Chromatid Exchanges: 
In comparison to chromosomal aberration method, sister chromatid 
exchange (SCE) analysis is more sensitive and nonspecific for the 
chemical in question. SCEs involve breakage of double stranded DNA in 
both chromatids followed by an exchange of whole DNA duplexes. The 
SCEs, like chromosome aberrations, induced by S phase-dependent 
agents, are formed by unpaired lesions that are present when the cell 
passes through S-phase and the chromosome replicates. This is the most 
sensitive method to detect the mutagenic property of the chemical and 
to determine which of the metabolites of a premutagenic and 
precarcinogenic agent might be the most likely ones to interact with 
DNA and cause its effects (Perry and Evans, 1975; Latt et al. 1981). 
SCE represent symmetrical reciprocal exchanges of segments between 
sister chromatids; generally, they do not result in alteration of the 
chromosome morphology or the genetic information. This detection 
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method is exquisitively sensitive as an in vitro screening test. For many 
mutagenic chemicals very low concentration is required to induce a 
significant response in SCEs than to produce effective chromosomal 
aberration (Perry and Evans, 1975; Stetka and Wolff, 1976). However, 
the DNA lesions that induce SCE are not necessarily the same as those 
that induce point mutations or chromosome breakage (Carrano et al, 
1978). 
Micronucleus Test: 
Micronucleus test can be applied successfully to diverse human 
tissues and is not unusually difficult or time-consuming (Heddle et al., 
1982; Stich et al, 1983), but it has not been validated for biomonitoring 
purposes. Some preliminary results, reported by Stich et al. (1983), show 
a relationship between betel chewing and the induction of micronuclei 
in buccal mucosa. Micronuclei are thought to originate from aberrant 
cell division and unequal chromosome distribution, although Heddle et 
al. (1982) reported that damaged chromosomes in micronuclei of colon 
cells may separate without cell division. The main advantages of this 
method are that it may be specific for clastogenic effects and that it 
measures effects directly in the target tissues of exposed persons. 
Micronuclie are acentric chromosome fragments or whole chromosomes 
lagging behind in the normal karyokinesis (Sorsa, 1984). These 
fragments or chromosomes are excluded from the post-mitotic daughter 
cells and form additional small nuclei or micro nuclei. Thus, the 
induction of micronucleated cells represents either chromosomal 
breakage (clastogenicity) or a failure in the spindle fibre mechanism 
(turbagenicity). The conventional micronucleus test in rodents is 
designed to detect the damage in the polychromatic erythrocytes of bone 
marrow. Extensive chemical evidence obtained from this test shows that 
micronucleus formation is qualitatively correlated closely with 
chromosomal breakage or loss. In humans micronucleated cells have been 
visualized, likewise, in dividing tissues, e.g., in bone marrow in vivo 
(Krogh Jensen and Nyfors, 1979) and in cultured lymphocytes in vitro 
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(Heddle et al., 1978). Hogstedt e/ al. (1983) was the first to show that 
human in vivo exposure to cigarette smoke can be detected as an 
increased frequency of micronuclei in the cultured lymphocytes of 
smokers. 
Cell Cycle Kinetics: 
An additional check on the potential of the mutagen to produce an 
effect on the cells can be made by analyzing the proportion of mitotic 
cells in their first, second or subsequent metaphases for each treatment 
group and calculating a proliferation index (PI) or mitotic index (MI). 
STEROIDS; USES AND APPLICATIONS; 
The steroids, a group of structurally related compounds which are 
widely distributed in animals and plants, include sterols (from which 
the name steroid is derived), vitamin D, the bile acids, a number of sex 
hormones, the adrenal cortex hormones , some carcinogenic 
hydrocarbons, certain sapogenins, etc. Steroids are group of lipids based 
on a skeleton of four fused r ings , the 1-2, 
cyclopentanoperhydrophenanthrene system. They are derivatives of 
cholesterol. 
Present study is concerned with steroidal hormones. In mammals 
five important groups of hormonal steroids occur: progestins, 
glucocorticoids and mineralocorticoids with 21 carbon atoms, androgens 
with 19 and estrogens with 18 carbon atoms. 
Sex hormones produced by the gonads and adrenals are necessary 
for conception, embryogenic maturation, and development of primary 
and secondary sexual chracteristics at puberty. The gonadal hormones 
are used therapeutically in replacement therapy and, in the case of 
estrogen, for contraception and osteoporosis. The adrenal cortex 
produces two major classes of s teroid hormones . The 
adrenocorticosteroids (glucocorticoids and mineralocorticoids) and the 
adrenal androgens. Their synthesis is stimulated by corticotropin 
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(ACTH). Hormones of the adrenal cortex are used in replacement 
therapy, in the treatment and management of inflammatory diseases such 
as rheumatoid arthritis, in the treatment of severe allergic reactions, 
and in the treatment of some cancers. In the present study six hormonal 
steroids were evaluated for their cytogenetic effects on human 
lymphocytes, two each from estrogens, progestins and androgens. 
1. ESTROGENS : Estrogenic hormones are secreted by the ovarian 
follicles. They either stimulate or regulate the growth and development 
of the uterus, the vaginal mucous membrane and also other structures 
such as mammary glands, subcutaneous fat, axillary and pubic hair and 
certain elements in the skin. The later includes the secondary female 
sex characteristics. Therefore, the estrogens are also called as female 
sex hormones. Estrogens are secreted throughout the period of activity 
of the ovaries, though at varying rates at different times of the menstrual 
cycle (Reynolds and Kathleen, 1996; Hardman and L,iri«bifd, 199C). 
The naturally occurring estrogens can be prepared synthetically. 
Improvement of natural estrogens can also be done by synthetic 
modification. For example the potency 17 b-estradiol, the most potent 
of natural estrogens, can be further improved by the addition of a side 
chain forming ethinyl estradiol. Both the estrogens used in the present 
study are synthetic i.e. Mestranol and Quinestrol. 
Estrogens are used as substitution therapy after the appearance of 
menopausal symptoms. Estrogens are also used in young women in 
whome there is failure of steroidogenesis. Applied locally, the estrogens 
are useful in the treatment of atrophic or senile vaginitis, vulvovaginitis 
or cervicitis resulting from hypoestrogenesis. A number of menstrual 
irregularities may be treated with these molecules like amenorrhoea, 
secondary amenorrhoea etc. They are of value in decreasing electrolyte 
imbalance, headache, tension, breast engorgement and nipple tenderness 
in premenstrual tension, however they are of dubious value in relieving 
neurological and mood changes in that disorder. In endometriosis. 
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estrogens are effective for only a short time, in eventualh resulting 
endometrial hyperplasia. In dysfunctional uterine bleeding, combined 
treatment with estrogens and progestogens is used (Herfindal and 
Gourley, 1996; Melmon and Morelli, 1992). 
Since estrogens suppress gonadotropin (FSH) release and also 
inhibit blastocyst implantation, they are used as contraceptives. A 
contrasting use is to assist reproduction as an adjunct in the prevention 
of habitual abortion. They may be used in the induction of parturition 
and in the postpartum period to reduce breast engorgement. 
Estrogens decrease plasma cholesterol and hence have been used 
as hypocholesteremic drugs, but side effects are usually unacceptable 
to the male recipient. Estrogenic also are used to treat acne vulgaris and 
hirsutism. They are also used to inhibit the growth of prostatic cancer 
of men and carcinoma of the breast or carcinoma elsewhere in the 
reproductive tract of women (Becker 1995). 
2. PROGESTINS: Progestins or progestogens are second type of 
hormones produced in the ovaries. Although it originates in the cells 
which may also produce estrogens and that it has a molecular structure 
very similar to that of the estrogens, progesterone has a unique 
physiological action. Under its influence the numerous minute glands 
which line the uterine cavity are transformed into secreting glands. This 
alteration is part of the change which is essential to provide the 
implantation of a fertilized ovum and for the continuing development of 
placenta. This endometrial alteration requires the cooperation of an 
estrogen. In the absence of an estrogen, a progestin that is devoid of 
estrogenic activity, will exert an atrophic effect on the endometrium 
(Katzung, 1995; Brody, 1994). 
Progestins also cause a change in the cervical secretions to suppress 
"feming" a dendritic crystallization of cervical muco polysaccharides 
when the cervical mucous in not dendritic, when it forms a tight net of 
fibers, through which sperms can not pass. The antifertilit> effect of 
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some progestins possibly may be due in part to the suppression formation 
of feming. Progestins in high doses suppress the pituitary release of 
lutenizing hormone and the hypothalmic release of the LH-releasing 
factor (LRF), thus preventing ovulation. Progestins also decrease uterine 
mobility, which may contribute to a contraceptive effect. In addition they 
antagonize the endometrial actions of estrogens, especially the natural 
estrogens. Progestins have the ability to stimulate development of the 
glandular portions of the mammae. They also exert some effect upon 
the capacity of tissues to retain water in the intercellular spaces. They 
also have a thermogenic action (Becker, 1995). 
The synthetic progestins used in this studyare Norethindrone and 
Norgestrel. These progestins used cyclically in the treatment of 
infertility in whichthe uterus is not receptive to implantation. The 
progestins sustain the secretory endometrium during the third and fourth 
weeks of the mertstpial cycle. They are used cyclically with estrogens 
in the treatment of secondary amenorrhoea and dysfunctional uterine 
bleeding. They also may be used to lessen premenstrual tension, although 
they cause salt and water retention, which is a factor in this disorder. 
The effect to suppress the release of LH and LRF is used to prevent 
ovulation, not only with some oral contraceptives but also in the treatment 
of primary dysmenorrhoea and endometriosis. In sexual infantilism in 
the female, progestins may be combined with estrogens to bring about 
genital development and maturation. Progestins may decrease breast size 
in mastodynia (Kuhl, 1996;Brody, 1994). 
In pre-eclampsia and toxemia of pregnancy due to hormonal 
imbalance, progestins plus estrogens may improve the condition,even 
though both types of hormones can cause salt and water retention and 
estrogens can cause hypertension. They may be used in huge doses as 
adjunctive treatment in endometrial carcinoma. They have been used in 
the past to prevent habitual abortion or in the treatment of threatened 
abortion. An intriguing use of progestins is to stimulate respiration in 
the Pickwickian syndrome (Hardman and Limbird, 1996). 
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3. ANDROGENS : Natural androgens or male hormones (i.e. 
testosterone) are synthesized and secreted from interstitial cells or 
Leydig cells of testes. However, it is mainly the metabolite, 
dihydrotestosterone, which stimulates and maintains the secondary sex 
organs; these are the penis, prostate gland, seminal vesicles, vas deferens 
and scrotum. It also exerts sustaining effects on the spermatogenic cells, 
and it stimulates the development of bones, muscles, nerves, skin and 
hair growth, and emotional responses to produce the characteristic adult 
masculine traits. Testosterone itself regulates the hypophyseal release 
of LH. This group of combined actions of this hormone is termed 
androgenic actions. Testosterone also antagonizes a number of the 
effects of estrogens, and sometimes is employed clinically for this 
purpose. This is specially important in the suppression of metastatic 
carcinoma of the breast. Since it promotes development of the clitoris, 
which is an anatomic bomolog of the penis, androgens may increase the 
libido of women (Herfindal and Gourley, 1996). 
The naturally occurring androgens (androsterone, testosterone) are 
derivatives of androstane. Testosterone and its esters (testosterone 
propionate) and derivatives (methyl testosterone) are the most 
commonly used androgenic steroids. In addition to their androgenic 
properties, however, these compounds exert widespread anabolic effects 
and promote the retention of calcium. In attempts to dissociate the 
virilizing and anabolic properties (for use in women) a number of 
compounds with high anabolic and androgenic ratios have been prepared. 
However, it has not been possible yet to abolish completely the 
androgenic effects. 
The two synthetic androgens used in the present study are Danazol 
and Oxymetholone. These and other synthetic androgens are used for 
varieties of purposes, e.g. among men or youths with hypogonadism 
(enuchism, klinefelter's syndrome). They have been employed to 
facilitate development of adult masculine characteristics when the 
adolescent process has been delayed. In cryptorchidism they may be used 
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adjunctively with gonadotropins. They also are very useful in therapy of 
patients with hypopituitarism and with Addison's disease. They are of 
significant value in the treatment of frigidity and occasionally in 
impotence. The use of androgens for relief of impotence not associated 
with evidence of testicular under activity (psychic causes) is known to 
be futile in most cases. Low doses of androgens have been used in 
pituitary dwarfism to accelerate growth, but care must be exercised not 
to arrest growth by epiphyseal closure. They also are used to promote 
hematopoiesis. In large supratherapeutic doses, anabolic steroids 
increase athletic performance and aggresiveness. Female performance 
is improved but at the expense of virilization and acne vulgaris (Melmon 
andMorelli, 1992). 
With estrogens, androgen therapy may be efficacious in the 
treatment of the menopause. The anabolic effects are possibly of some 
benefit in the post climacteric persons, and they may retard osteoporosis. 
They also help relieve vasomotor instability in post menopausal women 
in whom estrogens alone do not relieve symptoms. In functional 
dysmenorrhoea androgens may give relief through an antiestrogenic 
action. They may be used to treat endometriosis. They also may be used 
in the treatment of postpartum breast engorgement and for suppression 
of lactation. 
METABOLISM OF THE STEROID HORMONE : 
Naturally occurring estrogens and their esterified or conjugated 
derivatives are readily absorbed through the gastrointestinal tract, skin 
and mucous membranes. Estrogens are also quickly absorbed when 
administered intramuscularly. Administered orally, estradiol is rapidly 
metabolized and partially inactivated by the microsomal enzymes of the 
liver. The synthetic estrogen analogs e.g. ethinyl estradiol and mestranol, 
are well absorbed after oral administration, and through the skin or 
mucous membranes. Mestranol is quickly oxidized to ethinyl estradiol, 
which is metabolized more slowly than the naturally occurring estrogens 
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by the liver and peripheral tissues. Being fat soluble they are stored in 
adipose tissue from which they are slowly released. Therefore, the 
synthetic estrogen analogs have a prolonged action and high potency as 
compared to natural estrogens.Estrogens are transported in the blood 
bound to serum albumin and sex-hormone binding globulin. They are 
hydroxylated in the liver to derivatives that are subsequently 
glucoordinated or sulfated. The physiological inactive products are 
excreted in the urine. Oral effectiveness of synthetic estrogens is more 
because these are metabolized more slowly, whereas, naturally occurring 
estrogens are destroyed almost totally in a single pass through the 
liver.The half-life of estradiol is 40-50 minutes, whereas other estrogens 
persist much longer. Drugs that induce the hepatic microsomal mixed 
oxygenase system (e.g. phenobarbital, phenytoin, rifampin etc.) will 
accelerate estrogen metabolism. 
Progesterone is rapidly absorbed after its administration by any 
route. It has a short-half-life in the plasma, since it is almost completely 
metabolized in one passage through the liver. The glucuronidated 
metabolite (pregnanediol glucuronide) is excreted by the kidney. 
Whereas, synthetic progestins are less rapidly metabolized. Synthetic 
progestins used in contraception are more stable to first pass 
metabolism, allowing for lower doses when administered orally. 
Norethindrone and norgestrel have the same characteristics. These two 
are also called as nortestosterone progestins because of their structural 
similarity to the androgen. They also possess some androgenic activity. 
Like the estrogens and progestins, androgens bind to a specific 
nuclear receptor in a target cell. Although testosterone itself is the active 
ligand in muscle and liver, in other tissues it must be metabolized to 
derivatives such as 5-a-dihydrotestosterone (DHT). Testosterone after 
diffusing into the cells of the prostate, seminal vesicles, epididymis and 
skin, is converted to DHT,which binds to the receptor. In the brain 
testosterone is biotransformed to estradiol. The hormone/receptor 
complex binds to DNA and stimulates the synthesis of specific RNAs 
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and proteins. Testosterone analogs that cannot be converted to DHT have 
less effect on the reproductive system than they do on the skeletal 
musculature. Testosterone is rapidly absorbed by the liver and other 
tissues, and is metabolized to relatively or completely inactive 
compounds that are excreted primarily in the urine but also in the feces. 
Danazol has a longer half life in the body than does the naturally 
occurring androgens. 
Synthetic steroids may be metabolized in human by the same 
mechanisms as are the natural compounds. 
MECHANISM OF STEROID HORMONE ACTION 
Steroid action entails all of the sequential and simultaneous 
biochemical steps from the binding of hormone to a cellular receptor to 
the final biochemical or physiological adjustment that is the outcome 
of the presence of the particular steroidal hormone in sufficient amount. 
Steroid hormone action is typical of those hormones that primarily affect 
the cell nucleus. After steroid binding and activation of the cytoplasmic 
receptor, the hormone receptor complex is translocated into the nucleus 
by a characteristically temperature dependent process. Once the complex 
is in the nucleus, it binds to chromatin and activates RNA polymerase. 
This is followed by a copying of a specific DNA region that contains the 
code for the sequence of amino acids comprising a specific protein. 
The newly synthesized mRNA is transported out of the nucleus to the 
rough endoplasmic reticulum where it participates in protein synthesis. 
The newly synthesized protein is either incorporated into cellular 
components, used to activate an intracellular regulatory protein or it is 
secreted by the cell. The hormone-receptor complex may remain in the 
nucleus and exert its effects for several hours before it dissociates and 
re-enters the cytoplasm. The steroid is metabolized to an inactive form 
and subsequently diffuses out of the cell. 
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STEROID HORMONES AND CARCINOGENESIS : 
Several sex steroids have been studied for their carcinogenic 
potentials (Lang and Redmann, 1979). Estrogens induce the formation 
of endogenous DNA adducts both in human and animals and can ultimately 
lead to cancer development (Liehr et al., 1986; Liehr, 1990). 
Contraceptive steroids cyproterone acetate can have a tumour inducing 
potential in rat liver in addition to its tumour promoting activity (Wolff, 
1993). Estradiol is carcinogenic in experimental animals. Administration 
of estrogens leads to an increase in endometrial cancer in women (lARC, 
1979). Some other possible complications of contraceptive use include 
breast cancer, and cancer of the uterus, cervix and vagina. 
There is a high risk of development of cancer with excessive use 
of steroids. Several steroids have been reported to possess tumourogenic 
and carcinogenic activities (Kay, 1981). Several steroids have been 
reported to be mutagenic and carcinogenic on the basis of short term 
tests (Dunkel et al., 1985). Yet various steroids have been shown to play 
an active role in human carcinogenesis. Specially the steroidal hormones 
and their derivatives have been demonstrated to be mutagenic and 
carcinogenic in the bacterial as well as in the animal testing system (Kay, 
1981; Metzler, 1984). 
Estrogenic hormones have been shown to possess the tumourogenic 
activity and are assumed to serve as regulators of tumourous growth. 
These hormones probably maintain the neoplastic state of the cells in a 
variety of well characterized experimental animal tumour systems 
(Katzene llenbogen, 1986). Growth promoting effect on hepatocarcinoma 
has also been demonstrated to be mediated by estrogen receptors in the 
mated rats (Kohigashi et al., 1986). Steroids have been found to play a 
role in regulating aromatase activities in breast and endometrial cancer 
(James et al., 1986). Contraceptive steroids have been assessed for 
toxicological and carcinogenic hazards (Heywood, 1986). Moreover, the 
stereochemical complementarity of DNA and reproductive steroid 
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hormones have been found to correlate with biological activity (Lawrence 
etal., 1986). 
The following points of possible mechanisms is speculative for 
neoplastic growth: 
(1) Steroid hormones may increase the binding of chemical carcinogens 
to cellular constituents e.g. by influencing metabolic activation 
system. 
(2) Steroid hormones may activate oncogenic virus production e.g. 
mammary tumour virus in mice. 
(3) Exposure to hormones may result in lesions (preneoplastic) which 
provide an environment for the survival of cells with abnormal 
growth potentials. 
(4) These hormones may be immunosuppressive and could thus 
influence tumour occurrence and growth. 
(5) They may influence the rate of progression of preneoplastic cells 
to neoplastic cells. 
(6) They may preferentially stimulate proliferation of abnormal cell 
populations. 
(7) They may stimulate the DNA synthesis and mitosis essential for 
fixation of the transformed state. 
(8) Steroid hormones, by stimulating the proliferation of normal cells 
with a definite number of cell divisions, may exhaust the normal 
cell population and thus eliminate their inhibitory influence over 
the proliferation of abnormal cells (Nandi, 1978). 
STEROID HORMONES : EMBRYOTOXICITY AND TERATO-
GENICITY : 
Many steroidal sex hormones cause antifertility, embryotoxicity 
and foetotoxicity in several species, and such effects are usually dose 
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related. Some estrogens also produce teratogenic effects and impaired 
fertility in exposed offspring. Certain progestins, testosterone and 
testosterone derivatives have a virilizing effect on the foetus. 
In humans, birth defects have been observed in foetuses after 
maternal ingestion of various drugs. However, only in limited number 
of cases it is possible to ascribe a particular defect to specific drug. 
Masculinization of external genitalia in female foetuses have been 
observed after their exposure in utero to large doses of progesterone. 
Advancement of skeletal maturation has been noted (Breibart et al., 
1983). It has been reported that more congenital abnormalities occur in 
infants born to women who became pregnant while taking oral 
contraceptives (Nora et al. 1978). Significant embryolethality was 
observed after the administration of steroid (ethinylestradiol) in rats 
(Joshi et al., 1983). Injection of sex steroids lead to incomplete 
development of genital tracts in mice and rats (Bern, 1979; Kohnr.an, 
1978). A VACTERL syndrome was seen in a child of a mother given 
hormone therapy at the beginning of pregnancy (Kaufman, 1973). 
Chromosome abnormalities (principally triploidy and tetraploidy) in 
foetuses have been reported to be more common following the use of 
oral contraceptives by their mothers (Alberman et al., 1976; Carr, 1970; 
Harlap et al., 1979). 
The mutagenic potential of a few steroidal hormones used as oral 
contraceptives (OCs) has been studied in human with both positive and 
negative results. Carr (1967) found chromosomal abnormalities in 6 out 
of 8 spontaneous abortions in women who became pregnant after stopping 
the intake of oral contraceptive pills. This observation highlighted the 
possible mutagenic effect of oral contraceptives in female germ cells. 
Estradiol was reported to induce structural chromosomal aberrations in 
human embryonic fibroblasts (Serova and Kerkis, 1974). Increased 
incidence of vaginal and cervical adenocarcinomas have been reported 
in female offspring of mothers who have had synthetic estrogens during 
the first trimester of pregnancy (Greenwald et al., 1971; Herbst, 1971). 
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Cytogenetic study of peripheral blood lymphocyte culture was done 
on 50 babies born to mothers after oral contraceptive use, 23 women 
using oral contraceptives and 20 women who had never used oral 
gestagens. The chromosome analysis on the progeny revealed one baby 
to have D/G translocation type Mongolism. Cytogenetic changes of 
increased chromosome breakage and satellite association were observed 
in the 23 patients using oral contraceptives over the 20 patients on no 
gestagen therapy. (McQuarrie et al., 1970). 
STEROID HORMONES : MUTAGENICITY/GENOTOXI CITY/ 
CLASTOGENICITY: 
Steroid hormones play a major role in the growth, development and 
metabolism. They diffuse through the cell membrane and after 
conjugating with specific receptor proteins in the cytoplasm, pass 
through the iiucletir pore to form steroid-receptor protein - DNA 
complex. This complex alters the gene expression of many cellular 
processes including enzyme synthesis (Thomas and Thomas, 1993). 
Several sex steroids have been studied for their mutagenic and 
clastogenic potentials (Wheeler et al., 1986). Estrogens have been 
identified as mitotic inhibitors. It was suggested that structural 
specificity is required for mitotic inhibition (Rao and Engelberg, 1967). 
Estrogens are mitotic poisons, which at high concentration cause 
metaphase arrest, abnormal cell division and chromosomal aberrations 
(Wheeler et al., 1986). Contraceptive steroids induce DNA repair 
synthesis in rat hepatocyte cultures, indicating DNA damage (Neuman 
et al., 1992). The most potent of naturally occurring estrogens, estradiol, 
binds to isolated DNA and induce fragmentation (Yamafugi et al., 1971; 
P.O.P Tso Lu, 1964; Blackburn et al., 1974). It was found to induce 
very low frequencies of hyperploidies in human synovial cells in vitro 
(Lycette et al., 1970) and various numerical aberrations in pig oocytes 
in vitro (McGaughey, 1977). In human embryonic fibroblasts and kidney 
epithelial cells, estradiol was reported to induce structural chromosomal 
aberrations (Serova and Kerkis, 1974). Simultaneous addition of 
estradiol, progesterone and human chorionic gonadotropin (HCG) 
increased the SCE frequency in human lymphocyte culture, but their 
separate administration did not induce SCEs (Sharma and Das, 1986). 
Estradiol was found to be negative in Ames' test (Lang and Redmann, 
1979) and does not induce point mutations in mammalian cells in vitro 
(Drevon et al., 1981). Estradiol has been found to induce chromosomal 
aberrations and sister chromatid exchanges in human lymphocyte 
cultures in vitro (Ahmad et al., 2000a). Mestranol, the synthetic 
estrogen, has been found to induce chromosomal aberrations, sister 
chromatid exchanges and micronuclei formation in mouse bone marrow 
cells though it was non-mutagenic in Ames' test both with or without S^  
mix (Dhillon et al., 1994). Badr and Badr (1974) found lyndiol 
(lymstranol and mestranol) not to affect the frequency of dominant lethal 
mutations in mice. Similarly Dutokowski et al. (1979) reported non-
genotoxic effects for mestranol and norethindrone on micronuclei 
formation and induction of SCEs in lymphocytes cultured from six 
women. Neumann et al. (1992) found cyproterone acetate (CPA), a 
contraceptive steroid, to induce DNA repair synthesis in rat hepatocyte 
cultures,indicating DNA damage. Many other hormonal drugs have also 
been reported to be mutagenic and clastogenic (McQuarrie et al., 1970; 
Wheeler e/a/. , 1986). 
Some other sex steroidal hormones used as oral contraceptives 
(OCs) have been found to be mutagenic in plant chromosomes (Hakeem 
and Amer, 1965; Kabarity and Khodary, 1967; Goswami, 1978; Kabarity 
and Mazrooei, 1984). Ovral 50, a contraceptive steroid was found to be 
genotoxic in mammals like mice and dogs (Williams et al., 1968; Devi 
and Reddy, 1986). Badr and Badr (1974) demonstrated a high incidence 
of dominant lethal mutations in female mice given a large dose of OCs. 
OCs were not mutagenic in Drosophila melanogaster (Paradi, 1981). 
Goh (1967) reported an increased number of chromosomal breaks 
and rearrangements in lymphocyte cultures of women taking OCs. This 
finding was confirmed by McQuarrie et al. (1970), Littlefield et al. 
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(1971) and Badr et al. (1972). But Shapiro et al. (1972) did not find 
such effects. Husum et al. (1982) found no significant increase in the 
frequency of sister chromatid exchanges in the peripheral lymphocytes 
of women using OCs, whereas Murthy and Prema (1979, 1983) observed 
a significantly increased frequency of SCEs in OC users. In vitro studies 
of human lymphocyte cultures treated with OCs failed to induce a 
genotoxic effect (Stenchever, 1969; Timson, 1969; Devi and Reddy, 
1986). Anovlar 21, a combination drug and an OC containing the estrogen 
ethinyl estradiol and the progestin norethisterone acetate, was foimd to 
induce chromosomal aberrations in mouse bone marrow cells in a dose-
time related manner, whereas the drug was unable to induce micronuclei 
(Shyama e/a/., 1991). 
Reports on the mutagenicity of non-sex steroids is controversial. 
Some of these molecules do not exhibit mutagenicity in Ames/ 
Salmonella test system but are clastogenic in mammals (Bali et al., 
1990; Singh et al., 1994). A few of such drugs inhibit DNA synthesis in 
rapidly dividing liver cells in vitro at low dose concentrations (Loeb et 
al., 1973). Dexamethasone, a non-sex steroid, has been found to induce 
chromosomal aberrations and sister chromatid exchanges in human 
lymphocytes in vivo but not in invitro (Ahmad et al., 2000 b) whereas, 
other corticosteroid hydrocortisone induces chromosomal aberrations 
and sister chromatid exchanges in human lymphocytes in vitro (Shadab 
et al., 1999). 
Estradiol was found to induce C-mitoses, polyploidies and 
micronuclei in human peripheral lymphocytes in vitro but was unable to 
induce structural chromosomal aberrations and SCEs (Banduhn and Obe, 
1985). Wheeler et al. (1986) found that only estrogens have the ability 
to induce mitotic inhibition and aneuploidy in Chinese hamster cells in 
vitro. Estrogens studied were diethylstilbestrol (non-steroidal), 
dienestrol, hexestrol, b-estradiol, ethinyl estradiol and estriol. Most 
potent was diethylstilbestrol and least potent was estriol. In the same 
study progesterone, estrone and testosterone were also evaluated, but 
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none were found to cause mitotic disturbances. The steroidal hormones 
estradiol-17b, estriol, estrone and ethinyl estradiol were found to induce 
and enhance sister chromatid exchange in Chinese hamster ovary cells 
in vitro (Kochhar, 1988). In a study in 44 women by Pinto (1986) it was 
observed that significant increase in chromosome aberrations was 
associated with the use of hormonal contraceptives. Earlier, in a similar 
study it had been found that oral contraceptives have no effect on SCE 
(Husum et al., 1981). It was observed by Littlefield et al. (1975) that 
synthetic hormones do not directly damage lymphocyte chromosomes 
Kabarity and Mazrooei (1984) found that Anovlar can produce major 
cytological abnormalities. It induced a mitodeppressive effect, produced 
abnormal prophases and considerable number of micronuclei. Women 
using an estrogen-progestogen combination contraceptive exhibited an 
increased frequency of sister chromatid exchange. These elevated SCE 
frequencies tended to decline 3 months after the discontinuation of the 
pill. Women using a progestogen injectable contraceptive had unaltered 
SCE rates (Murthy and Prema, 1983). 
Very little study has been done to evaluate the genotoxic effects of 
androgens. 
STEROID HORMONES AND APOPTOSIS : 
Apoptosis is the scattered, random deaths of cells in healthy tissues. 
During apoptosis cells undergo shrinkage and separation from their 
neighbours, membrane blebbing, a characteristic form of nuclear 
chromatin condensation, nuclear membrane breakdown, and cytolysis into 
condensed apoptotic bodies. This process evokes little gross 
inflammation, though the shrivelled cells and apoptotic bodies are 
phagocytosed by surrounding cells and macrophages (Kerr, 1971; Kerr 
etal. 1972;Wyllie, 1981). 
It has been observed that glucocorticoids evoke apoptosis in rodent 
thymocytes in vivo and in vitro, and also in lymphocytes in vitro 
(Dougherty and White, 1945; Munck and Wira, 1970). DNA lysis occurs 
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in glucocorticoid evoked apoptosis in thymocytes. 
Sex steroids are also associated with apoptosis (Huggins and 
Hodges, 1941; Huggins et al., 1941). In the prostate, the glandular 
epithelium shows the morphological changes of apoptosis beginning 
about 3 days after castration (Martikainen and Isaacs, 1990). 
Antiandrogen or androgen withdraw! induce apoptosis in the prostate, in 
prostate organ cultures (Martikainen and Isaacs, 1990b), androgen-
dependent prostatic carcinomas, and in rat and human prostate derived 
cell lines in vitro (Tenniswood et al., 1992; Kyprianon, et al., 1990). 
Replacement of androgens can restore the prostatic epithelium. 
Glucocorticoids repress apoptosis in the prostate. Several specific genes 
and gene products have been associated with the apoptosis that follows 
androgen removal. 
The steroid-dependent cyclical regression of the uterine epithelium 
is another example of apoptosis occurring subsequently to hormone 
removal (Hopwood and Levison, 1976). Estrogen stimulates uterine 
epithelial growth; progesterone stimulates its differentiation. Removal 
of progesterone or use of antiprogestins results in morphological 
apoptosis of the epithelial cells without gross change in the stroma 
(Rotello et al., 1992). Interestingly, prolonged antiprogestin exposure 
in rats resulted in continued apoptosis of epithelial cells accompanied 
by invasion by granulocytes : a hallmark of inflammation not usually 
associated with the apoptotic process (Rumpell et al., 1993). 
Thus there is a difference that addition of glucocorticoids and 
removal of sex steroids evoke apoptosis and prolonged exposure to sex 
steroids can also lead to apoptosis. 
DEFINITION OF THE PROBLEM AND OBJECTIVES OF THE 
PRESENT WORK 
In many ways chemicals are a basic factor in the well-being and 
effective functioning of present day s.ojcieties, which were not 
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encountered by human ancestors, and to which he has not been adapted 
specifically. Among these substances are food additives, synthetic drugs, 
narcotics, antibiotics, cosmetics, contraceptives, pesticides, alcohol, 
tobacco in various forms, various air and water pollutants, petroleum 
products, plastics, synthetic textiles, man-made mineral fibres and 
different other synthetic materials. The quality of life at both the social 
and individual levels would be severely restricted without the use of most 
of the above described substances. Of all these chemicals, synthetic 
drugs and contraceptives can be far more dangerous to the population in 
terms of genetic defects than radiation because the use of these drugs 
is indispensable for survival. As a result, it is important to determine 
their mutation frequency in human cells. 
Synthetic steroidal hormones have potential application in 
pharmacology (Loeb etal., 1973; Kochhar 1988). These steroids possess 
antitubercular, antitumour, anti-inflammatory, antineoplastic, 
immunosuppressive, antibacterial, antimicrobial and antiviral activities 
(Killie, 1971; Haynes, 1974). The sex hormones are used widely in 
human medicine for a large variety of conditions, apart from their uses 
as oral contraceptive agents. They are used in the treatment of 
dysmenorrhoea, endometriosis, dysfunctional uterine bleeding, as 
replacement therapy in patients with gonadal dysgenesis and in women 
with symptoms of climacteric. They are also used in the prevention of 
postmenopausal osteoporosis, treatment of advanced breast and 
endometrial carcinoma. In obstetric practice, progestins are used in the 
management of threatened abortion and to prevent premature labour. And 
local estrogens are used successfully to 'prime' the unripe cervix to 
induction of labour. Estrogens are also used to develop secondary female 
sex characteristics in trans-sexual males and androgens to suppress these 
characteristics in trans-sexual females. Androgens are used in the 
treatment of male hypogonadism, in the treatment of symptoms of 
climacteric and in advanced mammary tumours in women. Clomiphene 
citrate is used to induce ovulation in anovulatory women and also in 
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oligospermic males. The use of androgens to improve athletic performance 
is well known. Sex hormones are also used in veterinary medicine and as 
supplements to feed stuffs to promote growth of food animals. 
The cytogenetic studies conducted on the possible chromosome 
damaging effect of steroidal hormones so far is inconclusive and 
controversial. A large number of steroids have been studied for their 
teratogenic (Joshi et ai, 1983), carcinogenic (Rosenfield et al., 1983), 
mutagenic and clastogenic (Wheeler et al., 1986) potentials. Although 
numerous literatures have been produced on the genotoxicity of 
estrogens and progestins, very little attention has been paid to the 
androgens which are being used extensively. 
Keeping in view the practical application of these compounds, 
genotoxicity study through a battery of in vitro assays have been 
attempted. Three groups of sex steroidal hormones have been chosen 
viz. (a) estrogens (b) progestins and (c) androgens. Two widely used and 
potent synthetic hormones from each group were evaluated for their 
harmful cytogenetic effects on humans. 
These steroids have been used with a view to study the following 
objectives: 
(1) To study the in vitro effects of the steroids on human lymphocyte 
culturing system. 
(2) To study the toxic effects of the steroids on human lymphocyte 
chromosomes. 
(3) Evaluation of the chromosome damage in parallel in the presence 
of metabolic activation (S^mix). 
(4) To study the effects of the steroids on the frequency of sister 
chromatid exchange (SCE). 
(5) To find the frequency of SCEs when compared in the presence of 
S^  mix, and finally, 
(6) To study the effects of the steroids on cell growth kinetics in the 
presence as well as in the absence of S^  mix. 
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MATERIALS AND METHODS 
The in vitro evaluation of the mutagenic and clastogenic potentials 
of six synthetic sex steroidal hormones were undertaken with human 
peripheral blood lymphocytes. Blood was obtained from healthy voluntary 
donors who were aged between 20-30 years, belonging to both sexes 
and having similarity in socioeconomic status. All the donors were not 
occupationally exposed to any sort of possible mutagens viz. drugs, 
alcohol and irradiation .Each of the six synthetic steroids were tested 
on human lymphocytes. The genetic end points used were chromosomal 
aberrations, sister chromatid exchanges and cell cycle kinetics assays 
in the absence as well as in the presence of exogenous metabolic 
activation system ( S^  mix). 
DESCRIPTION OF TEST CHEMICALS 
The test chemicals evaluated in the present investigation were six 
synthetic steroids, which were all sex steroidal hormones. Two estrogens 
namely mestranol and quinestrol, two progestins namely norethindrone 
and norgestrel, and two androgens namely danazol and oxymetholone 
were investigated. The chemical and physical properties of the test 
chemicals are as following : 
1. ESTROGENS 
(a) MESTRANOL (C^jH^.O^ mol. wt. 310.44) 
CH3O 
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Description : White to creamy white, odorless, crystalline powder; 
melts within a range of 4° between 146° and 154°C. 
Solubility : Freely soluble in chloroform; sparingly soluble in ether; 
slightly soluble in alcohol; insoluble in water. 
Uses : This drug is widely used as oral contraceptive in combination 
with norethynedrel and several other progestins. It suppresses the 
pituitary release of gonadotrophins rather than having antiovulatory 
effect. It is an effective estrogen but it is not marketed as a single entity, 
(b) QUINESTROL (C^jHj^ Mol.wt. 364.53) 
OH 
CH, L C-CH 
Description : White powder; melts at about 108°C. 
Solubility : Practically insoluble in water; soluble in alcohol, 
chloroform or ether. 
Uses : For estrogen replacement therapy, primarily for relief of 
vasomotor symptoms. This cyclopentyl ether of ethinyl estradiol is 
stored in adipose tissue after oral absorption. It is released slowly and 
metabolized to the parental compound. This drug is applied orally. 
2. PROGESTINS 
(a) NORETHINDRONE (C .^H^^O^ mol.wt. 298.42) 
C=CH 
CH,j^OH 
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Description : White to creamy white, odorless, crystalline powder; melts 
at about 205°C; stable in air. 
Solubility : Practically insoluble in water; sparingly soluble in alcohol; 
soluble in chloroform or dioxane; slightly soluble in ether. 
Uses : Among the progestational drugs, it ranks high in its ability to 
postpone menstruation. In addition to its progestational actions it has 
weak estrogenic actions owing to biotransformation to an estrogenic 
metabolite. This steroid is an important oral contraceptive used alone 
or combined with an estrogen especially mestranol and ethinyl estradiol. 
But it is more potent when used in combination. 
(b) NORGESTREL (C^fl^O^, mol. wt. 312.45) 
C=CH 
Description : White or nearly white, practically odorless, crystalline 
powder; melts within a range of 4°, between 205° and 212°C. 
Solubility : Insoluble in water; sparingly soluble in alcohol; freely 
soluble in chloroform. 
Uses : A progestin with potentially all the progestational actions, is 
marketed as an oral contraceptive, both as a single entity product and in 
combination with ethinyl estradiol. It is free from estrogenic activity. It 
has androgenic effects in animals but not in humans. 
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ANDROGENS 
(a) DANAZOL (C^ .H^ .NO^ , mol. wt. 337.46) 
CsCH 
Description : Pale yellow crystalline powder; melts at about 225°C. 
Solubility : Practically insoluble in water; sparingly soluble in alcohol. 
Uses : This drug is an impeded androgen. It binds to androgen, 
glucocorticoid and progesterone receptors, but it evokes no 
glucocorticoid, progestational or estrogenic effects except that it 
suppresses the release of LH and FSH in women. It suppresses ovarian 
steroidogenesis,induces the hepatic metabolism of progesterone and 
binds to a-macroglobulin causing partial displacement of other steroids. 
It is used in the treatment of endometriosis, in patients who do not or 
can not tolerate other drug therapy and in the management of fibrocystic 
breast disease, periareolar abscesses and several other diseases. 
(b) OXYMETHOLONE (C^^H^p^, mol. wt. 332.48) 
OH 
Description : White to creamy white crystals or crystalline powder; 
odorless and stable in air; tautomeric in nature and can exist either as 
tautomer or as a mixture of both and melts at about 175°C. 
Sqlvbility : 1 gm in > 10,000 ml water, 40 ml alcohol, 5 ml chloroform, 
82 ml Q\Tn^x or 14 ml dtdxane. 
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Uses : An androgenic steroid with relatively greater anabolic activity 
than androgenic activity. Consequently, it is employed mainly to promote 
nitrogen metabolism and weight gain in cachexia and debilitating diseases 
and after serious infections, bums, trauma or surgery. It is also used in 
treating osteoporosis, hypoplastic and aplastic anaemias. This drug is 
applied orally. 
SELECTION OF CONTROL CHEMICALS 
(a) NEGATIVE CONTROL (DIMETHYL SULPHOXIDE; DMSO) 
The test chemicals are organic compounds, hence mostly insoluble 
in water. Therefore, the organic compound, dimethyl sulfoxide (DMSO), 
which is being successively employed as a solvent for most of the organic 
chemicals, was used as the solvent for the test chemicals. It has been 
reported to be non-toxic to animals and humans (Prestcj et al.A9S7). 
This solvent control or negative control provides the baseline for the 
comparison of the data to see the significant effects. 
S = O 
Dimethyl Sulphoxide 
(b) POSITIVE CONTROL (CYCLOPHOSPHAMIDE;CP) 
Cyclophosphamide (endoxan) is the most versatile therapeutic drug 
which possesses the broadest spectrum and antitumour activity of all 
alkylating agents (Brock, 1967). It is known to have strong mutagenic 
effects which have been proved many a time on different systems. 
Cyclophosphamide acts by forming DNA- crosslinks by the reaction of 
chloroethyl moieties of CP with adjacent nucleotide bases. It is widely 
used as positive control in in vitro assays due to its potent mutagenic 
and clastogenic nature. 
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Cyclophosphamide 
\SS \Y SYSTEMS VISED 
Most of the cytogenetic studies being carried out involve the 
examination of metaphase chromosomes, mainly because at metaphase, 
chromosomes are thick, short, and chromatids are separate and easily 
visible. Thus, the evaluation of chromosomal damage at metaphase helps 
to study a greater number of dividing figures and gives more precise and 
detailed picture of the clastogenic agents than the anaphase and telophase 
analysis. 
Chromosomal changes can be studied in any cycling cell population, 
or in any non-cycling cell population that can be stimulated by a 
mitogenic agent to enter the cell cycle. In animals there are several cell 
types that fit for these criteria, however for human studies, to all intents 
and purposes, there are only two cell types that are practically suitable. 
These are bone marrow cells, which are a cycling population, and the 
peripheral blood lymphocytes, which are normally non-cycling, but can 
be stimulated to divide and to enter cell cycle by in vitro culturing with 
a mitogen such as phytohaemagglutinin (PHA). However, because of 
the ease of obtaining blood samples, in contrast to bone marrow samples, 
and because these cells are extremely sensitive indicators of the in vixu 
and in vitro induced chromosomal changes (structural and numerical); 
human peripheral blood lymphocytes were utilized for investigating the 
genotoxicity of six selected steroids. The parameters studied included 
chromosomal aberrations, sister chromatid exchange analysis and cell 
growth kinetics assay in the absence as well as in the presence of 
exogei^oMS metaboUc actWatioiv system. 
45 
PREPARATION OF S^  LIVER /MICROSOME FRACTION 
The S^  liver microsomal fraction was the exogenous metabolic 
activation system utilized for the present investigation. It was prepared 
as follows : 
1. INDUCTION OF RAT LIVER ENZYMES : 
For preparing S^  fraction, the standard procedures as recommended 
by Ames et a/ (1975) and Maron and Ames (1983) were followed. Swiss 
albino healthy rats (Wister strain, obtained from Disease Free Small 
Animal House, Haryana Agriculture University, Hissar, India), each 
weighing about 200 gm was given 0.1% (1 mg/ml) of phenobarbitone in 
drinking water for one week for the induction of liver enzymatic 
activities. 
L REMOVAL OF LIVERS FROM THE RATS : 
The rats were sacrificed through cervical decapitation. In order to 
ensure the sterility of S^  preparation, the liver lobes were removed 
asceptically using sterile surgical tools in laminar flow cabinet. Proper 
care was taken not to cut into the oesophagus or the intestine which 
could otherwise cause the contamination of liver homogenate. The 
removed liver lobes were immediately placed in chilled 0.15 M KCl. 
3. PREPARATION OF LIVER HOMOGENATE FRACTION (S, 
FRACTION): 
The whole procedure was carried out at 0-4°C using sterilized 
solutions and glassware. The livers were washed in fresh chilled KCl 
several times so as to remove the traces of haemoglobin which inhibits 
enzyme activity. The washed livers were transferred to a beaker 
containing three volumes of 0.15 M KCl (3 ml/gm wet liver) and after 
mincing with sterile scissors these were homogenized within a tissue 
homogenizer. The homogenate was centrifuged in refrigerated centrifuge 
for 10 minutes at 9000 rotation per minute (rpm). The supernatant (S 
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fraction) was decanted and saved in 1 ml aliquots in polypropylene 
storage vials, and stored in liquid nitrogen till further use. 
4. PREPARATION OF S, MIX : 
The Sg mix from S^  fraction was prepared fresh every time for use 
in the cultures. It contained 0.04 ml/ml S^  fraction, 8 i^M MgClj, 33 ^iM 
KCl, 5 \xM glucose-6-phosphate (G-6-P), 4 ^M NADP, 100 ^M Na^HPO^ 
and NaH2 PO^ buffer with 7.4 pH. 0.8 ml of S^  mix was added every time 
along with the test chemicals in the culture. 
IN VITRO TESTING OF CHROMOSOMAL ABERRATION 
PREPARATION OF CULTURE MEDIA : 
Culture media from RPMI-1640 medium (GIBCO BRL, Life 
Technologies) with L-glutamine and Hepes buffer without NaHCO^ was 
always prepared in advance and stored at 4°C but the storage never lasted 
longer than a week. 10.4 gm of medium was dissolved in 100 ml of 
sterilized distilled water by gentle shaking. Antibiotic - Antimycotic 
[100 X lyophilized (10,000 units/ml pencillin G sodium, 10,000 )ig/ml 
streptomycin sulfate, 25 ng/ml amphotericin B) GIBCO BRL, Life 
Technologies] was also added and the pH was adjusted between 6.8-7.2 
with N/10 NaHCOj and HCl. The media was then filter sterilized in the 
negative pressure millipore filtration assembly by using 0.22 ]xM 
millipore filters. This lOX filtered stock medium was then stored in 
sterilized, and tightly capped glass bottles at 4*'C in dark. 
PREPARATION OF WORKING MEDIA: 
The above prepared stock medium was used for making the working 
media as follows: 10 ml of this stock medium was dissolved in 90 ml of 
sterilized triple distilled water. 20 ml of fetal calf serum (Gibco BRL, 
Life Technologies) was also added. 2 ml of phytohaemagglutinin-M 
(PHA-M; Gibco BRL, Life Technologies) and 1 ml of heparin (500 lU/ 
ml; Micro Lab) was added to the total volume of working media as a 
mitogen and anticoagulant respectively. 
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Preparation of culture media and working media was done under 
sterile condition in the laminar flow cabinet. 
COLLECTION OF BLOOD SAMPLES : 
Peripheral blood was taken from male and female healthy donors 
for each culture. The donors were occupationally not exposed to any 
sort of mutagen. The bloods was taken fresh every time with needles 
(21 gauge) and disposable syringes (steriware). Heparin (500 lU/ml; 
Micro Lab) was used as anticoagulant. The blood was collected in glass 
vials which were tightly capped, gently mixed and stored at 4°C for half 
an hour to separate red blood cells (RBCs) from plasma. 
SETTING OF THE CULTURE: 
Lymphocyte cultures were carried out as per Moorehead et 
a/.(1960) with slight modifications by adding 0.8 ml of plasma containing 
white blood cells (WBCs) in 6ml of working culture media. The culture 
vials were then tightly capped to avoid CO^ loss. This was done under 
laminar flow cabinet and spirit lamp was also used to avoid 
contamination. The culture vials were gently shaken to mix their contents, 
and were incubated at 37°C in dark for 72 hours. Colchicine(0.2 )ig/ml; 
Micro Lab) was added to the culture 2'A hours prior to harvesting to 
arrest the cells at metaphase stage. 
SELECTION OF DOSES : 
Preliminary screening of the steroids with various concentrations 
was undertaken for determining their influence on the mitotic index (MI). 
Only those doses, which did not drastically reduced the MI but yielded 
sufficient number of scorable metaphases, were considered for the final 
experimental protocol. On the basis of these, the lower and the medium 
doses were selected and the highest dose selected was normally the 
maximum tolerated dose (MTD) beyond which the MI showed a steep 
decline. Following these norms the three doses selected for the various 
steroids were : 10, 25 and 50 ng/ml for Mestranol, Quinestrol and 
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Norgestrel and 25, 50 and 100 ^g/ml for Danazol and Oxymetholone. 
The doses selected for Norethindrone were 20, 40 and 75 |ig/ml 
STUDIES ON THE STEROIDS WITHOUT S, Mix : 
In the experiments where no exogenous metabolic activation was 
incorporated, the cultures were exposed to three different 
concentrations of each steroid for 24,48 and 72 hours. For this purpose 
the steroids were added to the cultures at 0, 24 and 48 hours after the 
initiation of cultures for 72, 48 and 24 hours of exposure 
respectively.Positive (Cyclophosphamide or CP,lxlO-'M) and negative 
(Dimethyl sulphoxide or DMSO, 5 \i\/m\) control cultures were also 
simultaneously set for all treatment durations. 
STUDIES ON THE STEROIDS WITH S, MIX: 
In the metabolic activation experiments, 30 hours old cultures were 
given six hours treatment with different concentrations of each steroid 
in the presence of S^ mix. 
The cells were collected after centrifugation and the pellet was 
washed twice in the pre-warmed medium to remove the chemical and 
the S^mix. Parallel cultures receiving the same dose of the steroids for 
similar treatment duration but without S^  mix were also simultaneously 
set for comparison. DMSO (5 \A/va\; SRL, Mumbai) and CP (1 x 10"' M; 
Khandelwal Labs, Mumbai) were used as negative and positive controls 
respectively in these metabolic activation experiments. 
HARVESTING OF THE CULTURES: 
After the 72 hours of cultures being completed, the culture vials 
were taken out from the incubator. These were gently shaken to mix their 
contents and then transferred to different centrifuge tubes. The cells 
were spundown by centrifugation (10 minutes; 1200 rpm) and the 
supernatant discarded. Pre-warmed hypotonic solution (0.075 M KCl) 
was added to the centrifuge tubes, while shaking continuously with the 
help of cyclomixer. 
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Hypotonic treatment (0.075 M KCl) was carried out for 10-12 
minutes at 37°C and the cells recollected by centrifugation. The cell 
pellet was suspended in 7 ml freshly prepared chilled fixative (3:1 ;: 
Methanol: Acetic acid) which was added drop by drop with a pasteur 
pipette while continuously shaking the pellet so as to avoid formation 
of clots. In order to ensure proper fixation, the cells were kept suspended 
in the fixative for a minimum period of one hour but preferably overnight. 
The cells were washed thrice with fresh fixative before preparing the 
slides. 
PREPARATION OF SLIDES AND STAINING: 
After giving the final washing in the fixative, the cells were 
resuspended in 0.2 ml of fresh fixative. Two to three drops of this cell 
suspension were dropped on clean, grease free, pre-chilled and wet 
microscope slides which were then air dried. 
One-day old slides were stained in 5% Giemsa (Loba Chem, India) 
for 3 minutes. After that the slides were rinsed in triple distilled water 
and then air dried. The slides were dipped in xylene for 5 minutes before 
mounting in DPX (BDH). 
ANALYSIS OF THE CELLS: 
In order to avoid bias in scoring of the chromosomal anomalies, 
all slides were coded prior to scoring. A total of 300 well spread 
metaphases were analysed for each concentration of the steroid and for 
each time duration, to analyze various chromosome and chromatid type 
aberrations. For scoring various chromosome and chromatid type 
aberrations, the following method as described by Savage (1975) and 
Bloom (1981) was followed. 
A. CHROMOSOME TYPE ABERRATIONS: 
Analysis of chromosomal aberrations included the following 
parameters : 
1. Terminal and interstitial deletions 
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2. Asymmetrical interchanges (usually dicentrics) 
3. Asymmetrical interchange (centric ring) 
4. Symmetrical interchanges (reciprocal translocations) 
5. Symmetrical interchanges (peri-and paracentric inversions) 
B. CHROMATID TYPE ABERRATIONS: 
Chromatid-type aberrations are generally classified in the same way as 
chromosome-type aberrations. The apparent unit of involvement in a 
chromatid-type aberration is, in most cases, the single chromatid, and 
not the whole chromosome as seen for chromosome type aberrations. 
The examination of the chromatid type aberrations considered the 
following parameters: 
1. Terminal deletions: 
2. Interstitial deletions 
3. Achromatic lesions ("gaps") 
4. Isochromatid deletions 
5. Asymmetrical interchanges (interarm interchanges, asymmetrical 
chromatid exchanges) 
6. Symmetrical interchanges (symmetrical chromatid exchanges 7. 
Asymmetrical and symmetrical intrachanges ( interarm 
intrachanges) 
8. Triradials 
C. MULTIPLE ANOMALIES: 
1. Polyploidy : An increase in the chromosome number in excess of 
diploid set in multiple of the haploid (N) number. 
2. Endoreduplications: The chromosome reduplication occurring in 
the absence of sister chromatid separation. 
3. Cells with multiple anomalies: The cells with 10 or > 10 aberrations. 
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4. Pulverization: The extreme fragmentation of the chromatin material. 
SISTER CHROMATID EXCHANGE (SCE) ANALYSIS: 
Mechanism of the sister chromatid exchange (SCE) detection 
: Sister chromatid exchange is a sensitive, rapid and objective method 
of observing reciprocal exchanges between sister chromatids. This 
method depends upon the phenomenon of 5-bromo-2-deoxyuridine 
(BrdU), an analogue of thymidine, incorporation into DNA in place of 
thymidine. After two rounds of cell division the chromatids are labelled 
with BrdU and consequently get differentially stained with Hoechst stain. 
The BrdU incorporation quenches the fluorescence of the fluorochrome 
33258 Hoechst. Therefore, the light energy is absorbed but not emitted 
by such dyes which results in the reduced staining of chromatid with 
Giemsa (Latt and Wolleb, 1975; Latt, 1976). 
Labelling of chromosomes with BrdU: Sister chromatid exchange 
analysis was carried out following the standard procedure of Latt et al. 
(1981) with suitable modifications. The cells in the cultures were 
exposed to nucleoside, BrdU (Sigma) after 24 hours of initiation of 
cultures, at the final concentration of 2 |ig/ml. The culture vials were 
tightly capped and covered with tin foil to avoid light exposure and 
incubated at 37°C for another 48 hours in the dark. 
Studies on the steroids without S, mix: After 48 hours of the initiation 
of cultures, three different log doses of each of six steroids were added 
into these cultures which did not contain any S^  mix. The culturing was 
further continued for 24 hours. Positive (CP, 1x10'M), negative (DMSO, 
5 p.l/ml) and untreated (normal) controls were also simultaneously 
studied. The detailed information regarding donors, doses, durations 
etc. has already been described. 
STUDIES ON THE STEROIDS WITH S,M1X: The steroids along with 
Sg mix was added into the cultures after 48 hours of its initiation and 
were reincubated at 37°C. After 90 minutes of pulse treatment, the cells 
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were spun down and supernatant discarded. The cells were then washed 
with pre-warmed medium twice so as to remove the traces of the steroids 
and liver metabolites. Finally, the cell pellets were resuspended in fresh 
and warm working media supplemented with fetal calf serum, PHA-P, 
antibiotics- antimycotic and BrdU, and cultured for another 24 hours in 
the dark at 37°C. In order to compare the effects of the steroids with and 
without metabolic activation, parallel cultures with same concentrations 
of the steroids and same exposure durations but without S^  mix were 
also simultaneously set. Positive (CP, IxlO'M), negative (DMSO, 5|il/ 
ml) and untreated (normal) controls in the presence of S^  mix were also 
simultaneously studied. 
Slide preparation and staining: After 2Vi hours of colchicine 
treatment, the cultures were harvested and processed following the same 
procedure as described for the chromosomal aberration analysis. 
The methods of Perry and Wolff (1974) and Latt eX al. (1981) with 
slight modifications were followed for the differential staining of SCEs. 
One day old slides were dipped in 0.5 }ig/ml of 33258 Hoechst stain 
(Sigma) dissolved in double distilled water in horizontal couplin jar. The 
slides were rinsed twice in distilled water. The air-dried slides were then 
put in flat glass dish with the layer of cells facing upwards. These were 
covered by thick layer (2-3 cm) of phosphate buffer (pH 6.8) and 
exposed to UV lamp (15W, 254 nm; Philips) from a distance of 10-15 
cm for 30-45 minutes. The slides were taken out from the buffer, washed 
twice in double distilled water and air dried. These were then incubated 
in 2XSSC (0.3M sodium chloride, 0.3M sodium citrate, pH 7.0) at 65°C 
in water bath for 90 minutes using vertical couplin jars. The slides were 
taken out and rinsed in distilled water. The air dried slides were then 
stained in giemsa for 3 minutes and again rinsed in distilled water. The 
dried slides were dipped in xylene for 5 minutes and mounted in DPX. 
Analysis of the cells: All slides were coded prior to scanning so as to 
avoid any confusion. 50 second-division metaphases with differentially 
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stained chromatids were scored for each steroid treatment in the absence 
as well as in the presence of S^  mix. The interstitial exchanges between 
two sister chromatids were scored as two exchanges and the terminal 
exchanges were scored as a single exchange. Students't' test was applied 
for calculating the significance of difference between the treated and 
the controls. 
CELL CYCLE KINETICS: 
The cells undergoing first (M,), second (Mj) and third (M3) division 
were detected by studying the BrdU labelled differentially stained 
chromosomes following the methodology of Tice et al. (1976) and 
Crossen and Morgan (1977). The cells with both the chromatids being 
darkly stained were scored as M, cells while those with one dark and 
one lightly stained chromatids as M^ cells, and those having mixture of 
both the differentially stained and uniformally stained chromatids were 
scored as M^ metaphases. 50 well spread metaphases were scored for 
each concentration and each treatment duration from each donor in the 
absence as well as in the presence of S^ mix. The replication index (RI) 
was calculated according to the formula of Tice et al (1976) as given 
below. The deviation from the controls was determined by using Chi-
Square test. 
RI = (M^l )+(M2X2.)+(M3X3)/100 
STATISTICAL ANALYSIS: 
Standard deviation (SD) and standard error (SE) were calculated 
using the following formula -
Mean X = X/n 
Variance 6^= X ' - I x ' ^ / n - l 
5 = VX2-Zx-2/n-l 
SE = SD/ViT 
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where x = variable 
n = number of observations 
Sx^ = sum of square of individual variables 
X= Mean of variables 
2x3 Chi-Square test (x^) for homogeneity test of variance was used 
to analyse the cell growth kinetics with the normal control. The level of 
significance was tested from standard statistical tables of Fisher and 
Yates (1963). 
The endoreduplication, ploidies, pulverizations and cells with 
multiple anomalies were not included in the statistical analysis. 
Student's two tailed 't' test was used for calculating the statistical 
significance in SCE and chromosomal aberrations by comparing the 
effects induced by different steroids with the respective controls. 
Following formula was used for this purpose. 
Xj (control) - X^ (treated) 
t = -
V(SE of control)2+(SE of treated)^ 
The statistical significance was calculated from Fisher and Yates 
table at (n,+n2-2) degree of freedom (df) at 0.05% level of significance 
(P)-
^^^e^i^^^ 
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RESULTS 
The following drugs were evaluated for their genotoxic effects on 
human lymphocytes. The students 't' test (paired) was applied for 
chromosomal aberrations and sister chromatid exchanges. The 2x3 chi-
square test was used for cell growth kinetics studies. The level of 
significance was compared at P < 0.05 for all parameters. 
1. ESTROGENS 
1. Mestranol 
(a) Chromosomal aberrations: 
The results of chromosomal aberration analysis are presented in 
table 3. At 10 mg/ml of dose, the drug was not effective at any exposure 
duration. At 24, 48 and 72 hours of incubation, the percentage of 
chromosomal aberrations were 3.67%, 4.67% and 5.00% respectively. 
These values were not significant as compared to the normal control 
value (3.00%). The percentage of aberrant metaphases were not 
significantly high. At 25 mg/ml of dose concentration, the drug affects 
both the aberrant metaphases as well as chromosomal aberration 
frequency. At 24, 48 and 72 hours of incubation the percentage of 
chromosomal aberrations were 18.00%, 22.00% and 27.00% respectively 
which were highly significant at P < 0.05 compared to the normal control 
value (Figures A-C in Appendix). However, peculiar results from 
observations were obtained at the highest concentration (i.e. 50 mg/ml). 
The frequency of chromosomal aberrations and aberrant metaphases 
decreased (as compared to the 25 mg/ml dose) and significant difference 
was noted at all exposure times. The decrease in the chromosomal 
aberration may be attributed to the toxic effects of the drug at this 
concentration on the mitotic index. The values observed were only 5.00%, 
6.00% and 6.67% respectively for 24, 48 and 72 hours of exposure. The 
CP gave a significant increase in the frequency of aberrant metaphases 
and ohfomospmal aberrations (29.00%, 52.00% and 66.67%) for all 
exposure ttnaes i.^ 24, 48 and 72 hours of incubation. 
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The results of the frequency of chromosomal aberrations in 
lymphocytes after mestranol treatment in the presence of metabolic 
activation is given in table 4. Again at lower concentration (i.e. 10 mg/ 
ml) the aberration frequency was low. The percentage of aberration was 
4.50%. This value was insignificant as compared to the normal control 
value i.e. (4.00%). At 25 mg/ml of concentration the aberration 
percentage was 29.50%. This value was significantly high statistically 
(at p < 0.05) (Figures D & E in Appendix). When the dose was increased 
i.e. at 50 mg/ml concentration, the aberration frequency decreased i.e. 
it became 10.00%. This value was not significantly high. The aberration 
percentage for CP was 49.50% which was highly significant statistically. 
(b) Sister Chromatid Exchange (SCE): 
Data on the mean frequency of sister chromatid exchange per cell 
in human lymphocytes after mestranol treatment is presented in table 5. 
At 10 mg/ml of dose concentration the value of mean SCE frequency 
was 1.90±0.099. This value was not significant. At 25 mg/ml of dose 
concentration, the mean SCE frequency was 5.04±0.224 which was highly 
significant as compared to the normal control value (i.e. 1.10±0.099) at 
p < 0.05. But when the dose was further increased to 50 mg/ml, the value 
of mean SCE frequency showed a steep decline. It was only 1.78±0.017. 
The drug was found to be effective in enhancing the SCE frequency only 
at 25 mg/ml of concentration. The mean SCE frequency for CP was 
6.36±0.152, which was highly significant compared to the normal control 
value. 
Table 6 documents the mean SCE value per cell in human 
lymphocytes after mestranol treatment in the presence of metabolic 
activation (S^mix). At 10 mg/ml dose concentration the value of mean 
SCE was 1.74±0.126. This value was insignificant. At 25 mg/ml 
concentration, there was a significant increase in the SCE frequency i.e. 
5.38±0.180 as compared to the value of normal control (1.46±0.090). 
At the highest concentration (i.e. 50 mg/ml), the drug slightly enhanced 
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Table 3 : Chromosomal aberrations in human lymphocytes after Mestranol 
treatment. 
Treat- Dura- Meta- Percent aberration Types of aberration (%) Aberration/ 
ment tion(h) phase Metaphase Chro- Chro- Total Cell + SE 
(UgAnl) Sea- Incl. Exd. matid mosome 
nned gap g ^ 
Mestranol 
10 24 300 4.33 2.67 3.67 0.00 3.67 0.04±0.028 
48 300 6.00 3.67 4.67 0.00 4.67 0.05±0.029 
72 300 6.67 4.33 4.67 0.33 5.00 0.05±0.029 
25 24 300 10.67 10.33 10.67 7.33 18.00* 0.18±0.045 
48 300 16.67 14.33 11.67 10.33 22.00* 0.22±0 057 
72 300 32.67 31.00 15.33 11.67 27.00* 0.27±0.060 
50 24 300 5.67 2.67 4.33 0.67 5.00 0.05± 0.029 
48 300 6.00 4.33 4.67 1.33 6.00 0.06±0.028 
72 300 6.33 6.00 5.00 1.67 6.67 0.07±0.027 
Control 
Normal 72 300 4.33 2.33 2.67 0.33 3.00 0.03±0.026 
DMSO 
(5^1/ml) 72 300 4.00 2.00 2.33 0.67 3.00 0.03±0.026 
(-ve control) 
CP(lxlO-'M) 24 300 14.33 13.67 15.33 13.67 29.00* 0.29±0 048 
(+vecontrol) 48 300 19.67 18.67 28.00 24.00 52.00* 0.52±0.066 
72 300 28.67 27.33 39.00 27.67 66.67* 0.67± 0.070 
CP 
SE 
Cyclophosphamide; DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
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Table 4 : Chromosomal aberrations in human lymphocytes after Mestranol 
treatment with and without metabolic activation (S, mix). 
Treat- Meta- Meta- Percent aberration Types of aberration (%) Aberration/ 
bolic phase Metaphase 
Acti- Sea- Incl Exd 
vation nned gap gap 
ment Chro- Chro- Total Cdl±SE 
(|ig/inl) matid mosome 
Mestranol 
10 -S, 300 6.33 3.67 3.67 0.00 3 67 0.04±0.028 
+S, 200 8 50 4.50 4.00 0.50 4 50 0.05±0.035 
25 -S , 300 14.67 11.33 10.67 8.67 19.34* 0.19±0.040 
+S, 200 19.50 15.00 16.00 13.50 29.50* 0.30±0.052 
50 -Sg 300 5 33 4.33 4.33 1.00 5.33* 0.05± 0.028 
+S, 200 5.00 3.50 6.50 3.50 10.00* O.lOttO.055 
Control 
Normal -S, 300 3 67 2.33 3.00 0.33 3.33 0.03±0.027 
+S, 200 4.00 2.00 3.50 0.50 4.00 0.04±0.035 
DMSO -S, 300 4 33 1 67 3 00 0 67 3 67 0 04±0.028 
(5MIW) 
(-ve control) +S, 200 4 50 2 00 2 50 1.00 3 50 0.04±0.034 
CP(lxlfrT^-S, 300 16.67 14.67 17 00 16 33 33 33* 0.33±0 027 
(+ve control) 
+S„ 200 20 00 19.00 26 50 23.00 49 50* 0.50±0 028 
CP 
SE 
* 
Cyclophosphamide, DMSO Dimethyl sulphoxide 
Standard error 
Significant at P<0 05 
Table 5 
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Sister Chromatid Exchange (SCE) in human lymphocytes after 
Mestranol exposure in vitro. 
Treatment 
(Mg/ml) 
Mestranol 
10 
25 
50 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration (h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
95 
252 
89 
55 
64 
318 
Range 
0-6 
2-10 
0-5 
0-4 
0-4 
3-13 
SCEs/Cell ±SE 
1 90±0 099 
5 04±0 224* 
1 78±0 017 
1 10±0 099 
1 28±0 110 
6 36±0 152* 
Table 6 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Mestranol exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Mestranol 
10 
25 
50 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration (h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
87 
269 
95 
73 
63 
389 
Range 
1-6 
2-11 
1-5 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1 74±0 126 
5 38±0 180* 
1 90±0 117 
1 46±0 090 
1 26±0 093 
7 78±0 150* 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 7 : Analysis of cell growth kinetics after Mestranol exposure in vitro. 
Treatment 
(Mg/ml) 
Mestranol 
10 
25 
50 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CPClxlO'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
36 
62 
33 
32 
34 
65 
M, 
55 
33 
54 
55 
50 
33 
in 
Ms 
09 
05 
13 
13 
16 
02 
Replication 
Index 
1.73 
1.43* 
1.80 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Significant 
Not significant 
Significant 
Table 8 : Analysis of cell growth kinetics after Mestranol exposure with 
metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Mestranol 
10 
25 
50 
Control 
Normal 
DMSO (SuVml) 
(-ve control) 
CP(lxl0- ' 'M) 
(+ve control) 
Cell 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
H 
36 
60 
39 
34 
33 
66 
M. 
53 
34 
50 
54 
53 
29 
in 
M3 
11 
06 
11 
12 
14 
05 
Replication 
Index 
1.75 
1.46* 
1.72 
1.78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Significant 
Not significant 
Significant 
CP 
SE 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
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the frequency of SCE (].90±0.117) in comparison to normal control 
value. But this value was not significant statistically. The SCE frequency 
of CP was 7.78±] .50 which was highly significant. 
(c) Cell growth kinetics: 
The data of the cell growth kinetics in human lymphocytes after 
mestranol treatment is given in table 7. The replication index at 25 mg/ 
ml concentration was significant (1.43) when compared to the normal 
control value (1.81). At lowest and highest dose concentration i.e. 10 
and 50 mg/ml, the values of replication indices were not significant (1.73 
and 1.80 respectively). The CP was found to be effective and also 
significant at P < 0.05 (1.37). Table 8 shows the effect of mestranol on 
cell growth kinetics of human lymphocytes in the presence of metabolic 
activation. The value of replication index was found to be significant 
only at 25 mg/ml concentration (1.46) as compared to the normal control 
value (1.78) at P < 0.05. At 10 and 50 mg/ml concentration the value of 
of replication indices obtained were found to be insignificant (1.75 and 
1.72 respectively). The positive control value (CP) was 1.38 which was 
significant statistically. 
2. Ouinestrol 
(a) Chromosomal aberrations: 
Table 9 summarises the data on the chromosomal aberration 
influenced by the drug quinestrol on human lymphocyte chromosomes. 
At 10 mg/ml of dose concentration the aberration frequency observed 
was 4.33%, 3.67% and 9.00% for 24, 48 and 72 hours of exposure 
durations. The aberration percentage at 10 mg/ml for 72 hours of 
exposure was significant. When the dose was increased i.e. at 25 mg/ml 
concentration, the aberration percentage observed, showed an increase 
with the increase in exposure duration (Figures F-H in Appendix). The 
actual values observed were 18.66%, 22.67% and 39.66% for 24, 48 
and 72 hours of exposure respectively. These values are significantly 
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higher than the normal control value (i.e. 3.00%) at P < 0.05. At the 
highest dose concentration i.e. at 50 mg/ml, the aberration frequency 
first increased but decreased later on with the increase in exposure 
duration. The aberration percentage for 24 hours of exposure was 33.67% 
which was highly significant statistically in comparison to the normal 
control value. But for 48 and 72 hours of exposure durations the 
percentage of aberrations were 6.00% and 4.33% respectively. This 
interesting result may be attributed to cell death at the highest 
concentration and for longer exposure duration. The positive control, 
CP, being a potent mutagen, influences the rate of aberration at all 
exposure duration (i.e. 29.00%, 52.00% and 66.67% respectively for 
24, 48 and 72 hours of exposure duration). 
The effects of quinestrol on human lymphocytes in the presence 
of metabolic activation (S^ mix) has been presented in table 10. The mean 
percentage value at 10 mg/ml was 9.50% in the presence of S^  mix, which 
was significantly higher than the aberration value observed for normal 
control (4.00%) at P < 0.05. At 25 mg/ml of dose concentration, the 
drug enhanced the rate of aberration (22.50%) which was highly 
significant at P < 0.05.At 50 mg/ml of dose concentration the value of 
aberration percentage observed was 51.50% which was again highly 
significant statistically in comparison to the normal control value 
(Figures I & J in Appendix). Thus a dose time relationship was observed. 
For positive control the value was again significantly high (49.50%). 
(b) Sister Chromatid Exchange: 
Table 11 shows the effect of quinestrol on the frequency of SCE in 
human lymphocytes. At 10 mg/ml concentration the mean SCE frequency 
observed was 1.72±0.100. Maximum SCE frequency was observed at 25 
mg/ml dose concentration (3.50±0.140). At the highest dose 
concentration the value of mean SCE frequency observed was maximum 
(2.38±0.090). Thus at all the dose concentrations the mean SCE values 
observed were significantly higher than the normal control value 
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(1.10±0.099) at P< 0.05. The data of the mean SCE frequency value of 
the positive control was 6.36±0.152. This value was highly significant 
compared to the normal control value. 
The data of SCE frequency in human lymphocytes after quinestrol 
exposure in the presence of metabolic activation is presented in table 
12. The value observed at 10 mg/ml concentration was not significant 
(1.84±0.086) as compared to the normal control value (1.46±0.090). 
AT 25 and 50 mg/ml concentration the mean SCE values observed were 
3.78±0.099 and 4.68±0.100 respectively. Both these values were highly 
significant as compared to the normal control value at P < 0.05. The 
slight increase in the observations in the presence of S^ mix in 
comparison to the values observed in the absence of S^  mix may be due 
to the metabolic activation of the drug by liver enzymes. The value for 
CP was 7.78±0.150 which was highly significant at P < 0.05. 
(c) Cell growth kinetics: 
The effect of quinestrol on the cell growth kinetics of human 
lymphocytes is presented in Table 13. No significant effect of the drug 
was observed at the lowest (10 mg/ml) concentration. The replication 
index (RI) was 1.74 for 10 mg/ml concentration of the drug. At 25 and 
50 mg/ml of dose concentrations, lower replication indices were observed 
(i.e. 1.46 and 1.40 respectively). These values were significant as 
compared to the normal control value (1.81) at P < 0.05. CP also showed 
a decrease in the replication index (1.37) which was significant at P < 
0.05 in comparison to the normal control value. 
Table 14 represents the data of the effect of quinestrol on the cell growth 
kinetics of human lymphocytes in the presence of metabolic activation (S^ 
mix). Here also the Rl was higher for 10 mg/ml concentration, the value 
observed was 1.75. The value was not significant statistically compared to 
the normal control (178). At 25 and 50 mg/ml, the replication indices 
observed were 1.46 and 1.43 which were highly significant in comparison to 
the normal control value of 1.78 (at P < 0.05). The observed value for CP 
was 1.38 which was highly significant. 
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Table 9 : Chromosomal aberrations in human lymphocytes after Quinestrol 
treatment. 
Treat- Dura-
ment tiai 
(Mg/ml) (h) 
Quinestrol 
10 24 
48 
72 
25 24 
48 
72 
50 24 
48 
72 
Meta-
phase 
Sca-
nned 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent aberration 
Metaphase 
Incl. 
gap 
5.43 
7.00 
7.22 
12.33 
24.67 
38.67 
28.00 
36.33 
42.67 
Excl. 
gap 
3.33 
5.33 
5.67 
12.33 
21.33 
36.00 
26.67 
35.33 
42.00 
Types of aberration (%) 
Chro-
matid 
4.33 
3.67 
5.67 
14.33 
16.00 
22.33 
19.00 
4.67 
3.00 
Chro-
mosome 
0.00 
0.00 
3.33 
4.33 
6.67 
17.33 
14.67 
1.33 
1.33 
Total 
4.33 
3.67 
9.00* 
18.66* 
22.67* 
39.66* 
33.67* 
6.00 
4.33 
Aboration/ 
CelUSE 
0.04±0.029 
0.04±0.028 
0.09±0.043 
0.19±0.041 
0.23±0.040 
0.40±0.043 
0.34±0.043 
0.06±0.028 
0.04±0.029 
Control 
Normal 72 
DMSO 
(5nl/ml) 72 
(-ve control) 
CP(lxlO'M) 
0.29±0.048 
300 4.33 2.33 2.67 0.33 3.00 
300 4.00 2.00 2.33 0.67 3.00 
24 300 14.33 13.67 15.33 13.67 
0.03±0.026 
0 03±0.026 
29.00* 
(+ve control) 
0.52±0.066 
48 300 19.67 18.67 28.00 24.00 52.00* 
72 300 28.67 27.33 39.00 27.67 66.67* 0.67± 0.070 
CP 
SE 
Cyclophosphamide; DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
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Table 10 : Chromosomal aberrations in human lymphocytes after Quinestrol 
treatment with and without metabolic activation (S, mix). 
Treat- Meta- Meta- Percent aberration Types of aberration (%) 
ment bolic phase Metaphase Chro- Chro- Total 
(Hg/ml) Acti- Sea- Incl Bed matid mosome 
vation nned gap g^ 
Aberration/ 
CelliSE 
Quinestrol 
10 
25 
50 
Control 
Noimal 
DMSO 
(5M]/ml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
-s, 
-^ s, 
-s. 
+s. 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
6 67 
9 00 
12 67 
17 50 
28 33 
31 00 
3 67 
4 00 
4 33 
4 50 
16 67 
20 00 
4 33 
5 50 
7 00 
15 00 
26 00 
30 00 
2 33 
2 00 
1 67 
2 00 
14 67 
19 00 
3 33 
7 00 
1100 
15 50 
23 33 
29 00 
3 00 
3 50 
3 00 
2 50 
17 00 
26 50 
100 
2 50 
5 00 
700 
19 33 
22 50 
0.33 
0 50 
0 67 
100 
16 33 
23 00 
4 33 
9 50* 
16 00* 
22 50* 
42 66* 
51 50* 
3 33 
4 00 
3 67 
3 50 
33 33* 
49 50* 
0 04±0 029 
0 10±0 027 
0 16±0 028 
0 23±0 030 
0 43±0 033 
0 52±0 050 
0 03±0 027 
0 04±0 035 
0 04±0 028 
0 04±0 034 
0 33±0 027 
0 50± 0 028 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 11 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Quinestrol exposure in vitro. 
Treatment 
(Mg/ml) 
Quinestrol 
10 
25 
50 
Control 
Normal 
Duration 
(h) 
48 
48 
48 
48 
DMS0(5^1/ml) 48 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
48 
No. of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
86 
175 
214 
55 
64 
318 
Range 
0-6 
1-8 
1-7 
0-4 
0-4 
3-13 
SCEs/Cell ±SE 
1.72±0.100 
3.50±0.140* 
4.28±0.090* 
1.10±0.099 
1.28±0.110 
6.36±0.152* 
Table 12 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Quinestrol exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Quinestrol 
10 
25 
50 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
C P ( l x l O ' ' M ) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No. of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
92 
189 
234 
73 
63 
389 
Range 
0-7 
1-8 
1-7 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1.84±0.086 
3.78±0.099* 
4.68±0.100* 
1.46±0.090 
1.26±0.093 
7.78±0.150* 
CP 
SE 
Cyclophosphamide; DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
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Table 13 : Analysis of cell growth kinetics after Quinestrol exposure in vitro. 
Treatment 
(Mg/ml) 
Quinestrol 
10 
25 
50 
Control 
Normal 
DMS0(5MJ/ml) 
(-ve control) 
CP(lxlO-' 'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cell; 
M, 
40 
58 
62 
32 
34 
65 
M, 
42 
38 
36 
55 
50 
33 
sin 
M3 
18 
04 
02 
13 
16 
02 
Replication 
Index 
1.74 
1.46* 
1.40* 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Significant 
Significant 
Significant 
Table 14 : Analysis of cell growth kinetics after Quinestrol exposure with meta-
bolic activation (S, mix). 
Treatment 
(Mg/ml) 
Quinestrol 
10 
25 
50 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxlO- 'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, 
37 
61 
60 
34 
33 
66 
M. 
51 
32 
37 
54 
53 
29 
in 
Ms 
12 
07 
03 
12 
14 
05 
Replication 
Index 
1.75 
1.46* 
1.43* 
1.78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Significant 
Significant 
Significant 
CP 
SE 
Cyclophosphamide; DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
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n. PROGESTINS 
1. Norethindronc 
(a) Chromosomal aberrations: 
Table 15 documents the effects of the drug norethindrone on the 
chromosomal aberration frequency of human lymphocytes. A wide range 
of concentrations (i.e. 20, 40 and 75 mg/ml) of the drug were used to 
see the genotoxic effects. It did not show any significant increase in the 
frequency of chromosomal aberrations at any of the concentrations nor 
were they effective at any exposure time. The percentage of aberrations 
observed at 20 mg/ml were 2.67%, 4.67% and 4.34%. AT 40 mg/ml these 
values were 5.66%, 5.33% and 4.67% and at 75 mg/ml the values observed 
were 5.00%, 8.00% and 8.34%. Three different values were observed at 
each dose concentration for three different exposure durations i.e. 24, 
48 and 72 hours respectively. All these values were statistically 
insignificant as compared to the normal control value i.e. 3.00%. The 
aberration caused by CP were 29.00%, 52.00% and 66.67% respectively 
for 24, 48 and 72 hours of exposure durations. These values were highly 
significant in comparison to the normal control value at P < 0.05. 
The effects of norethindrone on chromosomal aberration frequency 
of human lymphocytes in the presence of metabolic activation has been 
described in table 16. The drug was found to be unable to induce any 
clastogenic effect in this case. At 20, 40 and 75 mg/ml concentrations, 
the aberration percentages observed were 4.00%, 5.50% and 6.00% 
respectively. These values were not significant statistically as compared 
to the normal control value (4.00%). The CP in the presence of S, mix 
induces a significant genotoxic effect on the human lymphocytes. The 
aberration frequency observed for CP was 9.50%. 
(b) Sister Chromatid Exchange: 
The results of SCEs induced by norethindrone in human 
lymphocytes has been summarised in table 17. The mean SCE frequencies 
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of the drug at 20, 40 and 75 mg/ml of dose concentrations were 
1.18±0.055, 1.24±0.060 and 1.30±0.066 respectively. These values were 
not significant statistically compared to the normal control value 
(1.10±0.099). The mean SCE frequency was enhanced by the positive 
control drug (CP) and the value observed was 6.36±0.152 which was 
highly significant. 
Norethindrone did not prove to be effective in enhancing the SCE 
frequency in human lymphocytes even in the presence of S^  mix at any 
of the dose concentrations. The results have been presented in table 18. 
The mean SCE frequency values at 20,40 and 75 mg/ml were 1.30±0.065, 
1.24±0.060 and 1.34±0.067 respectively. All these values were not 
significant at P < 0.05 as compared to the normal control value i.e. 
1.46±0.090. Cyclophosphamide was able to enhance SCE frequency 
(7.78±0.150) which was highly significant statistically compared to the 
normal control value. 
Thus, the drug norethindrone was not able to induce chromosomal 
aberrations or to enhance SCE frequency in human lymphocytes. 
(c) Cell Growth Kinetics: 
Table 19 shows the analysis of cell growth kinetics after 
norethindrone exposure in human lymphocytes. The 2x3 chi-square test 
indicated no significant deviations from the normal control culture. The 
values of replication indices at 20,40 and 75 mg/ml concentrations were 
1.79, 1.81 and 1.75 respectively which were not significant as compared 
to the normal control value (1.81) at P < 0.05 whereas the replication 
index for CP was 1.37 which was statistically significant in comparison 
to the normal control value. 
The effects of norethindrone on cell growth kinetics of human 
lymphocytes have been shown in table 20. Again the values of replication 
indices obtained at different concentrations were not significant when 
statistically compared to the normal control value. The actual values 
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Table 15 : Chromosomal aberrations in human lymphocytes after 
Norethindrone treatment. 
Treat-
ment 
{[ig/rd) 
Dura-
tion 
(h) 
Norethindrone 
20 
40 
75 
Control 
Normal 
DMSO 
(5nl/ml) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
(-ve control) 
CP(lxlO-^M) 
0 29±0.048 
(+ve control) 
0 52±0.066 
72 
Meta-
phase 
Sca-
nned 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
24 
48 
300 
Percent aberration 
Metaphase 
Incl 
gap 
5 00 
6 33 
6 33 
7 00 
6 67 
7 33 
7 00 
7 67 
8 00 
4 33 
4 00 
300 
300 
28 67 
Excl 
gap 
100 
2 33 
1 33 
2 00 
167 
3 00 
3 00 
4 33 
3 67 
2 33 
2 00 
14 33 
19 67 
27 33 
Types 
Chro-
matid 
2 67 
4 00 
3 67 
4 33 
4 33 
3 67 
3 00 
5 33 
5 67 
2 67 
2 33 
13 67 
18 67 
39 00 
of aberration (%) 
Chro-
mosome 
0 00 
0 67 
0 67 
1 33 
1 00 
100 
2 00 
2 67 
2 67 
0 33 
0 67 
15 33 
28 00 
27 67 
Total 
2 67 
4 67 
4 34 
5 66 
5 33 
4 67 
5 00 
8 00 
8 34 
3 00 
3 00 
13 67 
24 00 
66 67* 
Aberration/ 
CelliSE 
0 03±0 025 
0 05±0 029 
0 04±0 029 
0 06±0 029 
0 05±0 029 
0 05±0 025 
0 05±0 029 
0 08±0 023 
0 08±0 021 
0 03±0 026 
0 03±0 026 
29 00* 
52 00* 
0 67±0 070 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 16 : Chromosomal aberrations in human lymphocytes after Norethindrone 
treatment with and without metabolic activation (S, mix). 
Treat- Meta- Meta- Percent aberration Types of aberration (%) Aberration/ 
ment bolic phase Metaphase Chro- Chro- Total Cell±SE 
(Hg/ml) Acti- Sea- Incl Excl. matid mosome 
vation nned gap gap 
Norethindrone 
20 -S, 300 5.33 1.67 2.67 0.00 2.67 0.03±0.025 
+S, 200 7.50 3.50 3.50 0.50 4.00 0.04±0.035 
40 -S, 300 7.67 2.67 2.33 0.00 2.33 0.02±0.024 
+S, 200 5.50 3.50 4.50 1.00 5.50 0.06±0.035 
75 -S, 300 6.00 1.67 3.00 1.00 4.00 0.04± 0.028 
+S, 200 8.50 5.00 4.50 1.50 6.00 0.06±0.035 
Control 
Nonnal -S, 300 3.67 2.33 3.00 0.33 3.33 0.03±0.027 
+S, 200 4.00 2.00 3.50 0.50 4.00 0.04±0.035 
DMSO -S, 300 4.33 1.67 3.00 0.67 3.67 0.04±0.028 
(5nl/ml) 
(-ve control) +S, 200 4.50 2.00 2.50 1.00 3.50 0.04±0.034 
CP(lxlO '^M) -S, 300 16.67 14.67 17.00 16.33 33.33* 0.33±0.027 
(+ve control) 
+S„ 200 20.00 19.00 26.50 23.00 49.50* 0.50± 0.028 
CP 
SE 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
Table 17 
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Sister Chromatid Exchange (SCE) in human lymphocytes after 
Norethindrone exposure in vitro. 
Treatment 
(Mg/ml) 
Norethindrone 
20 
40 
75 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CPClxlO-'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
59 
62 
65 
55 
64 
318 
Range 
0-4 
0-4 
0-5 
0-4 
0-4 
3-13 
SCEs/Cell ±SE 
1 18±0 055 
1 24±0 060 
1 30±0 066 
1 10±0 099 
1 28±0 110 
6 36±0 152* 
Table 18 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Norethindrone exposure with metabolic activation (S, mix). 
Treatment 
(Ug/ml) 
Norethindrone 
20 
40 
75 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP( lx lO ' 'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
65 
62 
67 
73 
63 
389 
Range 
0-4 
0-5 
0-4 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1 30±0 065 
1 24±0 060 
1 34±0 067 
1 46±0 090 
1 26±0 093 
7 78±0 150* 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 19 : Analysis of cell growth kinetics after Norethindrone exposure in 
vitro. 
Treatment 
(Mg/ml) 
Norethindrone 
20 
40 
75 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells in 
H 
38 
32 
40 
32 
34 
65 
M, 
45 
55 
45 
55 
50 
33 
M3 
17 
13 
15 
13 
16 
02 
Replication 
Index 
1.79 
1.81 
1.75 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
Table 20 : Analysis of cell growth kinetics after Norethindrone exposure with 
metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Norethindrone 
20 
40 
75 
Control 
Normal 
DMSO {5[iUm\) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cell; 
H 
38 
41 
36 
34 
33 
66 
M, 
46 
45 
53 
54 
53 
29 
>in 
M3 
16 
14 
11 
12 
14 
05 
Replication 
Index 
1.78 
1.73 
1.75 
1.78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
CP Cyclophosphamide; DMSO . Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0.05 
74 
obtained were 1.78, 1.73 and 1.75 respectively at 20, 40 and 75 mg/ml 
concentrations. The value of replication index for normal control was 
1.78. Whereas, the replication index value for CP was 1.38 which was 
significantly high at P < 0.05 when compared to normal control value. 
Thus norethindrone was not found to affect the cell turnover rates 
of human lymphocytes in vitro. 
2. Norgestrel 
(a) Chromosomal aberrations: 
Table 21 summarises the results of chromosomal aberrations in 
human lymphocytes after norgestrel exposure in vitro. The percentage 
of aberrations observed at 10 mg/ml were 3.33%, 3.00% and 5.67% after 
24, 48 and 72 hours of exposures. All these values were not significant 
statistically as compared to the normal control value (i.e. 3.00%). When 
the dose of the drug was increased to 25 mg/ml the aberration frequencies 
also showed an increase for different exposure durations. At 25 mg/ml 
concentration the observed aberration frequencies were 19.00%, 26.33% 
and 50.33% for 24,48 and 72 hours of treatment durations respectively. 
All these values were highly significant at P < 0.05 when compared to 
the normal control value. At 50 mg/ml dose concentration, the aberration 
frequencies showed a further increase, and the values obtained were 
22.00%, 28.00% and 54.66% respectively for 24, 48 and 72 hours of 
exposure durations (Figures K-M in Appendix). Again these values were 
highly significant statistically. For CP, the positive control, the 
aberration frequency values obtained were 29.00%, 52.00% and 66.67% 
for 24, 48 and 72 hours of treatment durations. These values were also 
highly significant. Thus, a time dose relationship was observed for 
norgestrel treatment. At 25 and 50 mg/ml of dose concentrations a high 
frequency of chromosome aberrations and aberrant metaphases were 
observed for all exposure times. 
Results obtained after the exposure of lymphocytes to norgestrel 
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in the presence of metabolic activation are presented in table 22. The 
drug was found to be effective in all treatments and an increased 
frequency of aberrant metaphases as well as chromosomal aberrations 
were observed, when the lymphocytes were exposed to the drug in the 
presence of S^  mix. The values of aberration frequency obtained were 
9.50%, 22.50% and 41.00% respectively for 10, 25 and 50 mg/ml of 
dose concentrations. These data were highly significant at P < 0.05 when 
compared to the normal control value i.e. 4.00%. The percentage of 
chromosomal aberrations was 49.50% for CP which was highly 
significant. 
(b) Sister Chromatid Exchange (SCE): 
Data on the mean frequency of SCE for lymphocytes after the 
treatment of norgestrel is presented in the table 23. The maximum 
frequency of SCE per cell was found to be 4.44±0.086 at 50 mg/ml of 
dose concentration. This value was highly significant than the mean SCE 
value of normal control (1.10±0.099) at P < 0.05. The increased mean 
SCE frequency was also observed at 25 mg/ml of dose concentration 
(2.98±0.104) but with less magnitude in comparison to that of 50 mg/ 
ml concentration. This value was also significant at P < 0.05. The mean 
SCE frequency at 10 mg/ml was not significant when compared to the 
normal control value. This value was 1.60±0.141. The mean SCE 
frequency for CP was observed to be 6.36±0.152 which was highly 
significant statistically. 
The data on the mean SCE frequency of lymphocytes when treated 
with norgesfrel in the presence of metabolic activation are given in table 
24. Here again both the doses i.e. 25 and 50 mg/ml enhanced the SCE 
frequency significantly, but the maximum value was recorded at 50 mg/ 
ml concentration. The actual values obtained at 25 and 50 mg/ml dose 
concentration were 3.34±0.120 and 5.22±0.136 respectively (Figures 
N & O in Appendix). Both these values were significantly higher than 
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the mean SCE values of normal control i.e. 1.46±0.126 at P <0.05. AT 
10 mg/ml concentration the value observed was 1.78±0.105 which was 
not significant statistically. The observed mean SCE frequency was 
highest for CP i.e. 7.78±0.150 which was also highly significant when 
compared to the normal control value. 
(c) Cell Growth Kinetics: 
The data for cell growth kinetics of the drug norgestrol is 
summarised in table 25. The replication indices at 25 and 50 mg/ml of 
dose concentration was found to be 1.52 and 1.47 respectively. Both 
these values were statistically significant at P < 0.05 when compared to 
the normal control value i.e. 1.81. The replication index observed at 10 
mg/ml was 1.82 which was not significant. The frequencies of Mj cells 
were high and that of M^  cells were lower at 25 and 50 mg/ml of dose 
concentrations. The value obtained for CP was 1.37 which was highly 
significant at P<0.05. 
Table 26 summarises the results obtained for cell growth kinetics 
of human lymphocytes after norgestrel treatment in the presence of 
metabolic activation. The pattern of results obtained was same as it was 
in the absence of metabolic activation. But here, slightly decreased values 
of replication indices were observed at 25 and 50 mg/ml of doses. At 25 
mg/ml the value was 1.44 and at 50 mg/ml it was 1.46. Both these values 
of replication index were significant at P < 0.05 when compared to the 
normal control value i.e. 1.78. At 10 mg/ml of dose again the value 
observed was insignificant (1.80) at P < 0.05. For CP result obtained 
was highly significant (1.38). 
III. ANDROGENS 
1. Danazoj 
(a) Chromosomal aberrations: 
The data of chromosomal aberrations in human lymphocytes when 
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Table 21 : Chromosomal aberrations in human lymphocytes after Norgestrel 
treatment. 
Treat-
ment 
(Hg^) 
Dura-
tion 
(h) 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMSO 
(5M]/ml) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
(-ve control) 
Meta-
phase 
Sca-
nned 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent aberration 
Metaphase 
Incl. 
gap 
6.00 
5.67 
8.33 
12.00 
26.67 
38.33 
18.33 
28.67 
40.67 
4.33 
4.00 
Excl. 
gap 
3.67 
2.67 
4.33 
10.33 
22.00 
36.00 
12.00 
25.00 
38.00 
2.33 
2.00 
Types of aberration (%) 
Chro-
matid 
3.33 
3.00 
4.00 
11.33 
18.00 
29.00 
14.00 
15.67 
34.33 
2.67 
2.33 
Chro-
mosome 
0.00 
0.00 
1.67 
7.67 
8.33 
21.33 
800 
12.33 
20.33 
0.33 
0.67 
Total 
3.33 
3.00 
5.67 
19.00* 
26.33* 
50.33* 
22.00* 
28.00* 
54.66* 
3.00 
3.00 
Aberration/ 
CelliSE 
0.03±0.027 
0.03±0.026 
0.06±0.029 
0.19±0.050 
0.26±0.040 
0.50±0.040 
0.22±0.048 
0.28±0.043 
0.55±0.044 
0.03±0.026 
0.03±0.026 
CP(lxlO^M) 24 300 14.33 13.67 15.33 13.67 29.00* 0.29±0.048 
(+vecontrol) 48 300 19.67 18.67 28.00 24.00 52.00* 0.52±0.066 
72 300 28.67 27.33 39.00 27.67 66.67* 0.67± 0.070 
CP 
SE 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error A , . > 
Significant at P<0.05 . . 
\ 
•yj 
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Table 22 : Chromosomal aberrations in human lymphocytes after Norgestrel 
treatment with and without metabolic activation (S, mix). 
Treat-
ment 
(ixg/ni) 
Meta-
bolic 
Acti-
vation 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMSO 
(SuVml) 
-s. 
+s. 
-s, 
+s. 
-s. 
+s, 
-s. 
+s. 
-s. 
(-ve control) +S, 
CPOxlCM) - S , 
(+ve control) 
+s. 
Meta-
phase 
Sca-
nned 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent aberration Types of aberration (%) 
Metaphase 
Incl 
gap 
8 33 
10 50 
11 67 
17 50 
18 33 
26 50 
3 67 
4 00 
4 33 
4 50 
16 67 
20 00 
Excl 
gap 
6 67 
8 50 
9 33 
14 00 
16 67 
25 00 
2 33 
2 00 
167 
2 00 
14 67 
19 00 
Chro-
matid 
6 00 
8 00 
13 00 
16 00 
17 00 
22 00 
3 00 
3 50 
3 00 
2 50 
17 00 
26 50 
Chro-
mosome 
0 67 
150 
4 67 
6 50 
9 33 
19 00 
0 33 
0 50 
0 67 
1 00 
16 33 
23 00 
Total 
6 67 
9 50* 
17 67* 
22 50* 
26 33* 
4100* 
3 33 
400 
3 67 
3 50 
33 33* 
49 50* 
Aboration/ 
CelliSE 
0 07±0 027 
0 10±0 052 
0 18±0 029 
0 23±0 038 
0 26±0 035 
0 41±0 054 
0 03±0 027 
0 04±0 035 
0 04±0 028 
0 04±0 034 
0 33±0 027 
0 50± 0 028 
CP • Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 23 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Norgestrel exposure in vitro. 
Treatment 
(Mg/ml) 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMSO (SnUml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
80 
149 
222 
55 
64 
318 
Range 
0-6 
1-8 
2-12 
0-4 
0-4 
3-13 
SCEs/Cell ±SE 
1 60±0 141 
2 98±0 104* 
4 44±0 086* 
1 10±0 099 
1 28±0 110 
6 36±0 152* 
Table 24 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Norgestrel exposure with metabolic activation (S, mix). 
Treatment 
(Mg/ml) 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMSO (S^yml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
89 
167 
261 
73 
63 
389 
Range 
0-5 
1-10 
2-13 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1 78±0 105 
3 34±0 120* 
5 22±0 136* 
1 46±0 090 
1 26±0 093 
7 78±0 150* 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 25 : Analysis of cell growth kinetics after Norgestrel exposure in vitro. 
Treatment 
(Mg/ml) 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CP(lxlO' 'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells 
M, M^ 
37 
53 
56 
32 
34 
65 
44 
42 
41 
55 
50 
33 
in 
19 
05 
03 
13 
16 
02 
Replication 
Index 
1.82 
1.52* 
1.47* 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Significant 
Significant 
Significant 
Table 26 : Analysis of ceil growth kinetics after Norgestrel exposure with meta-
bolic activation (S, mix). 
Treatment 
(Mg/ml) 
Norgestrel 
10 
25 
50 
Control 
Normal 
DMSO (5^1/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cell 
H 
38 
61 
57 
34 
33 
66 
M, 
44 
34 
40 
54 
53 
29 
sin 
M3 
18 
05 
03 
12 
14 
05 
Replication 
Index 
1.80 
1 44* 
1 46* 
1.78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Significant 
Significant 
Significant 
CP 
SE 
* 
Cyclophosphamide, DMSO . Dimethyl sulphoxide 
Standard error 
Significant at P<0 05 
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exposed to the drug danazol are presented in table 27. For this drug the 
dose concentrations selected for the evaluation of genotoxic potential 
were 25, 50 and 100 mg/ml. Here at all concentrations the values obtained 
for the percentage of chromosomal aberrations were not significant at 
any exposure duration. The values obtained for 25 mg/ml were 4.33%, 
4.67% and 6.00%, for 50 mg/ml these were 3.33%, 5.00% and 5.00%, 
and for 100 mg/ml of dose concentration the values obtained were 
6.00%, 8.00% and 7.00%. All these values were obtained respectively 
at 24,48 and 72 hours of exposure durations. All these values were found 
insignificant statistically when compared to the normal control data i.e. 
6.00%. The percentage aberrations of CP were 29.00%, 52.00% and 
66.67% respectively at 24,48 and 72 hours of exposure durations. These 
values were highly significant when compared to the normal control value 
at P<0.05. 
When the lymphocytes were exposed to the drug danazol in the 
presence of metabolic activation (S^ mix), the values obtained for the 
percentage of chromosomal aberrations were all insignificant, as were 
reported in the absence of S^  mix. All the values are documented in table 
28. The percentage aberration observed were 4.50%, 5.50% and 8.00% 
respectively at 25, 50 and 100 mg/ml of dose concentrations. When 
compared to the normal control value i.e. 4.00%, all the above values 
were found to be insignificant at P < 0.05. For CP the value obtained 
was 49.50% which was highly significant as compared to the normal 
control value at P < 0.05. 
(b) Sister Chromatid Exchange (SCE): 
The results are presented in table 29. The mean SCE value observed 
at 25, 50 and 100 mg/ml of dose concentrations were 1.12±0.019, 
1.34±0.012 and 1.44±0.069. These values were not significant when 
compared to the normal control value i.e. 1.10±0.099. For positive 
control the value for mean SCE frequency was 6.36±0.152. This value 
was highly significant as compared to the normal control value at P < 0.05. 
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Table 30 describes about the results obtained after the exposure of 
lymphocytes to danazol in the presence of S, mix. The pattern of result 
was same as it was in the absence of metabolic activation. The values of 
mean SCE frequency at 25, 50 and 100 mg/ml of dose concentrations 
were 1.34±0.125, 1.18±0.113 and 1.50±0.119. All these values were not 
significant as compared to the normal control value i.e. 1.46±0.090 at P 
< 0.05. For CP the value obtained was highly significant (7.78±0.150) 
statistically when compared to normal control. 
(c) Cell Growth Kinetics: 
Table 31 shows the analysis of cell growth kinetics after danazol 
exposure in human lymphocytes. The 2x3 chi-square test indicated no 
significant deviation from the normal control culture. The replication 
indices at 25, 50 and 100 mg/ml of dose concentrations were 1.84, 1.88 
and 1.91 respectively. These values were not significant when compared 
to the normal control value i.e. 1.81. The result obtained for CP was 
1.37. This value was highly significant when compared to the normal 
control value at P<0.05. 
When the above experiment was repeated in the presence of 
metabolic activation, the result obtained was quite similar i.e. all the 
values obtained were found to be insignificant. The result has been 
documented in table 32. Replication index values for 25, 50 and 100 
mg/ml dose concentrations were 1.81, 1.84 and 1.81 respectively. These 
values were not significant at P < 0.05 when compared to the normal 
control value (1.78). For CP the result was highly significant statistically 
i.e. 1.38. 
2. Oxvmetholone 
(a) Chromosomal aberrations: 
The results of chromosomal aberrations in human lymphocytes after 
exposure to the drug oxymetholone have been presented in table 33. The 
drug was found to be ineffective in inducing chromosomal aberrations 
in human lymphocytes at any dose concentration and for any exposure 
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Table 27 : Chromosomal aberrat ions in human lymphocytes after Danazol 
treatment. 
Treat-
ment 
(Mg/ml) 
Danazol 
25 
50 
100 
Control 
Normal 
DMSO 
(5|jl/ml) 
Dura-
ticxi 
(h) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
(-ve control) 
Meta-
phase 
Sca-
nned 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
Percent aberration 
Metaphase 
Incl 
gap 
6 33 
7 00 
7 67 
6 33 
6 00 
7 33 
7 00 
7 67 
7 33 
4 33 
4 00 
Excl 
gap 
3 00 
4 67 
4 67 
3 00 
3 67 
4 00 
3 67 
3 33 
4 33 
2 33 
2 00 
Types of aberration (%) 
Chro-
matid 
4 33 
4 67 
5 00 
3 00 
4 33 
4 33 
4 67 
6 00 
5 33 
2 67 
2 33 
Chro-
mosome 
0 00 
0 00 
100 
0 33 
0 67 
0 67 
133 
2 00 
167 
0 33 
0 67 
Total 
4 33 
4 67 
6 00 
3 33 
5 00 
5 00 
6 00 
8 00 
7 00 
3 00 
3 00 
Aberration/ 
Cell iSE 
0 04±0 029 
0 05±0 029 
0 06±0 028 
0 03±0 027 
0 05±0 029 
0 05±0 029 
0 06±0 028 
0 08±0 043 
0 07±0 026 
0 03±0 026 
0 03±0 026 
CP(lxlO^M) 24 300 14 33 13 67 
(+ve control) 48 300 19 67 18 67 
15 33 13 67 29 00* 0 29±0 048 
28 00 • 24 00 52 00* 0 52±0 066 
72 300 28 67 27 33 39 00 27 67 66 67* 0 67±0 070 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 28 : Chromosomal aberrations in human lymphocytes after Danazol 
treatment with and without metabolic activation (S, mix). 
Treat- Meta- Meta- Percent aberration Types of aberration (%) Aberration/ 
ment bolic phase Metaphase Chro- Chro- Total Cell±SE 
(ligAnl) Acti- Sea- Incl. Excl. matid mosome 
vation nned gap gap 
Danazol 
25 
50 
100 
Control 
Normal 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
DMSO - S , 
(SM n^l) 
{-ve control) + S , 
CP(lxiaTv!) - S , 
(+ve control) 
CP : 
SE : 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
5.67 
6.50 
6.33 
6.00 
7 33 
8.50 
3.67 
4.00 
4.33 
4.50 
16.67 
20.00 
2.67 
3.00 
3.67 
2.50 
3.00 
4.50 
2.33 
2.00 
1.67 
2.00 
14.67 
19.00 
4.33 
3.50 
3.33 
4.50 
5.67 
6.00 
3.00 
3.50 
3.00 
2.50 
17.00 
26.50 
0.33 
1.00 
1.67 
1.00 
2.33 
2.00 
0.33 
0.50 
0.67 
1.00 
16.33 
23.00 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error 
466 
4.50 
5.00 
5.50 
8.00 
8.00 
3.33 
4.00 
3.67 
3.50 
33.33* 
49.50* 
0.05±0.029 
0.05±0.035 
0.05±0.028 
0.06±0.035 
0.08±0.023 
0.08±0.028 
0.03±0.027 
0.04±0.035 
0.04±0.028 
0.04±0.034 
0.33±0.027 
0.50± 0.028 
Significant at P<0 05 
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Table 29 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Danazol exposure in vitro. 
Treatment 
(Hg/ml) 
Danazol 
25 
50 
100 
Control 
Normal 
DMSO (5^1/mi: 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
1 48 
48 
Table 30 : Sister Chro 
No. of 
Methaphase 
50 
50 
50 
50 
50 
50 
•matid Exchange 
Total 
SCE 
56 
67 
72 
55 
64 
318 
(SCE) 
Range 
0-6 
0-7 
0-7 
0-4 
0-4 
3-13 
in human 
Danazol exposure with metabolic activation (S, 
Treatment 
(Mg/ml) 
Danazol 
25 
50 
100 
Control 
Normal 
Duration 
(h) 
48 
48 
48 
48 
DMSO (5nl/ml) 48 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
48 
No. of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
67 
59 
75 
73 
63 
389 
Range 
0-6 
0-7 
0-7 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1.12±0 019 
1.34±0 012 
l.44±0.069 
1.10±0.099 
1.28±0.110 
6.36±0.152* 
lymphocytes after 
mix). 
SCEs/Cell ±SE 
1.34±0 125 
1.18±0 113 
1.50±0.119 
1.46±0 090 
1.26±0.093 
7.78±0 150* 
CP Cyclophosphamide; DMSO : Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 31 : Analysis of cell growth kinetics after Danazol exposure in vitro. 
Treatment 
(Hg/ml) 
Danazol 
25 
50 
100 
Control 
Normal 
DMS0(5nJ/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cell; 
M, 
37 
38 
35 
32 
34 
65 
M, 
42 
36 
39 
55 
50 
33 
; in 
M3 
21 
26 
26 
13 
16 
02 
Replication 
Index 
1.84 
1 88 
1.91 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
Table 32 : Analysis of cell growth kinetics after Danazol exposure with meta-
bolic activation (S, mix). 
Treatment 
(Mg/ml) 
Danazol 
25 
50 
100 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO' 'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells in 
M, 
40 
36 
37 
34 
33 
66 
M. 
39 
44 
45 
54 
53 
29 
M3 
21 
20 
18 
12 
14 
05 
Replication 
Index 
1.81 
1.84 
1.81 
1 78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
CP 
SE 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0 05 
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duration. The aberration percentage observed at 25 mg/ml were 3.00%, 
3.67% and 4.34%, at 50 mg/ml these values were 4.67%, 4.66% and 
6.66%, and at 100 mg/ml of concentration the percentage obtained were 
5.34%, 5.00% and 6.66%. The three different observations at all doses 
were obtained for different exposure durations i.e. 24, 48 and 72 hours 
respectively. All these values were not significant in comparison to the 
normal control value (3.00%) at P < 0.05. The aberrations percentages 
obtained for CP were 29.00%, 52.00% and 66.67% respectively for 24, 
48 and 72 hours of exposure durations. These values were highly 
significant statistically. 
Table 34 shows the effects of oxymetholone on the chromosomal 
aberrations in human lymphocytes in the presence of metabolic 
activation. The percentage of aberrations observed for 25, 50 and 100 
mg/ml of dose concentrations were 4.50%, 3.50% and 7.50% 
respectively. These values were totally insignificant in comparison to 
the normal control value (4.00%) at P < 0.05. The percentage of 
aberrations induced by CP was highly significant statistically. This value 
was 49.50%. 
Thus the drug oxymetholone was not effective in inducing 
chromosomal aberrations in human lymphocytes either in the presence 
or absence of metabolic activation. 
(b) Sister Chromatid Exchange (SCE): 
When the lymphocytes were exposed to the drug oxymetholone to 
see the increase in mean SCE frequency, it was observed that this drug 
is not potent enough to enhance the SCE frequency significantly. The 
results has been presented in the table 35. The mean SCE frequency 
observed at 25, 50 and 100 mg/ml of dose concentrations were 
1.18±0.083, 1.24±0.077 and 1.38±0.080 respectively. All these values 
were insignificant statistically, compared to the normal control value 
(1.10±0.099). For CP the value was 6.36±0.152 which was highly 
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significant at P < 0.05, when compared to normal control value. 
Table 36 shows the effects of oxymetholone on the mean SCE 
frequency of human lymphocytes in the presence of metabolic activation. 
The values of mean aberration frequency obtained for 25, 50 and 100 
mg/ml of concentrations were 1.64±0.103, 1.78±0.103 and 1.66±0.095 
respectively. These values were found insignificant when compared to 
the normal control value (1.46±0.090) at P < 0.05. CP enhanced the 
SCE frequency greatly in the presence of S^  mix. The value obtained was 
7.78±0.150 which was highly significant statistically. 
(c) Cell Growth Kinetics: 
Table 37 shows the analysis of cell growth kinetics after 
oxymetholone exposure in human lymphocytes. The 2x3 chi-square test 
indicated no significant deviations from the control cultures. The 
replication index values obtained were 1.88, 1.81 and 1.77 respectively 
at 25, 50 and 100 mg/ml concentrations. These values were not 
significant in comparison to the normal control value (i.e. 1.81) at P < 
0.05. Cyclophosphamide was found to have a statistically significant 
effect when compared to normal control value. The value obtained was 
1.37. 
In the presence of metabolic activation, human lymphocytes were 
exposed to oxymetholone to analyse the cell growth kinetics. The results 
obtained have been summarised in table 38. At 25, 50 and 100 mg/ml 
concentrations the drug did not show any significant result. The 
replication indices observed were 1.90, 1.78 and 1.74, which were all 
insignificant statistically in comparison to the normal control value 
(1.78). The replication index observed for CP was 1.38 which was highly 
significant at P < 0.05 when compared to the normal control value. 
Thus, oxymetholone was not found to affect the cell turnover rates of 
the lymphocytes either in the presence or in the absence of S^  mix in vitro. 
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Table 3 3 : Chromosomal aberrations in human lymphocytes after 
Oxymetholone treatment. 
Treat- Dura- Meta- Percent aberration Types of aberration (%) Aberration/ 
ment tion phase Metaphase Chro- Chro- Total Cell±SE 
(pg/ml) (h) Sea- Incl Exd matid mosome 
nned gap gap 
Oxymetholone 
25 24 300 3 67 3 67 3 00 0 00 3 00 0 03± 0 028 
48 300 4 00 4 00 3 67 0 00 3 67 0 04±0 028 
72 300 4 33 3 33 3 67 0 67 4 34 0 04±0 029 
50 24 300 5 00 5 00 4 00 0 67 4 67 0 05±0 029 
48 300 5 33 4 66 3 33 133 4 66 0 05±0 029 
72 300 5 33 4 00 5 33 1 33 6 66 0 07±0 037 
100 24 300 6 00 3 00 3 67 167 5 34 0 05±0 029 
48 300 6 00 4 67 4 00 1 00 5 00 0 05±0 029 
72 300 6 67 5 00 5 33 1 33 6 66 0 07±0 027 
Control 
Nornial 72 300 4 33 2 33 2 67 0 33 3 00 0 03±0 026 
DMSO 
(5nJ/ml) 72 300 4 00 2 00 2 33 0 67 3 00 0 03±0 026 
(-ve control) 
CP(lxlO^M)24 300 14 33 13 67 15 33 13 67 29 00* 0 29±0 048 
(+ve control) 48 300 19 67 18 67 28 00 24 00 52 00* 0 52±0 066 
72 300 28 67 27 33 39 00 27 67 66 67* 0 67±0 070 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table34: C h r o m o s o m a l a b e r r a t i o n s in h u m a n lymphocy tes af ter 
Oxymetholone treatment with and without metabolic activation (S, 
mix). 
Treat-
ment 
(Hg/ml) 
Meta- Meta- Percent aberration Types of aberration (% 
bolic phase Metaphase 
Acti- Sea- Incl Excl 
vation nned gap gap 
Chro-
matid 
Chro- Total 
mosome 
Aberration/ 
CelliSE 
Oxymetholone 
20 
50 
100 
Control 
Nomial 
DMSO 
(5nl/ml) 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
-s. 
+s. 
-s. 
(-ve control) +S, 
CP(lxlO-Tvl) 
(+ve control] 
-s. 
1 
+s„ 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
4 67 2 67 2 00 0 33 2.33 0 02±0 024 
3 50 1 50 3 50 1 00 4.50 0 05±0 035 
4 33 3.67 2 67 1.33 4.00 0 04±0 024 
5 00 3 00 3.00 0 50 3.50 0 04±0 033 
5 00 2 33 4 00 2.33 6.33 0 06±0 040 
5 00 3 50 5.00 2.50 7.50 0.08±0 030 
3 67 2.33 3 00 0 33 3.33 0 03±0 027 
4 00 2 00 3 50 0.50 4.00 0 04±0 035 
4 33 1 67 3 00 0 67 3 67 0 04±0 028 
4 50 2 00 2.50 1.00 3.50 0 04±0 034 
16 67 14 67 17 00 16.33 33.33* 0 33±0 027 
20 00 19 00 26 50 23.00 49.50* 0 50± 0 028 
CP : Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* . Significant at P<0 05 
Table 35 
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Sister Chromatid Exchange (SCE) in human lymphocytes after 
Oxymetholone exposure in vitro. 
Treatment 
(pg/ml) 
Oxymetholone 
25 
50 
100 
Control 
Normal 
DMS0(5^1/ml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
59 
62 
59 
55 
64 
318 
Range 
0-4 
0-5 
0-5 
0-4 
0-4 
3-13 
SCEs/Cell ±SE 
1 18±0 083 
1 24±0 077 
1 38±0 080 
1 10±0.099 
1 28±0 110 
6 36±0 152* 
Table 36 : Sister Chromatid Exchange (SCE) in human lymphocytes after 
Oxymetholone exposure with metabolic activation (S, mix). 
Treatment 
(Hg/ml) 
Oxymetholone 
25 
50 
100 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-'M) 
(+ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
Methaphase 
50 
50 
50 
50 
50 
50 
Total 
SCE 
82 
89 
83 
73 
63 
389 
Range 
0-6 
0-6 
1-7 
0-5 
0-5 
4-14 
SCEs/Cell ±SE 
1 64±0 103 
1 78±0 103 
1 66±0 095 
1 46±0 090 
1 26±0 093 
7 78±0 150* 
CP Cyclophosphamide, DMSO Dimethyl sulphoxide 
SE Standard error 
* Significant at P<0 05 
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Table 37 : Analysis of cell growth kinetics after Oxymetholone exposure 
in vitro. 
Treatment 
(|ig/ml) 
Oxymetholone 
25 
50 
100 
Control 
Normal 
DMS0(5nl/ml) 
(-ve control) 
CPClxlO-'M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cells in 
31 
35 
39 
32 
34 
65 
50 
53 
45 
55 
50 
33 
19 
14 
16 
13 
16 
02 
Replication 
Index 
1.88 
1.81 
1.77 
1.81 
1.82 
1.37* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
Table 38 : Analysis of cell growth kinetics after Oxymetholone exposure with 
metabolic activation (S , mix). 
Treatment 
(Mg/ml) 
Oxymetholone 
25 
50 
100 
Control 
Normal 
DMSO (5nl/ml) 
(-ve control) 
CP(lxlO-^M) 
(+ve control) 
Cells 
Scored 
200 
200 
200 
200 
200 
200 
Percent cell 
29 
36 
37 
34 
33 
66 
52 
50 
52 
54 
53 
29 
s in 
M3 
19 
14 
11 
12 
14 
05 
Replication 
Index 
1.90 
1.78 
1.74 
1.78 
1.81 
1.38* 
2x3 Chi-square 
test 
Not significant 
Not significant 
Not significant 
Significant 
CP 
SE 
Cyclophosphamide, DMSO : Dimethyl sulphoxide 
Standard error 
Significant at P<0.05 
'i>^eei4^i^M 
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DISCUSSION 
The cytogenetic effects of sex steroidal hormones (two each from 
estrogens, androgens and progestins) have been evaluated in vitro in the 
present study. The advantages and disadvantages of the test systems used, 
the parameters assayed and the effect of the steroids evaluated on these 
parameters are discussed below: 
A- GENERAL CONSIDERATIONS : 
All the results of mutagenicity (genotoxicity) evaluation of the 
steroids are eventually aimed at human safeguards. It is, therefore, ideal 
to evaluate them directly on humans who are exposed to these steroids, 
or test them for genotoxicity on a system that has the same sensitivity 
of response as the human genome. The human peripheral blood 
lymphocyte culture system is a single system that provides us with a 
large number of dividing cells. These can be easily cultured to yield 
large number of mitotic figures from chromosome analysis. The 
lymphocytes also contain some metabolizing enzyme systems that are 
able, to some extent, to activate certain promutagens into a mutagenically 
active state (Buckton and Evans, 1973). 
Studies on exposed individuals, and on cultured cells, have shown 
that the human peripheral blood lymphocyte is an extremely sensitive 
indicator of both in vivo and in vitro induced chromosomal structural 
changes. These changes in chromosome structure offer readily scored 
morphological evidence of damage to the genetic material. Although 
problems exist in the extrapolation from in vitro results to the in vivo 
situation, the lymphocyte offers several advantages as a test system in 
the following ways (Evans, 1982; Evans et al., 1979; Evans, 1970; 
Buckton and Evan, 1973); 
(i) Easy availability of large number of human cells. A few ml of 
peripheral blood can be easily and repeatedly obtained from an 
individual and each 1 ml of blood contains 1-3x10^  small lymphocytes. 
94 
(ii) The lymphocytes are distributed throughout the body, circulate in 
all tissues and a proportion are long-lived as well. 
(iii) Virtually all the peripheral blood lymphocytes are a synchronized 
cell population in the same G^ , or G, stage of mitotic interphase 
and, in healthy individuals, these cells are only infrequently 
involved in mitotic proliferation in vivo. 
(iv) A proportion of the lymphocytes can be stimulated by mitogens 
to undergo mitosis in culture. They are easy to culture and thus 
provide a ready source of dividing cells for the scoring of 
chromosome aberrations. 
(v) There are excellent techniques available for making chromosome 
preparations from lymphocytes and the cells have a low 
spontaneous chromosome aberration frequency (Buckton and 
Evans, 1973). 
Some disadvantages include: 
(i) Although the lymphocytes are a synchronized population, there 
are different sub-populations of cells even within the same 
individual . These can have varying responses to different 
mitogenic agents and probably differing intermitotic times which 
may be further influenced by variations in culture conditions. 
(ii) As in other cell systems, there is the possibility of non-uniformity 
of exposure and of preferential growth in culture of less heavily 
damaged cells. 
(iii) It is now recognised that in man only T-lymphocytes, i.e. the 
thymic-derived cells, can be stimulated in culture by 
phytohaemagglutinin (PHA) to undergo mitosis. The T-lymphocyte 
is closely concerned with the immune response, thus, where an 
analysis of in vivo exposure is to be undertaken, any recent 
previous exposure of an individual to an immunological stimulus 
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may positively or negatively alter the number of cells with 
chromosome aberrations, depending on when the cells are 
withdrawn from the individual. 
These disadvantages relate largely to the use of lymphocytes for 
studying mutagenic effects in vivo and are of less relevance to the use 
of lymphocytes for in vitro mutagen testing. 
IN VIVO VS IN VITRO EVALUATIONS 
It is ideal to study the effect of chemicals directly on persons 
exposed to these chemicals or drugs. But ethical reasons preclude the 
experimental approach on evaluation of genotoxicity on humans. The in 
vivo study is possible only in specific cases when individuals have been 
exposed to the agents either as a chemotherapeutic necessity (e.g. 
medicines) or occupational inevitability (e.g. exposure to styrene. 
aniline, polyvinyl chloride) or accidental reasons (e.g. exposure to 
radiation, atom bomb explosions etc.). 
The genotoxicity evaluation among patients on therapy is difficult. 
Patients may be on multiple therapy and the effects observed may either 
be additive, synergistic or antagonistic to each other. In vivo studies in 
humans have been found to have significant effect on chromosomal 
aberrations (Pinto, 1986) and SCE (Murthy and Prema, 1983). 
The in vivo cytogenetic evaluation also has its shortcomings. The 
cytogenetic abnormalities found in exposed persons represent the most 
drastic and obvious expression of genetic damage while the frequent and 
subtle genetic changes like mutations are not detected. Another 
limitation is that the peripheral lymphocytes which are cultured are not 
in the dividing cell cycle at the time when the chemicals exert their 
influence in vivo. Drugs which can cause primary genetic lesions in the 
G, phase only can manifest their detrimental effects while agents that 
cause genetic damage in the S-phase may not exhibit cytogenetic damage in 
lymphocyte cultures of person exposed to these agents (Gebhart, 1982). 
96 
These shortcomings of the in vivo evaluations can be overcome by 
in vitro treatment of peripheral blood lymphocytes in cultures. The 
experimental approach can be used and the effect of drugs/chemicals 
can be evaluated at a range of concentrations (including sub-toxic and 
toxic levels) on lymphocyte cultures of healthy individuals. This also 
permits the evaluation of effects of different time exposure to the drug 
and fate of lesion after consecutive cell division and the effect of drug 
during the G, as well as S-phase of the cell cycle. In vitro test, however, 
has its own shortcomings because there is no metabolizing system of 
the drugs and chemicals in it. But lymphocytes have been known to 
metabolise atleast some compound, e.g. activation of polycyclic 
hydrocarbon benzo (a) pyrene. The presence of erythrocytes in cultures 
is also known to aid in metabolising compounds like aniline, HCl 
(Wilmer et al., 1984), sodium selenite (Ray and Altenburg, 1978) and 
styrene and its analogues (Norppa et al., 1983; Norppa and Tursi, 1984). 
In the present study two estrogens mestranol and quinestrol, two 
progestins norethindrone and norgestrel, and two androgens danazol and 
oxymetholone were evaluated for their cytogenetic effects on human 
lymphocytes in peripheral blood cultures in vitro. All the drugs were 
also evaluated in the presence of metabolic activation (S^ mix.) 
CHROMOSOME ABERRATIONS; 
Chromosomal aberrations are categorised as structural and 
numerical chromosomal aberrations. 
I. Structural aberrations : 
The broadest classification of structural chromosomal aberrations 
is based on whether they are formed before or after semiconservative 
DNA replication. On this basis the types of structural chromosomal 
damage which can be cytologically distinguished at metaphase can be 
divided into two main groups: Chromosome-type aberrations and 
chromatid-type aberrations (Evans, 1962). The circulating lymphocyte 
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is in the G^ , or G, phase of mitosis and exposure to ionizing radiations 
and certain other mutagenic agents (radiomimetic chemicals) during this 
stage produces chromosome-type damage where the unit of breakage 
and reunion is the whole chromosome (i.e. both chromatids at the same 
locus). However, cells exposed to these agents while in the S or G^ stages 
of the cell cycle, after the chromosome has divided into two sister 
chromatids, yield chromatid-type aberrations and only the single 
chromatid is involved in breakage or exchange. Other agents (e.g. some 
of the alkylating agents) will produce only chromatid-type aberrations 
although the cells are exposed to the mutagen whilst in G^  or Gj phase. 
Therefore, chromosome type aberrations are produced by errors in DNA 
repair in unreplicated DNA, i.e. in G, or S phase in DNA regions that 
have not yet been replicated. When observed at metaphase or interphase, 
chromosome-type aberrations involve a change in both chromatids of 
the chromosome. Whereas, chromatid-type aberrations are produced by 
errors in DNA repair in G^  or S phase in DNA regions that have already 
replicated at the time of exposure or by errors in DNA replication on a 
damaged DNA template. When observed at metaphase, chromatid type 
aberrations involve only one of the two sister chromatids, with the 
exception of isochromatid fragments or deletions that involve both 
chromatids. Isochromatid deletions are thus difficult to distinguish from 
chromosome-type terminal deletions. They can be classified, if needed, 
into chromatid-type or chromosome-type on the basis of the other, 
clearly distinguishable types observed in a particular study. For the 
purposes of the present discussion, it is important to note that after 
cell division and a subsequent round of DNA replication, chromatid type 
aberrations can be converted into the so-called derived-chromosome type 
aberrations. The probability of this occurrence varies for different types 
of aberrations depending on the likelihood of lethality at the intervening 
cell division resulting from loss of an acentric chromosomal fragment. 
(A) Chromosome-type aberrations : Studies on somatic metaphases 
show that seven classes of chromosome-type aberrations can be 
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distinguished cytologically. Aberration types 1-5 involve only a single 
chromosome and are known as intrachanges whereas types 6 and 7 
involves the exchange of parts between chromosomes and therefore are 
classified as interchanges. 
(1) Terminal deletions : These are paired acentric fragments which result 
from a simple break across the chromosome and they are not associated 
with an obvious exchange aberration. 
(2) Minutes (interstitial, isodiametric or dot deletions): These are pairs 
of acentric fragments, smaller in size than terminal deletions, 
characteristically appear as paired spheres of chromatin. These are 
intercalary deletions. 
(3) Acentric rings: These are paired segments of chromatids without a 
centromere and are joined to give a ring. 
(4) Centric rings : Ring structures containing a centromere. The centric 
ring can be easily distinguished morphologically from the acentric type 
and is generally accompanied by one acentric fragment. 
(5) Inversions: Chromosome inversions can be classified into two 
categories: (a) paracentric inversions where both points of breakage 
and reunion lie on the same arm of the chromosome; and (b) pericentric 
inversions where the points of breakage and inversion lie on opposite 
sides of the centromere. 
In cells where two points of pericentric exchange are of unequal 
distance from the centromere, the abnormal chromosome can be easily 
distinguished by the altered position of the centromere. However, where 
the exchange points are equally distant from the centromere, and in the 
case of paracentric inversions, there is no change in the relative position 
of the centromere. The detection of such inversions may, therefore, be 
possible only through the use of chromosome banding techniques. 
(6) Reciprocal translocations (symmetrical interchange): These are 
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aberrations which involve breakage of two chromosomes and the 
reciprocal exchange of broken segments. Conventional staining methods 
will not allow the detection of reciprocal translocations involving the 
exchange of two equal-sized segments, and banded chromosome 
preparations are required. Interchanges may also occur in the centromere 
regions of two chromosomes giving whole-arm exchanges. If they involve 
acrocentric chromosomes are referred to as centric fusions or 
Robertsonian translocations. 
(7) Dicentric or poly-ccntric aberrations (asymmetrical interchange): 
Aberrations which arise from an exchange between two or more 
chromosomes results in the centric products re-uniting in such a way to 
form a dicentric or polycentric structure and an associated acentric 
fragment. 
Aberration types (1), (2) and (3) i.e. terminal deletions, minutes 
and acentric rings, are often loosely grouped together as acentric 
fragments. These are not associated with any obvious exchange event 
resulting in a rearrangement. Fragments associated with an exchange 
event e.g. the fragments observed in association with a dicentric, are 
scored as part of the exchange and not as separate aberrations in their 
own right. 
(B) Chromatid-tvpe aberrations : Chromarid-type aberrations are 
induced by ionizing radiations when cells are exposed in the S or G^ 
stages of interphase. Chromosome-type damage are produced in cells 
irradiated in G,. However, many chemical agents and viruses cause only 
chromatid-type damage even though the cells are exposed to the agent 
whilst in the G, phase and examined in their first subsequent division. 
These aberrarions are a consequence of errors in replication that occur 
at the DNA synthesis, or S phase following exposure. 
In contrast to the chromosome-type aberrations, according to some 
scientists, chromatid breaks and particularly gaps are unreliable 
indicators of real damage to the genetic material. Because gaps are also 
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caused by technical artefacts e.g. "poor" culture conditions, and the use 
of "drastic" processes during slide preparation. For this reason, if 
chromatid gaps and breaks are to be scored and included in the aberrations 
yield, it is particularly important that "control" blood cultures are 
cultured in a similar way and at the same time as those exposed to the 
agent being tested (Evans and O'Riordan, 1975). But another group of 
researchers strongly support the idea that chromatid breaks and gaps are 
also indicators of genetic damage, because the frequency of chromatid 
breaks and gaps increases with the increase in the concentration and 
exposure duration of mutagen in comparison to the normal control 
culture. In the present study chromatid breaks and gaps have been 
considered as indicators of genetic damage. 
(1) Chromatid and isochromatid gap: The gap or achromatic lesion 
appears as a non-staining and constricted region in the chromatid arm 
and the apparently "broken" segments of the chromatid area are in 
alignment. Where the gap involves both chromatid arms at the same 
position, this is referred to as an isolocus or isochromatid gap. 
(2) Chromatid break : Where there is a discontinuity with displacement 
in the chromatid arm so that the broken chromatid ends are not aligned. 
An apparently "simple" break results in a terminal deletion. 
(3) Chromatid minutes : Single, or unpaired, intercalary fragments. 
(4) Chromatid acentric rings : Intercalary fragments joined to give ring 
structures. 
(5) Centric rings : Intrachanges resulting in chromatid ring structures 
in which the centromere is included in the ring. 
(6) Inversions : Paracentric inversions are not readily scorable, but 
pericentric inversions may be detected because of the close pairing of 
chromatids. 
(7) Isochromatid aberrations : These involve exchanges between sister 
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chromatids and may be confused with chromosome type terminal 
deletions. They may be distinguished from chromosome type 
aberrations, however, since the majority of isochromatid breaks involve 
a union between sister chromatids either proximal or distal to the point 
of breakage. 
(8) Symmetrical interchanges : This type of aberration involves an 
exchange (exchanges) between two (or more) chromosomes. Simple 
exchanges between one chromatid in each of two chromosomes results 
in a configuration having four arms and referred to as quadri-radial. 
(9) Asymmetrical interchanges : An exchange between two or more 
chromosomes resulting in the formation of one (or more) dicentric 
chromatids. 
Within each major group of chromosome-type and chromatid-type 
aberrations is a range of different types of aberrations, broadly defuied 
as deletions and exchanges. Large terminal or interstitial chromosome-
type deletions observable under the light microscope are almost always 
lethal to the cells as a result of loss of the acentric fragment at the first 
or second cell division after formation. Whereas in case of chromatid-
type terminal and interstitial deletions one daughter cell is viable (the 
one receiving the undamaged chromatid). It can be reasonably argued, 
however, that the mechanism of formation and general shape of the dose-
response curve for small deletions that cause transmissible mutations 
is similar to that for larger (microscopically observable) interstitial 
deletions. Exchange aberrations can be intrachromosomal or 
interchromosomal. Each class includes transmissible (stable) and non-
transmissible (unstable) types. Intrachromosomal exchanges can produce 
transmissible inversions involving the centromere (pericentric) or within 
a chromosome arm (paracentric). Besides intrachromosomal exchange 
can also produce centric and acentric rings which are most frequently 
non-transmissible because of loss of acentric chromosomal material at 
division (i.e. the acentric ring itself or the acentric fragment 
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accompanying a centric ring). Acentric rings are the same as the 
interstitial deletions described earlier. 
Interchromosomal exchanges can produce reciprocal translocations 
that are transmissible, and dicentrics (with an accompanying acentric 
fragment) that are almost always non-transmissible. A reciprocal 
chromatid-type translocation between homologous chromosomes in 
mitotic crossing-over leads to the production of homozygosity for 
heterozygous loci for genes located distal to the translocations. This 
mechanism is relevant to producing homozygosity of recessive mutant 
tumour suppressor genes in cells that were originally heterozygous at 
these loci. Chromosome-type reciprocal translocations are transmitted 
to both daughter cells and do not cause loss of heterozygosity, whereas 
chromatid-type reciprocal translocations have a one-quarter probability 
of being present in a daughter cell. This is an important consideration 
for predicting potentially adverse outcomes attributable to chromosomal 
changes. The analysis of reciprocal translocations and inversions has 
until recently been difficult, relying on one or another version of 
chromosome banding. The recent development of whole-chromosome 
painting probes (Tucker et al., 1993), chromosome arm-specific probes 
(Lucas et al., 1996) and even total karyotypic differentiation (Specicher 
et al., 1996) have made the analysis much easier. These transmissible 
aberrations can be analysed in human and mouse cells. An aberration is 
a rare occurrence in comparison with the amount of induced DNA 
damage, most of which is efficiently repaired. The kinetics of repair of 
different types of DNA damage affects the types of structural alterations 
produced. 
Chromosome and chromatid gaps : 
One class of chromosomal change that requires separate attention 
is gaps or achromatic lesions. These changes appear as unstained regions 
of a chromosome where no obvious break or displacement is observed 
microscopically. The gaps have variously been attributed to damaged 
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DNA regions that have unwound or decondensed sites of DNA repair, 
and have been considered harbingers of cell death. Their frequency can 
clearly be increased by exposure to radiation and mutagenic chemicals 
but their further significance is unclear. When gaps are observed at the 
first metaphase after treatment, they are generally not seen at subsequent 
metaphases, as would be predicted if gaps are sites of decondensation, 
or repair, or indicate imminent cell death. The idea that they represent 
sites of damage is perhaps supported by the observation that the number 
of chromosomal breaks in treated cells which are induced to undergo 
premature chromosome condensation is very much higher than what is 
observed in normal metaphase cells. There is no agreement on how to 
distinguish deletions from gaps or how to interpret data on gaps, 
especially when they are the only chromosomal change observed in an 
assay. The United Kingdom Environmental Mutagen Society 
subcommittee on guidelines for mutagenicity testing (Scott et al., 1983) 
provides what is perhaps the most reasonable approach: an observation 
of gaps alone indicates the potential for true chromosomal aberrations 
but is insufficient for a firm conclusion to be drawn. 
Gaps Vs Breaks : 
The distinction between chromatid gap and break is very arbitrary. 
A gap cytogenetically is distinguished from a break depending on the 
length of the non-staining region in the chromosome. If the attenuated 
region is shorter than the width of the chromatid, it is classified as a gap 
and if longer than the width it is a break. But the problem in this 
classification is that chromosome at prometaphase are elongated with a 
small width of chromatid while at late metaphase they are condensed 
with larger width. This results in classification of more breaks in early 
metaphase and more gaps in late metaphase. 
Various studies have been done to look into the nature of gaps and 
breaks. A combination of studies with light microscopy, transmission 
electron microscopy and scaiming electron microscopy of x-ray induced 
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aberrations in Vicia jaha showed that gaps and breaks are different 
manifestations of the same event and that gaps may be complete breaks 
(Brecher, 1977). Breaks, for example, are thought to be a complete loss 
of material at the non-staining region with displacement of the distal 
fragment, whereas gaps are thought to have a chromatin bridges. But 
electron microscopic studies (Op.cit.) demonstrated that few breaks had 
chromatin material bridging the space while some gaps had no such 
chromatin bridges. Thus, the distinction between the two is arbitrary at 
the light microscopy level and both are apparently different 
manifestations of the same phenomenon. 
Comings (1974) offered a hypothesis regarding the nature of gap. 
According to him gaps and breaks represent the same basic lesions but 
differ in the time at which the lesions are induced. If a break in chromatin 
fibre occurs when the chromatin is fully extended (e.g. G,, S and early 
Gj phase), subsequent condensation of chromosome results in a 
chromatid break. But if the chromosome is already partially condensed 
(e.g. Gj phase) and a break occurs, a few fibres still hold the chromosome 
together, resulting in a gappy appearance. 
Silver staining technique of the chromatid core has shown that the 
chromatid core is not continuous in chromatid gaps (Satya Prakash et 
al., 1981). Some authors suggest that gaps are produced due to loss of 
despiralization of both DNA as well as chromosomal proteins (Stoain 
and Raicu, 1975). An increase in constriction and gaps in human 
chromosomes following mercapto-ethanol exposure suggests that gaps 
may occur from damage to the protein moiety of the chromatid causing 
deficient folding of the chromatin fibre in metaphase chromatid (Brogger, 
1982). 
However, under the influence of mutagen the frequencies of both 
gaps and breaks increase. It has been suggested by many authors that 
gaps are indicative of toxic phenomena from genetic point of view and 
the aberrations could be useful sensitive indicators of chemically induced 
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genetic damage (Anderson and Richardson, 1981; Gebhart, 1977, 1982, 
1984; Goetz et al., 1975; Dipaolo and Popescu, 1976; Hansteen et al., 
1984; Hsu, 1982; Brogger, 1982). 
Any damage altering the normal morphology of a chromosome (be 
it because of damage to DN A and chromatin or to the packing proteins 
of chromosomes) could interfere with normal functioning of the 
chromosome and ultimately to that of cell causing genotoxicity. 
Therefore, gaps were included in the present study for analysis. 
Numerical Alterations : 
Hyperploidy and hypoploidy i.e. increase and decrease in the number 
of chromosomes may result from incorrect segregation of chromosomes 
at anaphase and failure of the chromosomes to leave the metaphase plate 
or anaphase, so that they are not included in either daughter nucleus. In 
addition, partial chromosomal aneuploidy can arise from chromosomal 
deletions and from certain segregants of exchange aberrations. Increasing 
knowledge about the mechanisms of chromosome movement during 
mitosis has allowed identification of a number of steps at which induced 
changes can lead to aneuploidy (Preston, 1996). Traditionally, 
aneuploidy has been assessed by counting chromosomes at metaphase. 
More frequently, fluorescence hybridization techniques have been added. 
For example, the proportion of micronuclei containing whole 
chromosomes can be assessed by using a probe that can detect the 
kinetochore (Eastmond and Tucker, 1989). This approach can, of course, 
detect only aneuploidy that results from lagging chromosomes. Whole 
chromosome paint ing probes or preferably artificial bacterial 
chromosome probes that provide more discrete signals, can be used for 
the detection of aneuploidy in interphase cells (Kim et al., 1995; Bell 
el al., 1996). 
Changes in ploidy (duplication of whole chromosome complement) 
are also induced, generally as a result of inhibition of cytokinesis or 
failure of all chromosomes to segregate. The outcome can either be 
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polyploid} or endo reduplication. The later is a specific version of 
polyploidy in which replicated chromosomes maintain a parallel 
association along their lengths even at C metaphase (Therman et al, 
1983). Specific assays are not available for detecting changes in ploidy, 
but they should be noted when observed in the course of other assays 
for chromosomal alterations. 
ABERRATION YIELD AND TYPE IN RELATION TO TIME IN 
CULTURE: 
Probably the most important in vitro factor which influences the 
chromosome aberrations is the time factor during which the cells are 
maintained in culture. After two days in culture at 37°C the majority of 
transformed lymphocytes generally undergo their first mitosis. 
Preparation made from cells cultured for longer periods will contain 
increasingly high proportions of cells in their second or subsequent 
divisions. Consequently, if lymphocytes with chromosome type damage 
fail to undergo repeated division in vitro due to their genetic unbalance 
or mechanical difficulties at anaphase, examination of cells after 72 h 
of culture may not reflect the true in vivo aberration level. Furthermore, 
a proportion of the chromosome-type aberrations observed at this later 
time may be really of a "derived" type resulting from a duplication of 
aberrations that were initially chromatid type. Thus, for tests which are 
designed to detect the presence or absence of chromosome damage in 
lymphocytes following in vivo exposure of individuals to a suspected 
mutagenic agent, the blood samples should only be cultured for up to 50 
hours at 37°C. The same restriction applies to in vitro studies but 
consideration must also be given to the fact that the agent and the test 
may itself inhibit cell development and so it is necessary to prolong the 
time of culture to obtain mitotic cells. 
SISTER CHROMATID EXCHANGE (SCE) : 
SCE results from the breakage and rejoining of DNA at apparently 
homologous sites on the two chromatids of a single chromosome. They 
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were first visualized by Taylor el al. (1957) who used tritiated thymidine 
to differentially label the DN A of replicating cells and autoradiography 
to distinguish the silver grain pattern on the two sister chromatids. Latt 
(1973) and Perry and Wolff (1974) made this technique more simple. 
In principle, SCEs can be observed in any cells that has completed two, 
or the first of two, replication cycles in the presence of BrdU. The most 
common procedure for human lymphocytes is to grow the cells in BrdU 
for two replication cycles. 
SCEs are most efficiently induced by substances that form covalent 
adducts with the DNA, or interfere with DNA precursor metabolism or 
repair (Perry and Evans, 1975; Wolff, 1977; Perry, 1980; Carrano and 
Thompson, 1981; Latt et al., 1981). It is well documented that SCEs are 
produced during DNA replication (Wolff et al., 1974) and that the 
polarity of DNA is maintained in the process of exchange (Taylor, 1958; 
Wolff and Perry, 1975). The molecular mechanism by which the 
exchange is formed is not known but, since there is an absolute 
requirement for DNA synthesis, hypotheses have implicated the 
mechanisms of this process in SCE formation (Bender et al., 1974; 
Painter, 1980; Cleaver, 1981; Shafer, 1982). Baseline SCE frequencies 
are increased in some human diseases such as Bloom's syndrome 
(Chaganti et al., 1974) and multiple sclerosis (Sutherland et al., 1980; 
Vijayalaxmi et al., 1983). Cells from patients with the inherited disease 
Xeroderma pigmentosum are hypersensitive to the induction of SCEs 
by ultraviolet radiation and alkylating agents (Wolff e/ al., 1975; Wolff, 
1977). There is no clear relation, however, between the repair capacity 
of these cells and their sensitivity to SCE induction (de Weerd-Kastelein 
etal., 1977). 
Relevance of sister-chromatid exchange : 
An SCE represents the breakage of 4 strands of DNA (2 double 
helices), a switch of the strands from one to the other arm of the same 
chromosome, and the rejoining of the strands in their new locations. 
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The question is whether the breakage and rejoining events occur without 
producing any modification in the genetic code. There is evidence 
suggesting that this exchange process might not always be error-free. In 
particular, a considerable amount of information has been gathered 
concerning the relationship between induced SCEs and other genetic 
effects in vivo and in vitro. 
Because the technique for enumerating SCEs is relatively simple, 
this assay has been used quite extensively in genetic toxicology studies. 
It has been amply demonstrated that the frequency of SCE is dramatically 
increased when cells, or animals including human beings, are exposed 
to known mutagens or carcinogens (Perry and Evans, 1975; Latt et a I., 
1981; Lambert et al., 1982). Moreover, in earlier experiments using 
Chinese hamster cells in culture, it was found that the induction of SCEs 
was linearly related to the increase in single-gene mutations (HPRT 
locus), when the cells were exposed to several substances each of which 
differed in the type of lesion produced in DNA (Carrano et al., 1978; 
Carrano and Thompson, 1982). The ratio of induced SCE to induced 
mutation differed for each of the agents, suggesting that each type of 
lesion fonned is processed differently by the cell favouring either the 
formation of SCEs or mutations. It is possible that the same lesion is 
capable of producing both an SCE and a mutation and/or that the lesions 
that form mutations are a subset of those that form SCEs. The induction 
of mutatiors has been shown to be correlated with the induction of SCEs 
in mice for one chemical, ethylnitrosourea (Jones et al., 1985). In the 
same study, the induction of SCEs in mouse splenocytes after 
intraperitoneal administration of the chemical it was found that a linear 
relation is existing between SCEs and proportional to the increase in 
mutations at the HPRT locus. It suggests that the mutation-SCE relation 
is not unique to in vitro studies. 
Other investigations have compared the induction of SCEs to either 
the induction of transformation in vitro or tumour promotion in vivo. 
In a series of experiments, the induction of SCEs was shown to be 
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linearly and positively correlated with the induction of transformation 
of Syrian hamster embryo cells in vitro (Popescu et al., 1981). This 
relationship was held for exposure to five chemicals, but not for X-
irradiation. The ratio of induced SCEs to induced transformation 
frequency varied for each chemical. This is analogous with the results 
found for the SCE-to-mutation ratio described above. Cheng et a/. (1981) 
examined the induction of SCEs in mouse bone marrow, regenerating 
liver, and alveolar macrophages following intraperitoneal injection of 
ethylcarbamate and related chemicals. The relative potencies in inducing 
SCE paralleled the reported activities for the induction of lung adenomas 
in mice. For ethyl carbamate, the doses for the significant induction of 
SCEs in alveolar macrophages and lung adenomas were similar. Further, 
the slopes of the dose responses showed that the two end-points were 
of comparable sensitivity. 
The results of early studies on rabbits demonstrated that it was 
possible to measure an increase in SCEs in peripheral blood lymphocytes 
for many months following repeated low-level exposure to mitomycin 
C in vivo (Stetka et a/., 1978). Increased SCEs in human beings have 
been observed in cigarette smokers (Lambert et al., 1978; Carrano, 1982) 
and in individuals undergoing chemotherapy (Lambert et al., 1978; 
Musilova et al., 1979; Gillian Clare et al., 1982). The results of these 
studies suggest that a subpopulation of lymphocytes with high SCE 
frequency may be present for long periods after termination of exposure. 
These cells may represent persistent damge in long-lived lymphocytes 
or a sensitive subpopulation (Carrano and Moore, 1982). If this is true, 
they may offer a more appropriate approach to the quantification of 
persistent damage in vivo. 
Factors potentially influencing SCE frequency : 
The baseline SCE frequency in human peripheral lymphocytes 
averages about 7-10 per cell but has been reported to range from about 
2 to 45 per cell in unexposed individuals (Alhadeff and Cohen, 1976; 
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Lambert et al., 1976; Crossen et ai, 1977; Galloway, 1977; Carrano e( 
al., 1980). Even within the same laboratory the baseline frequency may 
vary by a factor of two or more. Several potential sources of variation 
have been identified and they generally fall into two categories: 
(a) Culture factors associated with the in vitro growth of the 
lymphocytes; and (b) biological factors associated with the genotype, 
life style, or general health of the individual. The biological factors 
usually cannot be mitigated and must be accounted for in the selection 
of appropriate control cohorts or ultimately in the statistical analysis. 
(a) Culture-associated factors : A major source of variation can be 
attributed to the concentration of BrdU relative to the number of 
lymphocytes in the culture. The frequency of SCE has been shown to 
increase by as much as 50%, when the BrdU concentration is raised 10-
fold (Carrano et al., 1980). The ability of BrdU to induce SCE has been 
well documented in human and other cell systems (Wolff and Perry, 1974; 
Lambert et al., 1976; Latt and Juergens, 1976; Mazrimas and Stetka, 
1978) and it has been further shown that the SCE frequency can increase 
if the BrdU concentration is held constant, but the cell number decrease 
(Stetka and Carrano, 1977). To avoid this situation, the effect of BrdU 
is minimized by standardizing both the concentration of BrdU and white 
blood cells at culture initiation. 
Other culture-associated factors influencing SCE frequency are 
culture time (Carrano etal., 1980; Lindblad and Lambart, 1981; Das and 
Sharma, 1984), culture temperature (Speit, 1980; Das and Sharma, 1984) 
and serum used (McFee and Sherill, 1981). To avoid all sorts of bias, 
standardized procedure is used. 
(b) Biological factors : Biological factors include sex, age, diet, 
genotype, medication and smoking. Each of these potentially plays a role 
in the induction or expression of SCEs. Although some information is 
available on the influence of these factors, the consequences are not 
always clear-cut. 
I l l 
Clear documentation of a sex difference for baseline SCE 
frequencies is absent (deArce, 1981; Waksvik e/«/., 1981; Carrano and 
Moore, 1982; Livingston et al., 1983). However, there is evidence for 
increased SCE frequencies in women taking oral contraceptives (Murthy 
and Prema, 1979). 
The independence of age and baseline SCE frequency in 
lymphocytes in adults has been observed (Hollander et al., 1978; 
Livingston et al., 1983). Lower SCE frequencies have been found in 
infants (Seshadri et al., 1982), in cord blood (Ardito et al., 1980) and 
in children with a mean age of 1.5 years (Husgafvel-Pursiainen et al., 
1980). De Arce (1981) reported that people in the age range of 30-40 
years had a higher number of SCEs per cell than those between the ages 
of 0-10 or 60-70 years. Schmidt and Sanger (1981) found a significant 
increase in SCE with age when comparing age groups of 1-18 months, 
10-13 years, 26-32 years and 63-85 years. However, this might be due 
to differential, BrdU incorporation between cultures. With the exception 
of lower SCE frequencies in new born infants, the weight of evidence 
suggests that baseline SCE frequencies do not change with age. 
The role of genetic factor in the baseline SCE frequency is 
controversial, with majority of reports suggesting that there is no 
significant difference in the SCE frequency of different families (Cohen 
etal., \9S2;PedeTsonet al., 1979; Waksvikera/., 1981; Butler, 1981). 
Various drugs have been found to increase SCE frequency in human 
lymphocyte chromosomes in vitro (Ahmad et al., 2000a). Increase in 
SCE frequency is also associated with nutrition factors in certain cases 
e.g. in children suffering from severe protein calorie malnutrition 
(Murthy et al., 1980), which decreased after nutritional rehabilitation. 
Increased SCEs have also been reported in chronic alcoholics (Butler 
et al, 1981). Elevated SCE frequency has also been observed in cigarette 
smokers (Lambert et al., 1978; Ardito et al., 1980; Hopkin and Evans, 
1980; Lambert and Lindblad, 1980; Carrano, 1982; Husum etal., 1982 
112 
Livingston et al., 1983). However, this effect has not been observed in 
aJ] studies (Hollander et al., 1978; Hedner el al., 1983). 
Since the frequency of SCE has been found to be greatly increased 
on exposure to mutagenic agents, therefore, SCE is considered to be 
sensitive indicator of DNA damage (Latt, 1974; Perry and Evans, 1975; 
Carrano e/a/., 1978; Gebhart, 1981, 1982, 1984). 
Chromosomal Aberration Vs Sister Chromatid Exchange : 
It has been found that there is a positive correlation between 
chromosomal aberration and SCE frequency for most of the mutagenic 
chemicals (Latt, 1974). But, there are some mutagenic agents which cause 
increase in chromosomal aberration only and not in SCE frequency e.g. 
X-rays (Perry and Evans, 1975), certain anti-tubercular drugs in 
combination in vivo (Madhuri et al., 1983) and some antibiotics in vitro 
(Manjula et al., 1984). On the other hand there are other mutagenic 
chemicals that increase SCE frequency only and do not increase 
chromosomal aberrations e.g. aniline (Abe and Sasaki, 1977; Ishidate 
and Odashina, 1977). Another group with a small number of mutagenic 
agents are also there which neither cause chromosome aberrations nor 
induce SCEs e.g. sodium azide (Arenaz and Nilan, 1981). 
Thus SCEs and chromosome aberrations are two different endpoints 
depicting cytogenetic damage due to mutagenic action. The mechanism 
of these endpoints is probably different, one system can not replace the 
other. Therefore, both the endpoints should be scored to assess the 
genetic damage caused by drugs and chemicals. 
CELL GROWTH KINETICS: 
Cell cycle kinetics analysis is based on the differential staining 
technique of sister chromatids. It is a sensitive method for detecting 
delay or stimulation in human lymphocyte cultures. Potential of the 
mutagenic agent to produce an effect on the cells is tested by analysing 
the proportion of mitotic cells in their first, second and third replication 
113 
cycle (M,, M^ and M^ respectively). (Tice et al., 1976; Crossen and 
Morgan, 1977; Morimoto and Wolff, 1980). 
The rate at which mitosis occurs is measured by the mitotic index 
or proliferation index or replication index. A statistical difference 
between the test compound treated and control groups indicates the 
ability of the chemical to induce cell-cycle delay or cytotoxicity. In some 
instances this type of information can be important for indicating that 
metabolic activation in the test compound had occurred even though it 
was not clastogenic. Thus the index gives an idea about the stimulation 
of lymphocytes to divide and the mitotic activity in culture (Melarango 
and Smith, 1984; Sinha et al., 1984). Any change in mitotic index 
following drug exposure compared to concurrent control, provides 
information on mitostimulative or mitodepressive activity of the drug. 
Treatment resulting in SCE formation has been found to induce cell 
cycle delay (Morimoto. 1983; Craig-holmes and Shaw, 1976). However, 
the relationship between the proliferation rate as measured by cell 
growth kinetics and the induction of SCEs is controversial; It has been 
foimd that SCE levels in B-lymphocytes (early proliferating cells) were 
significantly lower than those in T-lymphocytes from the same individual 
(Santessen et al, 1979). Again Snope and Rary (1979) and Block et al. 
(1982) also found a lower SCE frequency in the more rapidly dividing 
cell populations. Lindblad and Lambert (1981) found that though the 
percentage of B and T lymphocytes did not correlate with SCE frequency, 
a significantly higher SCE rate was presented in slowly proliferating 
cultures. On the other hand, low SCE and longer cell cycle were observed 
in leukemic cells (Becher et al., 1981) and increased SCE rate and 
shortened cell cycle time were observed in trisomic cells of a Down 
syndrome mosaic (Heidemann et al., 1983). Many other workers 
however failed to find any relationship between SCE rate and cell cycle 
kinetics for example, in second generation metaphases collected from 
different culture ties (Beek and Obe 1979). Morimoto and Wolff (1980) 
and Morgan and Crossen (1981) also found no significant differences 
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in SCE frequency. Guilotto et al. (1980) also concluded that the 
incidence of SCE appeared to be independent of the proliferating 
properties of cultured lymphocytes, such as length of the cell cycle, 
fast or delayed response to PHA and number of divisions performed in 
vitro. Lambert et al. (1982) set up repeated cultures in three tissue 
culture media and found a great variability in proliferation kinetics 
between tissue culture media and between donors.Speit et al. (1986) 
also studied the SCE frequency and proliferation of cells in repeated 
human lymphocyte cultures. They found no systematic relationship 
between the proliferation of culture and basal SCE values. Also, a great 
variation in the two parameters was observed in repeated cultures. 
B. CYTOGENETIC EFFECTS OF STEROIDAL HORMONES 
L Estrogens : 
According to Wheeler et al. (1986) estrogens are mitotic poisons 
which at high concentrations, cause metaphase arrest, abnormal cell 
division and chromosomal aberrations. 
The overall conclusion that emerge from the results of present 
investigation reveals that estrogens are potent mutagens and they are 
well associated with a significant increase in the incidence of 
chromosomal abnormalities per cell as well as with an increase in the 
number of abnormal cells in lymphocyte cultures in vitro, when 
compared to the normal control culture. Both of the estrogens used in 
the present study i.e. mestranol and quinestrol, were found to be 
genotoxic. These synthetic steroidal hormones induce chromosomal 
aberrations in the absence as well as in the presence of metabolic 
activation (S^ mix.) Although at higher doses of these drugs the 
frequencies of chromosomal aberrations decreased drastically, probably 
due to cell death. 
The two estrogens, mestranol and quinestrol, taken for the analysis 
are widely used drugs in the treatment of varieties of diseases. Mestranol 
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is a widely used oral contraceptive, besides it is being used in hormonal 
replacement therapy. It is a combination drug which is used with 
ethynodiol diacetate, norethylnodrel ornorethindrone. Quinestrol is used 
in replacement therapy which gets metabolized inside the body to 
ethinylestradiol. This metabolic product is the most widely used 
estrogen in oral contraceptive combination and one of the most potent 
estrogen known. 
Reports on the mutagenic activity of sex steroids or oral 
contraceptives in vitro and in vivo are contradictory. Gob (1967) 
demonstrated a variety of complex chromosomal rearrangements in the 
peripheral blood leucocytes of women taking oral contraceptives. Carr 
(1967) found that there is no evidence of an increase in congenital 
anomalies in pregnancies which result after discontinuing oral 
contraceptives, al though in another investigation he repor ted 
chromosome abnormalities in 6 out of 8 abortuses collected from women 
who became pregnant after taking oral contraceptives. Two types of 
anomalies were observed triploidy and X-monosomy. Trisomy was the 
most common type of chromosomal defect observed at birth (Carr, 
1970). Gob and Carr suggested that the imbalance in steroidal hormones 
in the blood was the causative factor of chromosomal breaks. A 
somewhat lower frequency of chromosomal breaks was found in cross 
cultures after the women had stopped taking the pills. However, 
Stenchever and his associates (1969) did not find obvious chromosomal 
effects in vitro of various gestagens in lymphocyte cultures with varied 
concentrations and with controls. Gob (1967) suggested that the oral 
contraceptives may cause chromosome breaks as do some other drugs 
and pointed out that the breakage was not observed in peripheral venous 
sampling after discontinuation of "the pills". In another study by 
McQuarrie et al. (1970), cytogenetic changes of increased chromosome 
breakage and satellite association were observed in 23 patients using 
oral contraceptives. Cytogenetic aberrations in lymphocytes from 
women taking oral contraceptives have also been observed by Badr et 
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al. (1972). In contrast, another group of scientists demonstrated that 
oral contraceptive pills do not have potential to induce chromosome 
breakage in pill users (Shapiro et al., 1972). It was also found that 
synthetic hormones may induce cytogenetic abnormalities in germ cells 
of rats, dogs and hamsters. Littlefield et al. (1975) suggested, after 
comparing the results of cytogenetic studies of lymphocytes culture 
from normal women, pregnant women and women taking oral 
contraceptives, that the increase in breakages in cultures from the oral 
contraceptive users was not related with length of time on pill or stage 
of the pill cycle, and thus the synthetic hormones do not directly damage 
lymphocyte chromosomes. Timson (1969) dealt with the in vitro and in 
vivo cytogenetic effects of lyndiol (an oral contraceptive). He observed 
no chromosome abnormalities in either conditions. The same steroid 
was again studied by Bishun et al. (1975), who also did not find any 
significant effect on chromosomal aberration incidence. Another study 
involving chromosomal examinations of babies whose mothers had taken 
oral contraceptives was undertaken by Rice-Wray et al. (1970). They 
did not find significant level of structural or chromosomal abnormalities 
in the cells examined from the babies. Fitzgerald et al. (1973) compared 
the results of chromosomal aberrations in lymphocytes of women taking 
oral contraceptives for over 4.5 years from control women. He also 
reported no increase in chrmosomal aberrations in their cells. 
DeGutierrez and Lisker (1973) studied 35 patients on mestranol and 
ethynodiol acetate, and failed to confirm any chromosomal abnormalities 
in the women after culturing their blood for 65 hours. These results were 
also confirmed by Mills et al. (1975), and Matton-Van-Leuven et al. 
(1974). On the other hand Littlefield and Mailhes (1975) observed a 
statistically significant increase in average breakages in a series of 
cultures from the group of oral contraceptive users. Rohbom and 
Hansmann (1974) found a slight but not significant increase of non-
disjunction due to norethisterone acetate treatment. Estradiol, the most 
potent naturally occurring estrogen, was found to induce very low 
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frequencies of hyperploidies in human synovial cells in vitro (Lycette 
et al., 1970), and various numerical aberrations in pig oocytes in vitro 
(Mc Gaughey, 1977). In human embryonal fibroblasts and kidney 
epithelial cells, estradiol was reported to induce structural chromosomal 
aberrations (Serova and Kerkis, 1974). In contrast, Banduhn and Obe 
(1985) observed no structural chromosomal aberration in human 
lymphocytes in vitro after estradiol treatment. In another study the use 
of hormonal contraceptives was found to be associated with a highly 
significant increase of chromosome aberrations (Pinto, 1986). 
Ovral 50, an oral contraceptive, was found to be genotoxic in mice 
(Devi and Reddy, 1986) whereas, the same drug was unable to induce 
genotoxic effects in human lymphocyte cultures in vitro. Anovlar 21, 
another oral contraceptive containing estrogen, ethinyl estradiol, and 
progestin, norethisterone acetate, causes a statistically significant 
increase in chromosomal aberration in cultured mouse bone marrow 
(Shyama et al., 1991). Dhillon et al. (1994) found that mestranol was 
capable of causing chromosomal aberrations in mouse bone-marrow cells 
in vitro. Ethinyl estradiol, a potent estrogen, was found to induce 
chromosomal aberrations in male Syrian hamster kidney cells in vivo 
and in mouse bone-marrow cells in vivo. Estradiol-17b another potent 
estrogen was found to induce various structural chromosomal aberrations 
in human lymphocyte chromosomes in vitro (Ahmad et al., 2000a). 
In the present study of the various chromosomal aberrations 
induced by mestranol and quinestrol, chromatid, and chromosome 
fragments and breaks were more frequent. In certain cases, at higher 
doses, multiple anomalies were also observed. Similar observations have 
been made earlier by McQuarrie et al. (1970) in human lymphocytes, 
and in anovlar treated plant chromosomes by Kabarity and Mazrooei 
(1984). Breaks and structural aberrations observed in the present study 
were not restricted to any particular chromosome or segment and were 
random. Few metaphases were also observed with 45 chromosomes and 
few others with 47 chromosomes. A few metaphases were observed with 
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endoreduplication in quinestrol treated cultures at highest dose and time 
duration. This effect might have resulted due to inhibition of microtubule 
formation during cell division. In most of the metaphases, more than 
one chromosomes were found affected. Because the breaks were random, 
no any particular fragile site was observed for any particular 
chromosome. It has been observed in earlier studies that the common 
effects of steroid hormones on chromosomes are stickiness in 
diakinesis and metaphase, and bridges and sometimes lagging 
chromosomes in anaphase (Hakeem and Amer, 1965). Anovlar has been 
found to cause chain of bivalents in addition to stickiness, which may be 
due to the sticking of the ends of the different bivalents with each other 
(Kabarity and Mazrooei, 1984). The trend of abnormalities caused by 
mestranol and quinestrol were similar. Quinestrol might have been 
metabolized into ethinyl estradiol, its parent compound, by the human 
lymphocytes as has been reported by Iskandar and Vijayalaxmi (1981). 
The potency of ethinyl estradiol as a mutagen is controversial 
(Stenchever et al, 1969). 
In the observation of different chromosomal abnormalities in 
lymphocyte cultures in vitro, caused by estrogen mestranol and 
quinestrol, it was found that chromatid breaks were more frequent than 
chromosome breaks. This indicates that the drug introduces replication 
errors or breaks replicated chromatids (Ahmad et al, 2000a). Shyama 
et al. (1991) suggested that frequent chromatid breaks were due to the 
effects of the drug on the DNA strand at its late S-phase or after the 
DNA has replicated or duplicated. The peripheral lymphocytes are cells 
which remain in G^-stage of their cell cycle and do not divide inside the 
body. But the majority of chemical mutagens affect the chromosomes 
only when the cell is dividing and passing through the S-phase. When 
the DNA is uncoiled during S-phase for replication of the DNA mol-
ecule, the mutagens make action on it. Therefore, it is necessary for 
the cells to go through S-phase at least ones between treatment with the 
chemical mutagen and observations. So, the mitogen (PHA) stimulates 
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the lymphocytes to enter cell cycle in vitro. It can be said that the fre-
quency of chromatid type aberrations observed, following exposure of 
G cells to the drug, are produced by errors in DNA repair in cells in G^ 
or S-phase. The chrotamid type aberrations may be due to errors in DNA 
regions that have already replicated at the time of exposure or by errors 
in DNA replication on a damaged DNA template . Aberration is a rare 
occurrence in comparison to the amount of induced DNA damage, most 
of which is efficiently repaired. The kinetics of repair of different types 
of DNA damage affects the types of structural alterations produced. 
Most clastogenic chemicals produce aberrations almost exclusively by 
errors of DNA replication on an adducted template. However, given the 
relatively slow overall rate of repair of DNA damage induced by most 
chemicals, there is least probability to produce aberrations by repair 
error. The probability of obtaining such coincident repair is greatly en-
hanced by using a DNA repair inhibitor, such as cytosine arabinoside. 
Chromosome-type aberrations are formed in cells in Gj treated with 
chemicals that are commonly described as S-phase-dependent (Preston 
and Gooch, 1981). Thus, it is essential in any cytogenetic assay for so-
called S-phase dependent chemicals to ensure that the cells observed at 
metaphase have passed through the S-phase between treatment and sam-
pling. If the induced frequency of all aberration classes is required, cells 
should be sampled for metaphase analysis at their first mitosis after a 
single treatment. Since several types of aberration produce cell lethality 
and/or loss of an acentric fragment at division, observation at the sec-
ond or subsequent mitosis after treatment leads to a lower aberration 
frequency than that induced (Preston, 1999). 
The frequency of chromatid aberrations produced by DNA 
replication errors is influenced most strongly by the dose to the cell, 
the phase of the cell cycle, DNA repair kinetics, DNA replication fidelity 
and maintenance of cell cycle checkpoints. Thus, different cell types 
can have different sensitivity to chromosomal aberration induction as a 
consequence of differences in these factors. 
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Numerical changes which were also observed in the case of 
mestranol and quinestrol treatment (i.e. monosomies, trisomies and a 
rare event of diploidy) can arise from errors in chromosomal segregation. 
The apparent complexity of the control and the mechanisms of the 
mitotic process means that alterations of a number of components can 
result in failure to segregate the sister chromatids to separate daughter 
cells or in a failure to segregate a chromosome to either pole (Bickel 
and Orr-Weaver, 1996). The mechanisms underlying chromosomal loss 
are pertinent to those involved in the formation of centromere-containing 
micronuclei. 
A limited set of chemicals has been demonstrated to cause 
aneuploidy through interaction with components of chromosome 
movement. These include benomyl, griseofulvin, nocodazole, colchicine, 
colcemid, vinblastine and taxol. These chemicals affect tubulin 
polymerization or spindle microtubule stability. Till date, other 
mechanisms of aneuploidy induction have not been clearly identified. 
Three different doses i.e. 10, 25 and 50 mg/ml concentrations and 
three different time durations i.e. 24, 48 and 72 h were taken for this 
study. It was observed that at 10 mg/ml concentration mestranol is unable 
to induce significant level of chromosomal aberrations. Whereas 
quinestrol induces significant increase in chromosomal aberration only 
for 72 h of incubation. Both the drugs show maximum activity at 25 mg/ 
ml of dose concentration, and the highest increase for 72 h of treatment. 
Whereas, at the highest concentration (50 mg/ml) mestranol did not 
induce significant increase in chromosomal aberration, but the other drug 
quinestrol affects the chromosome only for 24 h of treatment duration. 
This decline in the frequency of aberration with increase in the dose 
concentration for both the drugs and with increase in time duration at 
50 mg/ml concentration for quinestrol, may be due to some or all of the 
following reasons, namely (i) repair of damaged genetic material; (ii) 
elimination of the drug and its metabolites; (iii) elimination of cells/ 
chromosomes with damaged genetic material; (iv) inactivation of the 
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drug and its metabolites; (v) and due to cell cycle delay or cell killing 
effect. 
Both the synthetic steroidal estrogens i.e. mestranol and quinestrol, 
were also evaluated for their cytogenetic effects in the presence of 
metabolic activation. Both the drugs were found to be ineffective at 10 
mg/ml dose concentration whereas, highly effective at 25 mg/ml 
concentration. And also found effective at 50 mg/ml concentration in 
contrast to the results obtained in the absence of S^  mix. This increase 
in the chromosomal abnormalities may be due to the action of the 
metabolites of the drugs. Drugs are metabolized by the microsomal 
activation system. In this case the metabolites of the drug might have 
been more potent cytogenetically than the drug themselves and 
consequently have caused more chromosomal abnormalities. But these 
metabolites were less potent than the drugs in terms of their abilities to 
induce probable cell billing effect. The effect of mestranol on human 
lymphocyte chromosomes in the presence of S^  mix has not been studied 
earlier. But it has not been found potent enough to cause reverse mutation 
in Salmonella typhimurium in the presence of S^  mix. (Dhillon et al., 
1994). However, in various other studies, in combination of different 
drugs in the presence of S^  mix, mestranol has been found to cause 
reverse mutation in Salmoneila typhimurium. Quinestrol has not been 
studied earlier for its genotoxic effects either in the presence or in the 
absence of metabolic activation. But, ethinylestradiol, the parent 
molecule of quinestrol (to which it is metabolized to), has been found 
to be ineffective in causing mutation in Salmonella typhimurium and in 
Chinese hamster lung V79 cells in the presence of metabolic activation. 
It was observed in the present investigation that both the estrogens 
mestranol and quinestrol affected the SCE frequency in a similar fashion 
that had been observed in the case of chromosomal aberrations. 
Maximum value of SCE was observed at 48 h of treatment durations for 
all dose concentrations. But statistically significant value of SCE was 
observed only for 25 mg/ml dose concentration in the case of mestranol 
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both in the presence and absence of S^mix. Quinestrol increased the 
frequency of SCE in human lymphocyte chromosomes in the absence of 
S5 mix only for 25 mg/ml concentration. Whereas in the presence of S^  
mix the drug was effective at two concentrations i.e. 25 mg/ml and 50 
mg/ml, but the frequency of SCE was maximum at 50 mg/ml 
concentration. The decrease in the frequency of SCE at the highest 
concentration might have been due to the cell killing effect of the drug. 
Similar type of observations have been made earlier also by different 
groups of scientists. Murthy and Prema (1979) reported an increased 
SCE frequency in peripheral lymphocytes of oral contraceptive users. It 
was again observed that estrogen progestogen combination contraceptive 
exhibited an increased frequency of SCE but the progestogen injectable 
contraceptive alone did not (Murthy and Prema, 1983). Similar results 
for estradiol were observed by Banduhn and Obe (1985). Dose response 
effect was observed by Kochhar (1988) for four different estrogens in 
cultured Chinese hamster ovary cells. The drug mestranol was found to 
induce SCE in mouse bone-marrow cells (Dhillon et al., 1994). Another 
group of researchers observed that the use of oral contraceptives had no 
influence on SCE (Husum etai, 1982). Hill and Wolff (1983) reported 
that estradiol and estriol were unable to induce SCE in human 
lymphocytes. Estradiol-17b was found to be effective in contrast to the 
above reports in inducing SCE in human lymphocytes in vitro in the 
presence as well as in the absence of S^  mix (Ahmad era/., 2000). The 
combination of drugs mestranol and norethisterone were found to be 
ineffective in inducing SCE. 
The mechanism of sister chromatid exchange is that it is produced 
during DNA synthesis and is presumed to be a consequence of errors in 
the replication process itself, perhaps at the site of stalled replication 
complexes (Painter, 1980; Heartlein ei al., 1983). The creation of 
intracellular condition that slows down replication, for example, could 
also induce sister chromatid exchange (Preston, 1999). 
The overall results of the present investigations on the cell growth 
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kinetics show that both the drugs inhibit in vitro proliferation of 
lymphocytes in the presence as well as in the absence of metabolic 
activation. It has been reported earlier that the estrogen, estradiol, 
strongly inhibits proliferation of human lymphocytes, but another 
estrogen, estriol, was a weak inhibitor (Hill and Wolff, 1983). Estradiol 
also inhibits DNA and protein synthesis in mouse fibroblasts which may 
result in the inhibition of cell proliferation, whereas the estriol did not 
inhibit DNA and protein synthesis (Kuchler and Grauer, 1962). Both in 
the presence and absence of metabolic activation estradiol was found to 
inhibit cell proliferation (Ahmad et al., 2000a). Mestranol and quinestrol 
has not been evaluated for their cell growth inhibiting potential earlier, 
but the present finding is supported by earlier studies on most of the 
estrogens. Proliferation of lymphocytes in culture is dependent on the 
time of phytohaemagglutinin (PHA) mediated transformation of small 
resting (G J lymphocytes into blast cells and the length of the cell cycle 
after the proliferation has taken place (Morimoto and Wolff, 1980). It 
has also been observed that T-lymphocytes respond to PHA first (Greaves 
et al., 1974). As activated T-cells are necessary to produce a later B-
cell response, so it is possible that these estrogens slow down the T-
cell proliferation, thus B-cell transformation is delayed in treated 
cultures. On the other hand it has also been reported that the estrogens 
accelerate the mitotic activity immediately after administration of the 
first dose (Gopala Krishna and Inamdar, 1971). However, accelerated 
level never exceeds normal level that is established in the target tissues 
in due course. Cell growth is inhibited after estrogen exposure due to 
an extended G^ phase. The average length of time for G^ in actively 
dividing lymphocytes is 3.5 h (Hill and Wolff, 1983). The cells may be 
arrested in G^ or may stop division due to damage to DNA and cell 
division may be blocked. Such G^ blocks are well known after cells are 
X-rayed. Chinese hamster ovary cells has been reported to be blocked 
m G^ phase when treated with nitrosourea (Rao and Rao, 1976). In the 
same study by using the premature chromosome condensation technique. 
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it was observed that a linear relationship exists between the number of 
extensively damaged G^ chromosomes and the accumulation of G^ cells 
in treated cultures, and it was suggested that chromosome damage is a 
contributing factor to the G^ arrest (Rao and Rao, 1976). 
Progestins : 
The two important and widely used progestins i.e. norethindrone 
and norgestrel, were evaluated for their genotoxic potential. The results 
reveal the fact that norethindrone was not potent enough to cause 
genotoxic damage in human lymphocytes in vitro. Whereas the other 
progestin norgestrel was highly effective in inducing chromosomal 
aberrations at higher doses with a dose time relationship. 
Norethindrone is an important oral contraceptive which is used 
either alone or in combination with mestranol or ethinylestradiol (both 
estrogens). Norgestrel which is a synthetic progestin with potentially 
all the actions and uses of progestins, it is marketed only as an oral 
contraceptive both as a single entity product and in combination with 
ethinyl estradiol. Genotoxic effects of either of two drugs have not been 
studied earlier in any test system. Whereas, genotoxic effects of various 
other progestins have been evaluated, Goh (1967) and Carr (1967) have 
reported chromosomal abnormal i t ies in the per iphera l blood 
lymphocytes of women taking oral contraceptives. Goh (1967) suggested 
that oral contraceptives may cause chromosome breaks and pointed out 
that the breakage was not observed in peripheral venous sampling after 
discontinuation of the pills and suggested that the individuals are capable 
of removing "mutant cells". Although it might be possible to remove the 
somatic mutant cells by discontinuation of the steroidal contraceptive, 
the germ cells may not be removed so easily. Ovulation can accomplish 
this slowly. The chances of pregnancy incorporating the mutant cell are 
possible if these cells are affected (McQuarrie et al., 1970). Therefore, 
the greatest danger of oral contraceptives lies in the potential damage 
to the gametes. Since contraceptive hormones are in circulation, they 
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presumably have free access to germ cells . The existence of 
chromosome damage in these cells can lead to a hazardous situation. 
Badr et al. (1972) have also reported about the cytogenetic 
aberration causing potential of progestogens in lymphocytes from women 
taking oral contraceptives. Whereas other studies have not demonstrated 
increased chromosome breakages in women taking progestins as oral 
contraceptive (Shapiro et al., 1972). Littlefield et al. (1975) have 
observed chromosome damage in lymphocytes from women exposed to 
progestins. They concluded that the effect of synthetic hormones on 
chromatin is not directly related to concentration of circulating hormone 
molecules or length of time of exposure. It has been reported that 
norethindrone does not have potential to induce cytogenetic damage in 
female swiss albino mouse bone-marrow cells in vitro. Norethindrone 
acetate, a synthetic derivative of norethindrone, was also studied by 
different groups of scientists and the result found was again contradictory 
(Stenchever et al., 1969; Shyama et al., 1991). Norgestrel has been 
reported to be studied in combination with ethinylestradiol. It induces 
cell transformation in primary baby rat kidney. The embryolethality 
induced by combination drug norethindrone and ethinylestradiol might 
have been due to mutation caused by these drugs. 
In the presence of metabolic activation, similar types of results 
were observed. Norethindrone was not able to induce any genotoxic 
damage whereas norgestrel induced chromosomal aberrations with 
increased intensity, and a time and dose relationship observed may be 
due to the more potent metabolites in the case of norgestrel. 
Norgestrel was found to induce aberrations such as breaks, gaps, 
terminal deletions and pulverization. A dose dependent increase in 
aberrations was also noted. Among the various aberrations observed, 
gaps, breaks and terminal deletions were very frequent and they increased 
significantly at higher doses. Gaps were found in significant frequencies 
even at 25 mg/ml, whereas breaks were observed in significant 
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frequencies only at 50 mg/ml dose concentration. CP also induced 
significant frequencies of aberrations. Metaphases with fragmentation 
and multiple aberrations were observed with CP-treated cultures. 
Aberration frequencies increased with increase in treatment duration of 
the various aberrations observed, breaks and gaps were seen at all time 
intervals, but pulverization was noted in few metaphases at maximum 
treatment duration and highest dose concentration only. In the case of 
norgestrel it was observed that chromatid breaks were more common 
than the chromosome breaks, as has been observed in the case of the 
estrogens in the present study. This indicates that the drug affects the 
DNA strand either at its late S-phase or after the DNA has replicated or 
duplicated. 
The present result on SCE analysis shows that norethindrone did 
not induce significant increase in SCE frequency at any treatment duration 
and for any dose concentration. But the drug norgestrel was found to 
enhance the SCE frequency at significant level at 25 and 50 ug/ml 
concentration both in the presence as well as in the absence of S^  mix. 
However, here also, higher incidence of SCE was observed in the presence 
of Sp mix. 
In some earlier studies contradictory results have been found 
regarding the SCE inducing potential of progestins. Husum et al. (1982) 
observed that oral contraceptives containing progestins do not enhance 
SCE frequency in the cultured lymphocytes of user women, though 
Murthy and Prema (1979) observed significant increase in SCE fi-equency 
in a similar study. In another study Murthy and Prema (1983) found that 
women using progestogen contraceptives have normal SCE rates. This 
may mean that Ae increased SCE rates observed in the combination type 
contraceptive users could be due to mutagenic activity of the estrogen 
or its metabolites. Norethindrone acetate has been found to increase 
significant level of SCE frequency in human male lymphocytes in vitro. 
There exists a relationship between increased SCE rates and altered 
mutation frequency (Carrano et al., 1979), the long term persistence of 
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increased SCEs in hormonal contraceptive users may have some ill 
effects on the health of users. It may be important to find out whether 
the changes in SCEs associated with the use of contraceptives could be 
reversible. Prema and Murthy (1983) reported that the frequency of SCE 
in eight women during the use of combinational contraceptives increased 
significantly and markedly decreased later on, in those women who 
discontinued the contraceptive. This may mean that cells with increased 
SCEs are being replaced with cells with 'normal' SCEs in these women. 
It may, therefore, be argued that due to persistent use of contracptives 
the increased SCEs might have resulted into cell death because of 
excessive and intense point mutations. 
The overall results of the present investigations on the cell growth 
kinetics showed that Norethindrone did not inhibit the in vitro 
proliferation of lymphocytes both with and without metabolic activation. 
However, the other progestin studied i.e. norgestrel, strongly inhibited 
the proliferation of lymphocytes and arrested the growth both in the 
presence as well as in the absence of metabolic activation. The effect 
was more prominent in the presence of metabolic activation. Earlier 
studies show negative result about the cell proliferation inhibiting 
potential of progestins. Norethindrone acetate in combination with 
ethinylestradiol do not affect the mitotic index significantly (Shyama 
et al., 1991). Similar type of result was obtained for norgestrel in 
combination with ethinyl estradiol by Kabarity and Mazrooei, (1984). It 
may be suggested that inhibited growth of cells after norgestrel treatment 
was observed due to an extended G^ phase. 
The reduction in mitotic index (MI) with increasing dose 
concentration of norgestrel may be attributed to inhibition of DNA 
synthesis, preventive effect of the drug on protein binding in the cells 
and induction of genetic damage. Widemayer and Shaver (1972) studied 
the chromosome complement of blastocysts recovered from rabbits 
injected with progesterone or estradiol during the time of ovum 
maturation or the first cleavage division. They found that the spindle 
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fibre apparatus was disturbed due to the treatment. A lower mitotic index 
than normal was found in whole mounts of those blastocysts. 
Androgens : 
In the present study the results of the androgens i.e. danazol and 
oxymethalone show that both the drugs are not potent enough to induce 
statistically significant increase in chromosomal aberrations in human 
lymphocyte chromosomes in vitro either in the presence or in the 
absence of metabolic activation (S^ mix). Very little work has been done 
on androgens in the past time. Testosterone did not induce gene mutation 
in Salmonella typhimurium and shown negative result in micronucleus 
test in vivo (Ingerowski et al., 1981). SCE analysis reveals the fact that 
both the drugs did not enhance the SCE frequency either in the presence 
or in the absence of metabolic activation. The values obtained were not 
signification statistically at P < 0.05. Similar types of results were 
obtained for cell growth kinetics assay. Both the drugs i.e. danazol and 
oxymethalone were found unable to inhibit cell proliferation in the 
presence as well as in the absence of metabolic activation. 
Thus it was concluded that androgens in general, and danazol and 
oxymethalone in particular are not genotoxic and do not have potential 
to induce significant level of structural or numerical chromosomal 
aberrations, sister chromatid exchanges and cell proliferation inhibiting 
effect at any concentration and for any exposure duration in human 
lymphocyte chromosomes. It was observed that metabolites of both the 
drugs (i.e. drugs in the presence of S, mix) were also ineffective in 
producing any type of genotoxic effect. 
Thus, the overall conclusion may be derived from the present 
investigation that the use of synthetic steroidal drugs, particularly those 
drugs which are used as oral contraceptives, is associated with a 
significant increase in the incidence of chromosome abnormalities per 
cell as well as with an increase in the number of abnormal cells, and 
also with gene mutation which is exhibited as SCE. It is established that 
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there is an apparent relationship of chromosome abnormalities, sister 
chromatid exchanges and cell growth kinetics with mutagenesis, 
carcinogenesis (Mitelman and Pero, 1979; Sandberg, 1980) and 
teratogenesis (Purtilo et ai, 1978; Joshi el al., 1983). Therefore, in 
vitro screening for chromosome aberrations and other cytogenetic 
damage has become an established tool in the evaluation of potential 
hazards to the genetic material due to environmental agents. Synthetic 
steroidal drugs particularly those drugs which are used as contraceptives 
have been more widely studied than any other drug in history (Pinto, 
1986). However, the great limitation of this morphological approach is 
that only gross genetic damage is visible in chromosomal aberration and 
negative findings do not exclude other types of genetic damage such as 
those resulting in point mutations. Although point mutations are visible 
in the case of SCEs, but when the value of SCE is insignificant the point 
mutations are not considered hazardous, although a single base pair 
change sometimes lead to death of the cell. Therefore, there must be a 
system to detect single gene mutations also. The present observation 
also suggest that for a complete evaluation of mutagenic effects, a 
battery of test systems should be used, since no single test can be 
expected to detect all mutagens and mutations. 
The phenotypic expression of genetic damage, either as visible 
chromosome aberrations or single point mutations, is dependent on the 
developmental time when the damage occurs, namely pre-or post-natal 
life and the type of cell, somatic or germinal, in which the damage occurs 
(German, 1979). If such damage occurs in somatic cells of the developing 
embryo it can lead to malformations and abortions in extreme cases. 
The malformations could be the result of (a) chromosome breakage with 
consequent extensive cell death; (b) unbalanced stable chromosome 
abnormalities; (c) single gene mutations. The teratogenic effects of 
synthetic steroidal drugs might have been the result of genetic damage 
reported in several studies (Nora and Nora, 1973, 1975; Janerich et al., 
1974, 1980; Royal College of General Practitioners, 1976; Janerich and 
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Piper, 1978; Bracken et al., 1978; Rothman and Louik, 1978; Kasan and 
Andrews, 1980; Harlap et al., 1979; Joshi et al., 1983). The reasons 
could be explained by one or more of the above described mechanisms. 
An excess of chromosomally abnormal spontaneous abortions have been 
reported in mothers who use synthetic steroids as oral contraceptives 
when compared with non-users (Alberman et al., 1976). Any genetic 
damage occurring in germ cells of a person taking these drugs would 
only be manifested in his or her offspring either in the form of single 
gene mutations or chromosome abnormalities leading to teratogenesis 
or carcinogenesis. Even if a recessive mutation or balanced chromosome 
abnormality is not expressed in the first generation, it could possibly 
manifest several generations later, due to fetal germ or somatic cell 
mutations. 
The theoretical possibility of genetic damage during post-natal life 
will apply directly to the health of the drug user. Any mutational effect 
on adult somatic cells could lead to cancer and although data are 
accumulating on the possible association between the use of these drugs 
and different types of cancers, yet these are not conclusive and still more 
study need to be done (Nissen et al., 1978; Royal College of General 
Practitioners, 1981; Swan and Petitti, 1982; Weiss et al., 1976). 
Therefore, care should be taken of the potential hazards of such 
drugs, especially if they are in use for longer periods of time. The basic 
chemical structure of all synthetic steroids used in this study is same 
i.e. they are composed of 1,2, cyclopentanoperhydrophenanthrene ring. 
Then what is the factor which is responsible for a drug to become 
genotoxic? May be the molecular structure of a drug is the deciding 
factor to determine whether the drug is harmful or not. Another 
mechanism involved is the generation of free oxygen radicals in the 
growth medium which results in an increase of chromosome breakage 
and SCE rates of human lymphocyte cultures. This can be prevented in 
the presence of the enz>'me superoxide dismutase (Emerit et al., 1981). 
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Free oxygen radical species are supposed to be generated by 
electrophilic groups on the synthetic steroids (Islam et al., 1991). The 
synthetic steroids initiate the SOS response and thus brings about the 
mutation in DNA. The DN A damage and/or mutation with the concomitant 
SOS-like response brought about by mutagenic steroids might also play 
an important role in the neoplastic transformation. Oxygen radical 
formation in the living system increases the risk of chemical 
carcinogenesis and certain steroids might be instrumental in the 
causation of cancer owing to their typical ring structure which could 
intertact with the DNA bases on the one hand and might also provide a 
favourable micro environment for the generation of toxic radicals on 
the other. The mutagenicity appears to involve the formation of hydrogen 
paraoxide as well as superoxide and hydroxy radicals (Islam et al., 1991). 
Therefore, it can be concluded that androgens (danazol and 
oxymetholone) and the progestin, norethindrone, do not produce free 
oxygen radicals in the lymphocytes. Their molecular structure differed 
from the estrogen (mestranol and quinestrol) and the progestin, 
norgestrel, in such a way that they were not able to produce f'ce oxygen 
radicals and thus were not able to induce significant level of cytogenetic 
damage in the lymphocytes. Whereas, both the estrogens (mestranol and 
quinestrol) and the progestin, norgestrel, were having such a molecular 
structure that they generated free oxygen radicals in the human 
lymphocytes and induced mutagenesis. 
It is, therefore, advisable to be careful of the potential hazards of 
these drugs to which we are continuously exposed day in and day out in 
modern life. This demands the lowest possible use of effective and 
acceptable doses of these drugs so as to minimize any potential risk. 
Otherwise, they may become capable of attacking the genetic material 
directly in their unmetabolized as well as metabolized state. 
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Abstract 
The cytogenetic effect of a hormonal steroid, estradiol-17p, was assessed m peripheral blood human lymphocyte culture 
Sister chromatid exchanges (SCE) and chromosome aberrations (CA) were scored as genetic end points Significant 
induction of CA was observed at 25 |Jig/ml and 50 (Ag/ml concentrations of estradiol-17p in the absence of microsomal 
activation The drug was effective in all treatments in the presence of rat liver Sy microsomal fraction (Sy mix) and 
exhibited increased frequency of chromosomal aberrations The drug was effective in increasing the SCE frequency which 
was found to be maximum at the dose of 50 (xg/ml concentration (i e , 4 34 ± 1 22) both with and without metabolic 
activation It was found that estradiol-17(3 itself and possibly its metabolites are potent mutagens beyond a particular dose in 
human lymphocytes © 2000 Elsevier Science B V All nghts reserved 
Keywords Estrddiol 17(3 Chromosomal aberration Sister chromatid exchange Lymphocyte 
1. Introduction 
Sex hormonal steroids are used as medicine for 
human for a large variety of conditions, apart from 
their uses as oral contraceptive agents, viz, in the 
treatment of dysmenorrhea, endometnosis, dysfunc-
tional uterine bleeding, climacterics and in the 
prevention of postmenopausal osteoporosis They 
diffuse through the cell membrane and after conju-
gating with specific receptor proteins in the cyto-
plasm, pass through the nuclear pore to form 
steroid-DNA complexes This complex alters the 
Corresponding author Fax +91 571 409081 
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gene expression of many cellular processes including 
enzyme synthesis [ 1 ] Estradiol also binds to isolated 
DNA [2,3] and induces fragmentation [4] Several 
sex steroids have been studied for their teratogenic 
[5], carcinogenic [6], mutagenic and clastogenic [7] 
potentialities Estrogens have been identified as mi-
totic inhibitors It was suggested that the structural 
specificity is required for mitotic inhibition [8] Es-
trogens are mitotic poisons, which at high concentra-> 
tion, cause metaphase arrest, abnormal cell division 
and CA [7] Estrogens also induce the formation of 
endogenous DNA adducts both in human and ani-
mals and can ultimately lead to cancer development 
[9,10] Contraceptive steroids induce DNA repair 
synthesis in rat hepatocytes cultures, indicating DNA 
damage [11] These drugs can also have a tumor 
inducing potential in rat liver in addition to its tumor 
nSI 5718/00/$ see front matter © 2000 blsevier Science B V All nghts reserved 
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promoting activity [12]. Estradiol is carcinogenic in 
experimental animals. Administration of estrogens 
leads to an increase in endometrial cancer in women, 
and estradiol can be expected to have a similar effect 
[13]. Esrtradiol-17p is one of the sex hormones, and 
occurs in two forms alpha and beta. Beta estradiol 
has the greatest physiological activity of naturally 
occurring estrogens. The alpha form is relatively 
inactive. Estradiol was found to induce very low 
frequencies of hyperploidies in human synovial cells 
in vitro [14] and various numerical aberrations in pig 
oocytes in vitro [15]. In human embryonic fibroblasts 
and kidney epithelial cells, estradiol was reported to 
induce structural chromosomal aberration [16]. Si-
multaneous addition of estradiol, progesterone and 
human chorionic gonadotrophin (HCG) increased the 
SCE frequency in human lymphocyte culture, but 
their separate administration did not induce SCEs 
[17]. The hormone is negative in the Ames test [6] 
and does not induce point mutations in mammalian 
cells in vitro [18]. In the present study, we investi-
gated the genotoxic effect of estradiol-17p on human 
chromosomes in lymphocytes cultures in vitro. 
2. Materials and methods 
2.1. Chromosomal aberration analysis 
Metaphase chromosome analysis for the detection 
of CAs was performed according to conventional 
technique [19]. Lymphocyte cultures were set up by 
adding 0.5 ml of heparinized whole blood, from two 
adult and healthy male donors (who were not occu-
pationally exposed to mutagens) to 4.5 ml of TC-199 
medium (Flow Laboratories) supplemented with 15% 
fetal calf serum (Gibco), antibiotics (Penicillin and 
Streptomycin 100 lU/ml each; Hoechst) and 
L-glutamine (1 mM; Gibco). Lymphocytes were 
stimulated to divide by adding 0.1 ml of phyto-
haemagglutinin-M (PHA-M; Microlab). The cultures 
were incubated at 37°C and 5% CO, for 72 h in the 
dark. Estrtadiol-17p (Wyeth Lab, India), at a final 
concentration of 10, 25 and 50 (xg/ml was added for 
24, 48 and 72 h of duration by adding the steroid 
after 0, 24 and 48 h in reverse order after the 
initiation of cultures. Dimethylsulphoxide (DMSO 5 
p,g/ml; SRL Bombay, India) was added to the 
simultaneously kept cultures for 72 h of incubation 
as negative control. And for positive control, cyclo-
phosphamide (CP 1 X 10 ' M) was added for 24, 48 
and 72 h of incubation. 
In the metabolic activation experiments, 6 to 30 h 
old cultures were given treatment with 10, 25 and 50 
(xg/ml concentrations of the drug in the presence of 
rat liver Sy microsomal fraction. Liver S^ fraction 
was prepared from healthy albino rats induced with 
phenobarbital and it was stored in liquid nitrogen 
until use. S, mix was freshly prepared for use. The 
cells were collected after centrifugation and the pel-
lets were washed twice in the pre-warmed medium 
to remove the chemical and the S,, mix. The parallel 
cultures receiving the same doses of the drug for 
similar treatment duration but without Sg mix were 
also simultaneously set for comparison. Colchicine 
(0.20 (xg/ml; Microlab) was added to the cultures 
prior to harvesting. The cells were collected by 
centrifugation (10 min; 1200 rpm), hypotonic treat-
ment (0.075 M KCl) was given for 10-12 min at 
37°C and the cells recollected by centrifugation were 
fixed in methanol: acetic acid (3:1). Preparation of 
slides, staining and scanning was done under code. A 
total of 300 well-spread metaphases were analyzed 
per treatment per duration for all types of chromatid 
and chromosome type of aberrations. In case of 
cultures with metabolic activation, only 200 well-
spread metaphases were analyzed. 
2.2. Sister chromatid exchange analysis 
Analysis of SCEs was carried out following the 
fluorescent plus Giemsa techniques [20,21]. The cells 
in the cultures were exposed to 5-bromo-2-de-
oxyuridine (BrdU 2 |jLg/ml; Sigma) after 24 h of the 
initiation of cultures. The test compounds were added 
together with the BrdU. To minimize photolysis of 
BrdU another 48 h of cultures were maintained in 
the dark. 
For SCE analysis in the presence of metabolic 
activation system, the drug along with Sy mix was 
added into the culture after 48 h of its initiation and 
re-incubated at 37°C. After 90 min of this pulse 
treatment the cells were spun down and the super-
natant discarded. The cells were washed twice to 
remove the traces of the steroid and the liver metabo-
lites. Finally, the cells pellets were re-suspended in 
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fresh medium supplemented with fetal calf serum, 
PHA-M and BrdU, and put to culture for another 24 
h in the dark at 37°C. For comparison, parallel 
cultures without S^  mix were also set simultane-
ously Hoechst 33258 stain (0 5 |xg/ml, Sigma) was 
used along with \07c Giemsa stain for differential 
staining of the sister chromatids The slides were 
coded prior to scoring, and 50 well-spread metaphase 
cells were scanned per concentration and the number 
of exchanges scored. 
3. Results 
3 I Chromosomal aberrations 
The chromosomal aberration frequencies in hu-
man lymphocytes induced by 10 to 50 |xg/ml estra-
diol-17p are presented in Table 1 At 10 |i.g/ml of 
dose, the drug was not effective at any exposure 
time. At 25 ixg/ml and 50 (xg/ml of concentration, 
the drug affects both the aberrant metaphases as well 
as chromosomal aberration frequency At 25 |jLg/ml, 
the values for 24, 48 and 72 h of incubations were 
18 20%, 18.80% and 48.60%, respectively, while at 
50 |xg/ml the values were 19 33%, 2100% and 
54 34'/r at 24, 48 and 72 h of incubations, respec-
tively, which were highly significant at p <005 
compared to the normal control value 
The drug was effective in all treatments and an 
increased frequency of aberrant metaphases as well 
as chromosomal aberrations were observed when 
treated with S^  mix (Table 2). These values were 
9 60%c, 20 00% and 18 00%; at 10, 25 and 50 |JLg/ml 
of concentrations, respectively These data were 
highly significant at p <0 05 when compared to 
normal control (3 5%) The percentage of chromoso-
mal aberration was 61 00% for CP, which was highly 
significant 
3 2 Sister chromatid exchanges 
Data on the mean frequency of SCEs for cells 
after the treatment of estradiol-17p are presented in 
Table 3 The enhanced SCE rate was observed and at 
Table 1 
Chromobomdl aberrationb in human lymphocytes atter estradiol I7p treatment 
Treatment 
(|j,g/ml) 
Estradiol 17^ 
10 
2^ 
50 
C ontrol 
Normal 
DMSO 
(•S|xg/ml) 
( — ve control) 
CP 
(1 X 10 M) 
(+ ve control 
Duration 
(h) 
24 
48 
72 
24 
48 
72 
24 
48 
72 
72 
72 
24 
48 
72 
Metaphase 
scanned 
300 
100 
WO 
WO 
100 
100 
100 
100 
100 
100 
100 
100 
100 
100 
Percent aberration 
metaphase 
Including 
gap 
7 11 
5 00 
8 10 
11 34 
26 67 
19 70 
16 00" 
23 00" 
19 67 
2 10 
1 10 
2100 
19 00 
40 00 
Excluding 
gap 
170 
2 70 
3 70 
11 34 
20 00 
39 00 
15 00 
20 00 
38 33 = 
1 60 
1 00 
20 00 
15 00 
14 00 
Types of aberration (Vi) 
C hromatid 
170 
2 70 
100 
12 50 
11 50 
21 10 
11 11 
12 67 
2167 
1 10 
2 00 
24 00 
44 00 
45 00 
Chromosome 
0 00 
0 00 
1 50 
5 70 
7 10 
27 10 
6 00 
831 
10 67 
100 
100 
6 00 
24 00 
21 00 
Total 
170 
2 70 
4 50 
18 20 
18 80 
48 60 
19 ^'^ 
21 00 
54 34* 
2 10 
100 
10 00 
68 00 
66 00 
Aberration/ 
cell F SE 
0 04 + 001 
0 01-t 0 00 
0 05 + 0 01 
0 184 002 
0 19+0 02 
0 49 + 0 04 
0 19 + 0 01 
0 21 + 0 01 
0 54 + 0 05 
0 02 ± 0 01 
0 03 +0 01 
0 10 ± 0 03 
0 68 ± 0 09 
0 66 + 0 09 
CP Cyclophosphamide, DMSO dimethyl sulphoxidt St standard error 
Significant at p < 0 05 
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Table 2 
Chromosiomal aberrations in human lymphocytes after estradiol-17(i treatment with and without metabolic activation 
Treatment 
(fjLg/ml) 
Estradiol-17li 
10 
25 
50 
Control 
Normal 
DMSO 
(5 (JLg/ml) 
(— ve control) 
CP 
(1 X 10 ^ M) 
( + ve control) 
Metabolic 
activation 
s. 
+ S,j 
-s . 
+ s, 
-s . 
+ s,, 
-s . 
+ S,, 
- s . 
+ Sg 
- s . 
+ Sy 
Metaphase 
scanned 
^00 
200 
300 
200 
300 
200 
300 
200 
300 
200 
300 
200 
Percent aberration 
metaphase 
Including 
g-iP 
8 70* 
10 50" 
11 30" 
16 00 
10 00-
14 00 
2 30 
4 50 
3 30 
4 50 
6 30" 
40 50* 
Excluding 
gap 
7 90* 
9 00' ' 
11 30* 
15 00* 
9 30* 
13 00* 
1 70 
3 0 0 
1 70 
3 50 
4 67 ' 
39 50 ' 
Types of aberration (%) 
Chromatid 
6 60 
8 60 
12 50 
15 00 
8 30 
13 50 
1 30 
3 50 
2 00 
3 50 
1000 
37 50 
Chromosome 
0 60 
100 
5 60 
5 00 
4 0 0 
4 50 
0 30 
0 0 0 
0 0 0 
0 0 0 
8 67 
23 50 
Total 
7 20' ' 
9 60" 
18 10" 
20 00* 
12 30" 
18 00" 
1 60 
3 50 
2 00 
3 50 
18 67* 
6100" 
Aberration/ 
cell ± SE 
0 07 ± 0 02 
0 09 ± 0 02 
0 18 ± 0 02 
0 20 ± 0 01 
0 12 ± 0 02 
0 18 ± 0 02 
0 02 ± 0 01 
0 04 ± 0 01 
0 02 ± 0 00 
0 04 ± 0 01 
0 19 ± 0 03 
0 61 ± 0 07 
CP Cyclophosphamide, DMSO dimethyl sulphoxide, SE standard error 
-•Significant at p < 0 0 5 
50 |Jig/ml of concentration the maximum frequency 
of SCE per cell was found to be 4.34 ± 1 22. This 
value was highly significant compared to the mean 
SCE value of normal control, i.e., 1 74 ± 0.14 
In the presence of S^ mix, both doses (25 and 50 
|xg/ml) enhanced the SCE frequency significantly. 
I.e., 4 58 + 0.41 and 6.08 ± 1.31, respectively (Table 
4) Both these values were significantly higher than 
Table 3 
Sister chromatid exchange (SCE) in human lymphocytes after estradiol-17p exposure in vitro 
Treatment 
(|jLg/ml) 
Estradiol 17fi 
10 
25 
50 
Controh 
Normal 
DMSO (5 (JLg/ml) 
( - ve control) 
CP(1 X 10 ' M ) 
( + ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
76 
171 
217 
87 
96 
340 
Range 
0 - 6 
1-9 
2-11 
0 - 5 
0 - 6 
2 -11 
S C E s / 
cell ± SE 
152 ± 0 14 
3 42 ± 0 52* 
4 34 ± 1 22-^ 
1 74 ± 0 14 
1 92 ± 0 12 
6 80 ± 1 29* 
CP Cyclophosphamide, DMSO dimethylsulphoxide, SE standard error 
Significant at p < 0 05 
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Table 4 
Sister chromatid exchange (SCE) in human lymphocytes after estradiol-17(3 with metabolic activation 
Treatment 
((Ag/mO 
Estradiol 17fi 
10 
25 
50 
Controls 
Normal 
DMSO (5 M.g/ml) 
( - ve control) 
CP(1 X 10 ^M) 
(+ ve control) 
Duration 
(h) 
48 
48 
48 
48 
48 
48 
No of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
97 
229 
304 
78 
89 
380 
Range 
0-5 
1-11 
2-12 
0-5 
0-6 
4-12 
SCEs/ 
cell ± SE 
1 94 + 0 50 
4 58 ± 0 41* 
6 0 8 ± 131* 
156 ± 0 12 
1 78 ± 0 11 
7 60 ± 1 34* 
CP Cyclophosphamide, DMSO dimethylsulphoxide, SE standard error 
" Significant at p < 0 05 
the mean SCE value of 1.56 ±0.12 observed in 
normal controls ( p < 0.05) 
4. Discussion 
The results of the present mvestigation demon-
strate that the use of estradiol-17|3 is associated with 
clastogenicity. A significant increase in the incidence 
of chromosomal abnormalities per cell as well as an 
increase in the number of abnormal cells were ob-
served when compared with normal control At 10 
|j,g/ml of concentration, the results were insignifi-
cant for all treatment duration (24, 48 and 72 h). 
However, at 25 |xg/ml concentration a significant 
increase in aberration frequency was observed. But 
the maximal effect was observed at the highest con-
centration, an observation m line with the majonty of 
clastogens. Of the various chromosomal aberrations 
induced by estradiol-17p, chromatid and chromo-
some fragments and breaks were more frequent than 
other types of aberrations, such as nng and bridge 
formation, acentnc fragments, etc. 
The increased clastogenicity by estradiol-17p at 
the longest treatment duration as compared to the 
shorter treatment duration could be attnbutable to the 
inherent ability of the human lymphocytes to metab-
olize certain compounds per se [22]. The common 
effects of steroid hormone on chromosomes are 
stickiness in diakinesis and metaphase, and bndges 
and sometimes lagging chromosomes in the anaphase 
[23]. Similar observations were made in Anovlar (a 
steroid) treated plant chromosomes [24]. Chromatid 
breaks were seen more frequently than chromosome 
breaks in the metaphase plates analyzed. This indi-
cates that the drug introduces replication errors or 
breaks replicated chromatids. Estradiol-17^ induced 
reversible mitotic delay in HeLa cells, which were 
localized at the beginning of mitosis. The duration of 
mitotic lag was dose dependent [25]. The present 
data on the time-response analysis revealed a signif-
icant increase in chromosomal aberration at 72 h of 
treatment [26]. 
In the presence of S, microsomal activation sys-
tem, the clastogenic effects of estradiol-17p were 
more prominent. In the absence of S, mix, the 
chromosomal aberrations observed were also signifi-
cant but slightly less. The time-response analysis in 
the presence of S, revealed significant increase at 48 
h of incubation and decreased later on [27]. The 
maximum frequency of chromosomal aberration was 
found at 48 h long treatment on mouse bone marrow 
cells, while it decreased later on and gave no signifi-
cant result. This suggests that the drug and/or its 
metabolites were active dunng this (48th h) penod. 
The decline in the frequency of aberrations observed 
at the later time intervals may be due to some or all 
of the following reasons, (i) repairs of damaged 
genetic matenal, (ii) elimination of the drug and its 
metabolites, (in) elimination of cells/chromosomes 
with damaged genetic matenal, (iv) or due to cell 
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cycle delay and cell killing effect, and (v) inactiva-
tion of drug or its metabolites The results obtained 
from the SCH analyses indicated the drug has strong 
SCh inducing potential The frequency of SCH fur-
ther increases if the drug is treated in the presence of 
Sy mix There exists a relationship between in-
creased SCE rates and altered mutation frequency 
[28]. Therefore, it can be concluded that estradiol-17|3 
is capable of attacking the genetic material directly 
in Its unmetabolized as well as metabolized state 
Because of the apparent relationship among chro-
mosome abnormalities, mutagenesis and carcino-
genesis [29], in VIVO and in vitro screening for 
chromosome aberrations is an established tool in the 
evaluation of the potential hazards to the genetic 
material due to environmental agents The theoretical 
possibility of genetic damage during post-natal life 
will apply directly to the health of the drug user Any 
mutational effect on adult somatic cells could lead to 
cancer [30] People should, therefore, be careful and 
aware of the potential hazards of such drugs, espe-
cially if they are continuously exposed to for such 
long periods 
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ABSTRACT : Dexamethasone. a steroidal hormone has potential application in pharmacology This drug possesses anti-
inflammatory, immunosuppressive, antibacterial, antimicrobial and antiviral activity The cytogenetic effects of this drug 
was studied on human chromosomes in lymphocyte cultures in vitro and in vivo There was no increase in the 
chromosomal aberration and sister chromatid exchange (SCE) frequency with dexamethasone at any concentration which 
was equivalent to plasma level and slightly higher than the plasma level in vitro However, a significant increase in the 
frequency ol chromosome aberration as well as SCE was seen in patients given i^ierapeutic doses of dexamethasone 
when compared to the control ot two types—(a) Arthritis patients before starting the drug therapy, and (b) the normal 
healthy individuals from the general population The most frequently observed abberrations were chromatid gaps and 
breaks Therefore, our study indicates that dexamethasone is clastogenic m vivo but not in vitro 
Key words : Dexamethasone - Chromosome aberration - Sister chromatid exchanges - Human lymphocytes - Arthritis 
patients " 
Introduction 
Hormonal steroids are being widely used 
therapeutically They form steroid-DNA complex 
after entering the cells, alter the gene expression 
and u l t imate ly al ter the expression of many 
cellular processes including enzyme synthesis. 
Quite a large number of hormonal steroids have 
been studied for their teratogenic (Joshi et al., 
1983), carcinogenic (Lang and Redman, 1979) 
mutagenic and clastogenic (Wheeler et al., 1986) 
potentialities. However, most of the work has been 
concentrated on the sex hormones, while very 
l i t t l e a t t e n t i o n h a s been paid to t h e o the r 
members being extensively used as steroidal drug. 
Dexamethasone is one of the corticosteroidal drugs 
which is p r i m a r i l y used for cu r ing severe 
inflammations, allergic reactions, shock, neoplasia 
and adrenal insufficiencies. 
Repor t s on t he m u t a g e n i c effects of 
corticosteroids are controversial. It could not 
exhibit mutagenicity in the Ames/Salmonella test 
system (Bah et al., 1990). 
It has been reported that the administration 
of low dose of dexamethasone to rapidly dividing 
cells results in an inhibition on DNA synthesis in 
the liver cells in vitro (Loeb et al., 1973). The 
clastogenic effect of corticosteroid hormones on 
human lymphocytes is evident (Azfer and Afzal, 
1996, Ilmskikh, 1979). The frequencies of sister 
chromatid exchanges (SCEs) and micronuclei also 
increase with dose, and thereby indicates the dose 
related clastogenicity of the drug in the m vivo 
system (Bali etal., 1990; Singh et al., 1994). A 
negative result was obtained by Dhillon (1990) 
that corticosteroids could not induce clastogenicity 
in human chromosomes. In the present study we 
inves t iga ted t he effect of dexamethasone on 
human chromosomes in lymphocyte cultures in 
vitro and in vivo in the Indian population. 
Materials and Methods 
Chromosomal aberrat ion analys is : 
Peripheral blood samples were obtained from 
healthy adults who were not exposed to mutagen. 
0.5 ml of blood (lymphocyte) was cultured into 4.5 
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ml of TC-199 medium supplemented with 20% 
foetal calf se rum, phy tohaemagg lu t in in and 
antibiotics Dexamethasone (Wyeth Lab India), at 
a final concentration of 20, 40 and 60 p.g/ml, was 
added at the 24, 48 and 72 h old cultures Cultures 
without the drug served as controls 
In VIVO studies were conducted in Arthritis 
patients trom Jawaharlal Nehru Medical College, 
A M U , Ahgarh Patients who were on therapeutic 
doses of dexamethasone for over 4 weeks were 
examined Two types of controls were taken (i) 
Arrhritis patients before taking any treatment and 
(ii) normal healthy individuals from the general 
population 
Whole blood was cultured by the method of 
Moorehead et al, (1960) and were prepared by 
flame drying method and stained with giemsa 
(ICX) and screened for the p resence of 
chromosomal aberrations 
S i s t e r c h r o m a t i d e x c h a n g e (SCE) 
analysis : SCE analysis was performed using the 
fluorescent plus giemsa techniques of Perry and 
Wolff (1974) Bromodeoxjoindine (5' BrdU) was 
added to a concen t ra t ion of 3 Hg/ml 
Simultaneously 20, 40 and 60 ^g/ml doses of 
examethasone were added in respective cultures 
at the 24 h , The cultures were prepared by air 
drying One day old slides were stained with 5 0 
^g/ml Hoechst 33258 in the dark for 30 mm They 
were f u r t h e r washed wi th d i s t i l l ed w a t e r , 
mounted in 2x SSC with cover slip, and exposed 
to sunlight for 2 h They were again washed and 
stained in 5% giemsa SCE were scored blindly in 
50 M.I cells per concentration 
S t a t i s t i c a l a n a l y s i s : The differences 
between the data of control and the experimental 
groups were statistically evaluated with Student's 
't' test 
Results and Discussion 
The concentrations tested were not cytotoxic 
to the lymphocytes Very high and cytotoxic 
toncentrat ions were not tested No significant 
increase in the chromosomal aberration frequency 
could be observed in any of the treated cultures 
as compared to the normal cultures (Table 1) 
Tune-dose r e l a t i onsh ip could not prove the 
genotoxicity of dexamethasone The aberrations 
commonly observed were breaks, gaps, exchange 
and fragments at all concentration and duration 
of t reatment 
Results obtained in the in vivo study of the 
effect of dexamethasone are summarised in Table 
2 The difference between the values of general 
control and p a t i e n t cont ro l in r e g a r d to 
chromosomal a b e r r a t i o n s (3 00 + 0 60 and 
3 38 ± 0 62) was not significant This indicates 
that Arthritis disorder per se does not exert any 
inf luence on t h e c h r o m o s o m a l a b e r r a t i o n 
f requency The f requency of ch romosomal 
aberrations was significantly increased in patients 
under dexamethasone therapy as compared to the 
two types of controls (P < 0 05) The frequency of 
SCE ana ly s i s in h u m a n lymphocy te a f te r 
dexamethasone exposure in vitro is presented m 
Table 3 The mean SCE frequency of the drug at 
20, 40 and 60 ug/ml of doses were not significant 
as compared to the normal controls 
The results of in vivo SCE frequencies in 
human lymphocytes is described in Table 4 The 
difference between the mean SCE of the general 
control and patient control was statistically not 
significant The mean SCE frequency of the 
patient exposed to dexamethasone on the other 
hand was found to be significantly higher than the 
mean SCE value observed m both the controls 
The resu l t s of t he p r e s e n t inves t iga t ion 
showed t h a t d e x a m e t h a s o n e did not induce 
chromosomal aberration in vitro but significantly 
increased the aberration frequency m vivo The 
differences in the m vivo and in vitro studies can 
be explained on the basis of the fact that some 
chemicals and drugs are not mutagen ic and 
clastogemc by themselves but require metabolic 
activation (Wright, 1980) It is probable that the 
products of dexamethasone metabolism could be 
clastogemc (Iskandar and Vijayalaxmi, 1981) The 
possibility that the increase m the aberrations m 
the cells of patients on dexamethasone therapy 
could be due to their Arthritis disorder is ruled 
out by the fact t ha t there was no significant 
difference in t h e c h r o m o s o m a l a b e r r a t i o n 
f requency be tween t h e u n t r e a t e d A r t h r i t i s 
patients and the normal healthy individuals from 
the genera l popu la t ion A p r e d o m i n a n c e of 
c h r o m a t i d gaps and b r e a k s was observed 
suggesting, that the drug acts mostly in the late 
S or G2 phase of cell-cycle The chromosomal 
aberration observed mainly m groups of A, B and 
C chromosomes are probably due to their larger 
size and more DNA contents Similar observations 
were also made by Madhuri et al (1981) in the 
case of combined chemotherapy with isoniazid and 
para-aminosalicylic acid in vivo, while Manjula et 
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Figs 1-4. 1. Analysis of human lymphocyte chromosomes treated with dexamethasone in vitro. 2. Chromosomal 
aberration analysis of patients exposed to dexamethasone. 3. Sister chromatid exchange in human lymphocyte 
after dexamethasone exposure m vitro. 4. Sister chromatid exchange m human lymphocyte of the patients exposed 
to dexamethasone. (CD-Control dexamethasone; GC-General control; PC-Patient control; PED-Patient exposed to 
dexamethasone). 
ai, (1982) studied the effect of cephaloridine in 
vitro. 
It has been reported t h a t glucocorticoids 
induce clastogenicity in human lymphocjftes (Bali 
et a/., 1990). The higher doses of the drug exhibit 
clastogenicity but with a lesser magnitude. The 
reduction could be attributed to their toxic effect 
at the highest concentration and the cells with 
increased aberrations could have been eliminated 
as a result of apoptosis (Thompson, 1994) and got 
r ep laced w i t h n o r m a l cells p e r h a p s d u e to 
compensatory division in the remaining healthy 
cells. Our findings are further corroborated by the 
reports of Loeb et ai, (1973) and Rubin (1982) 
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Table 1 : Analysis of human lymphocyte chromosomes treated with dexamethasone in vitro 
Treatment 
(|ig/ml) 
No. of 
metaphases 
No. of breaks No. of gaps 
Chromatid Isochromatid Chromatid Isochromatid 
Others %Total ± SE 
Control 
20 ng 
40 ^g 
60 ng 
24h 
48h 
72h 
24h 
48h 
72h 
24h 
4ah 
72h 
300 
300 
300 
300 
300 
300 
300 
300 
300 
300 
-
2 
1 
2 
3 
2 
1 
2 
3 
4 
3 00 + 0 93 
3 67± 1.09 
4 0 0 ± 1 13 
4.67 ±1.22 
4 33 ± 1 16 
4 00± 1 13 
4 00 ± 1 13 
4 67 ± 1 22 
5 00 ± 1 26 
5 33 + 1 30 
SE=Standard error 
Table 2 : Chromosomal aberration analysis of patients exposed to dexamethasone 
General control 
Patient control 
Patient exposed 
to dexamethasone 
No. of 
metaphases 
800 
850 
1000 
No. of breaks 
Chromatid 
15 
12 
60 
Isochromatid 
5 
5 
10 
No. of gaps 
Chromatid 
3 
3 
7 
Isochromatid 
-
3 
3 
Others %Total + SE 
3 00 ± 0 60 
(Ex2, F2) 3 38 ± 0 62 
(Ex1,F4) 10 63 ± 0 97* 
SE=Standatd error, Ex=Exchange, F=Fragment, "Significant at P<0 05 
Table 3 ; Sister chromatid exchange in human lymphocyte after dexamethasone exposure in vitro 
Treatment Duration (h) No. of metaphases Total SCE Range SCE/cell ± SE 
Control 
Dexamethasone 
20 ug/ml 
40 pig/ml 
60 ug/ml 
48 
48 
48 
48 
50 
50 
50 
50 
114 
135 
135 
120 
0-4 
0-7 
0-7 
0-4 
2.28 ± 0 14 
2 70 ± 0 30 
2.70 ± 0 30 
2 40 ± 0 20 
SE=Standard error; SCE=sister chromatid exchange 
Table 4 : Sister chromatid exchange in human lymphocytes of the patients exposed to dexamethasone 
Duration (h) No. of 
metaphases Total SCE Range SCE/cell ± SE 
General control 
Patient control 
Patient exposed to 
dexamethasone 
48 
48 
48 
50 
50 
50 
125 
139 
239 
0-5 
1-8 
2-12 
2 50 ± 0 16 
2 78 ± 0 40 
4 68 ± 0 85* 
SE=Standard error; "Significant at P<0.05, SCE=sister chromatid exchange. 
indicating that the continuous presence of the 
steroidal drug inhibits DNA synthesis, prevention 
of protein binding of the drug causes reduction in 
mitotic cell population and produce induction of 
genetic damage following the treatment of the 
glucocorticoid drugs in both animals and humans. 
The non-mutagenicity of dexamethasone in the m 
vitro system has been reported by Singh et al, 
(1994). 
The increased frequency of chromosomal 
aberra t ions in vivo in p a t i e n t s cont inuous ly 
exposed to dexamethasone may be attributed to 
Dexamethasone in human lymphocytes 115 
the inherent abihty of the human l5Tnphocytes to 
metabol ize ce r t a in compounds Moreover, as 
dexamethasone has a longer biological half-life 
(36-54 h) than other corticosteroids, patients using 
dexamethasone had continuous presence of the 
drug which affected DNA and spindle forming 
microtubules (Banduhn and Obe, 1985) In the 
case of in vivo study it is clear that in arthritis 
patients adverse effect of dexamethasone in the 
lymphocytes did not give sufficient time for the 
possible repair of induced lesions in the DNA 
The frequency of SCE were enhanced in the 
patient who were under the regime of therapy 
SCE arise from the DNA breaks and the reunion 
of b roken and exchanged f r agmen t s at the 
homologous loci (Latt et al, 1981) The observed 
rise 111 the frequency of SCE could be attributed 
to the dexamethasone's influence on increasing 
the number of DNA lesions The present study is 
in line with Naumova (1977) and Ilinskikh (1979) 
who observed DNA suppression and bone marrow 
deterioration effects due to the glucocorticoids 
From t h e p r e s e n t f ind ings it a p p e a r s t h a t 
d e x a m e t h a s o n e is a genotoxic d r u g The 
theoretical possibility of genetic damage during 
post-natal life will apply directly to the health of 
the drug user Any mutat ional effect on adult 
somatic cells could lead to cancer (Weiss, 1976) 
One should, therefore, be mindful of the potential 
hazards of such drugs , especially if they are 
continuously used for such longer periods of time 
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EFFECT OF HYDROCORTISONE ON H U M A N LYMPHOCYTE 
C H R O M O S O M E S IN VITRO 
G. G. H. A. Shadab, Md. Equebal Ahmed and Mohammad Afzai^ 
Section of Genetics, Deptt. of Zoology, Aligarh Muslim University 
Aligarh-202 002, U.P. India 
Abstract 
Hydrocortisone is a potent steroidal 
drug used therapeutically for a number of 
reasons. Hormonal steroids have be«n 
reported to cause damage to human chro-
mosomes, l o test genotoxicity. human 
lymphocytes were cultured In 'TC-199 
medium suppliirented with 20% fetal calt 
serum, phytohaemagglutinin and antibio-
tics. Hydrocortisone (Wyeth Lab India) 
at a final concentration of 10.25 and 50 
jug/ml, was added at the 24,48 & 72 hrs old 
culture. Moorehead ei al. ( i960) £r flame 
drymg method were used for in vitro 
culture & staining was done with Giemsa 
(10%). Chromosome aberration analysis, 
Sisterchromatid exchange (SCE) analysis 
and Statistical analysis was done. Present 
study showed that hydrocortisone affects 
the lymphocytes in vitro and induce chro-
mosomal aberrations with increased fre-
quency in the presence of metabolic activa-
tion, maximum aberration was recorded at 
25 /tg/ml concentration SCE also increased 
with higher dose but was less mutagenic 
at the highest concentration. Metabolic 
activation did not alter result in this case. 
It is concluded that this drug could inhibit 
the proliferation of human lymphocytes. 
Introductictn 
- Hormones are informational molecules 
secreted by endocrine glands in response 
to changes in the environment inside or 
outside the body. Hormones may stimulate 
or inhibit specific biological processes in 
the target organs to modify their activities. 
They play vital role in metabolic regulation, 
growth and control of several body func-
tions. Natural Steroidal hormones ( e g . 
gonadal and adrenocortical hormones ) or 
their synthetic derivatives perform their 
functions by forming steroid-DNA com-
plexes that influence the gene expression 
( Rubin^^ Makin"" ). Several naturally 
occuring as well as synthetic steroids have 
since long been widely used therapeutically 
(Azfer 96). Several steroids have been 
reported to possess anti inflammatory 
(Boltralik*). anesthetic (Evelyne era/."*), 
anabolic (Fennessey era / . " ) , angiostatic 
(Larrian*"), antiangiogenic (Judah etal^^). 
cardioactive (Karel & Thomas^*) and anti-
diabetic (Ryoji etal^), activities 
Address for correspondence *Dr, Mohammad Afzal, Reader, Section of Genetics. Deptt. 
of Zoology. A M.U Aligarh-202 002. U. P. India. 
Certain steroids have also been reported 
to control energy metabolism throughout 
pregnancy (Bird etal.'^). Steroid alkaloid 
formulations have been used for skin 
disorder treatment (Chain etal.*). Also 
there are soma steroidal compounds which 
increase resistance against drugs & toxic 
agents ( Kourounakis'^ ) Sex hormonal 
steroids are used in human medicine for a 
large variety of conditions, apart from their 
uses as oral contraceptive agents viz in the 
treatment of dysmenorrhoea, endometriosis 
and dysfunctional urine bleedings and 
climacterics. They are also used in the 
prevention of postmenopausal osteoporc&is. 
Progestines have been used in the manage-
ment of threatened abortion and to prevent 
premature labour. 
Inspita of their therapeutic use there 
are many reports indicating the teratogenic 
(Joshi ef a/ .", Mitchell etal^^), mutagenic 
end clastogenic (Mc Quarrie et a/.'"', Wheeler 
eta/^'') and carcinogenic (Lang and 
Redmann". Rosenfield et al.^^ ) potentia-
lities of these hormones. Most of the above 
reports are concerned with oral contracep-
tives or sex hormones being widely used 
and very little work has been done to 
evaluate the effects of other hormones 
being extensively used as drugs. Keeping 
this in mind the present experiment was 
done to observe the genotoxicity of some 
widely used steroidal drug. We evaluated 
the genotoxicity of several steroids in 
human invitro. Present work is about 
hvdrocostisone which is a polent glucocor-
ticoid and used primarily for curing severe 
inflammations, allergic reactions, shock, 
neoplasias and adrenal insufficiency (Labus 
& Lennon'») 
Mater ials and Methods 
(a) In vitro testing of chromosomal aberra-
tions— 
(i) Preparation of culture media-
Tissue culture medium (TC 199, Flow 
Lab) with L-glutamine and Heper buffer 
without NaHCOj was always prepared in 
advance and stored at 4'C but the storage 
never lasted longer than a week. 1.574 gm 
of medium was dissolved in 100 ml of 
triple distilled water by gentle shaking. 
Penicillin (100 lU/ml) & streptomycin 
(100 lU/ml Hoechst) were also added and 
the pH was adjusted from 6 8-7.2 with 
N/10 NaHCOa and HCI. The Medium was 
then filtered and sterilized in the negative 
pressure millipore filtration assembly by 
using 0.45 um millipore filters. This filtered 
medium was used for culture of lympho-
cytes. 
(ii) Collection of blood samples-
Peripheral blood was collected from 
the healthy adult donors (20-25 years old). 
Blood was taken fresh everytime through 
vein puncture under septic conditions using 
disposable needles (21 gauge) and dis-
posable syringes (Steriware). Heparin 
(500 lU/ml; Micro Lab) was used as anti-
coagulant The tightly capped glass vials 
filled with blood were gently mixed and 
stored at 4°C for half an hour to separete 
red blood cells (RBCs) from plasma. 
(iii) Setting of the cultures— 
Lymphocyte culturing was done by 
adding 0.8 mi of plasma containing white 
blood cells (WBC) in 4 5 ml of culture 
medium supplemented with 0 1 ml phyto-
haemagglutinin-P (PHA-P, Microlab) and 
15% foetal calf serum (Gibco). The 
tightly capped culture vials were gently 
mixed and incubated at 37°C indark for 
72 hours. Colchicine (0.20ug/ml Microlab) 
was added 21 hours prior to harvesting to 
arrest the calls at metaphase stage. 
(iv) Selection of doses 
Only those doses, which do not reduce 
the Ml but yield sufficient number of 
scorabie metaphases, were chosen for the 
experiment. On this basis the lower and 
the medium doses were selected and the 
highest dose selected was normally the 
maximum tolerated dose (MTD) beyond 
which the Ml showed a steep decline. 
Following these norms the different doses 
selected for hydrocosticse were 10, 25 and 
50 jug, ml 
(v) Studies with and without 59-mix.— 
Without 59 mix the cultures were 
exposed to three different concentrations 
for 24, 48 and 72 hours. Positive ( CP, 
1 x 1 0 - ' m ) and negative (OMSO, 5 ul/ml) 
control cultures were also simultaneously 
set for all treatment durations For studying 
result with metabolic activation, 30 hours 
old cultures were given 5 hours treatment 
with different concentration of hydrocosti-
sone in the presence of 59-mix. The 
parallel culture without 59 mix were done 
for comparison simultaneously. Ihe DMSO 
(5 ul/ml; SRL, Bombay) were used as 
negutive and positive controls respectively. 
(vi) l-iarvesting of the cultures-
After 72 hours the cultures were centri-
fuged (lOmin, 1200 rmp) 8 the buttons 
of cells were saved by discarding the 
supernatant Hypotonic treatment (0.075 
Mkci) was carried out for 10-12 minutes 
at 37°C and the cells were recollected in 
5 ml freshly prepared chilled fixative before 
preparing the slides. 
(vii) Slide preparation and staining— 
After final washing in the fixative, the 
cells were resuspended in 0.2 ml of fresh 
fixative, Two to three drops of this cells 
suspension were dropped on clean, grease 
free, prechilled wet microscope slides which 
were then air dried. One day old slides 
were stained in carbol fuschin (Sigma) 
for 15 minutes and rinsed in 0.95% alcohol 
and finally in absolute alcohol for proper 
differentiation. After air drying, these 
slides were dipped in xylene for 5 minutes 
before mounting m depex (BDH). 
(viii) Analysis of the Cells— 
To avoid mistakes in scoring of the 
chromosomal anomalies, all slides were 
coded prior to scoring. A total of 300 well 
spread metaphases were analysed for each 
concentration of the steroid testing and for 
each time duration to snalyse various 
chromosome and chromstid-type aberra 
tions. Evans" method of analysis was 
followed. 
b) Analysis of Sister Chromatid Exchanges 
( S C E ) -
(i) SCE detection mechanism — 
Sister chromatid exchange is a sensitive 
rapid and objective method of observing 
reciprocal exchanges between sister chro-
matids. In this 5-bromo-2-deoxyuridine 
(BrdU) incorporate with DNA in place of 
thymidine (Azfer and Afzal"). 
After two rounds of cell division the 
chromatids are labelled with BrdU and 
consequently these differentiate with 
Hoechst stain. Due to BrdU incorporation 
the light energy is absorbed but not emitted 
by dyes which results in the reduced 
staining of Chromatid with Giemsa (Latt 
and Wolleb^^ Latt^i'^^), 
(ii) Labelling of chromosome with BrdU— 
SCE analysis was carried out following 
the standard procedure of Latt et al.^^ 
with suitable modifications. The cells in 
the cultures were exposed to nucleoside, 
BrdU (Sigma) after 24 hours of culture 
initiation at the final concentraiion of 2 
/xg/ml. The culture vials were tightly 
capped and covered with tin foil to avoid 
light exposure and incubated at 3 7 X for 
another 48 hours in dark. Doses of hydro-
cortisone were 10, 25 and 50 (/xg/ml) with 
negative control (DMSO 5 /^ig/ml) b positive 
control (CP 1 x 1 0 - ' m ) . 
(iii) Studies on the steroids without and 
with S 9 -
After 48 hours of the culture initiation, 
three different log dosfs of each steroids 
were added into the cultures without 89 
mix. The culturing was further continued 
for 24 hou's. Positive, negative and un-
treated controls were also simultaneously 
studied For Studying metabolic activa-
tion, steroids along with SB-mix was added 
into the cultures after 48 hours of its 
initiation and remcubated at 37°C. After 
centrifugation the cell pellets were sus-
pended in fresh, warm medium supple-
mented by foetal calf serum, PHA-P and 
BrdU and cultured for another 2^ hours in 
dark at 37°C. Positive, negative and control 
in the presence of S9-mix were also simul-
taneously studied for comparision. 
(iv) Slide preparation and staining— 
After 2\ hours of colchicine treatment, 
the culturss were harvested and processed 
following the same procedure as for the 
chromosomal aberration analysis. For the 
differential staining of SCEs, the methods 
of Perry and Wolft^ *" and Latt et al.^'^ with 
slight modifications were followed — 
(v) Analysis of the cells— 
100 second division metaphases (50 
metaphases/donor) with differentially 
stained chromatids were scored for each 
sterioid doses of steroid treatment in the 
absence of S9 and 50 metaphases ( 25 
metaphases/donor ) were scored for each 
treatment in the presence of 59 mix. The 
interstitial exchanges between two sister 
chromatids were scored as two exchanges 
and the terminal exchanges were scored 
as a single excnange. Students-t'test was 
applied for calculating the significance of 
difference between the treated and the 
controls. 
c) Statistical Analysis-
All the dates were analysed Statistically 
Standard deviation (SD) and standard 
error (BE) were calculated by using the 
following formula-
mean 
variance 
X 
52 = - : 
x2-nX2 
n - 1 
x2-n.X2 
SE = 
V x^-n.A 
— f T T i -
SD 
V n 
Where x =. variable 
n — number of observations 
£ x^  -r sum of square of individual 
variables 
X = mean of variable. 
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Students two tailed t' test was used for 
caJculating the statistical significance in 
SCE and cfiromosomal aberrations by com-
paring the effects induced by different 
doses of steroids with the respective control. 
The fol lowing formula was used for this 
purpose-
t = 
X, (control) — X.. (treated) 
"(SE of control)^ -f (SE of treated)'' 
Resul ts 
a) Chromosomal aberrations—Table-1 
Summatises the data on the influence of 
chromosomal aberrations. At lO^ug/mlof 
dose significant increase in the percentage 
of chromosomal aberrations was found 
when the drug was continued for 72 hours 
of incubation (7.3"/o). This value is higher 
than the normal control value (2.3%). At 
24 and 48 hours of incubation, this dose 
did not influence the chromosomal aberra-
tions (3.7% in 2.7%). 
At 25 ji/g/ml of concentration the drug 
influenced the chromosomal aberration in 
all exposure times. The values were 18.0%, 
18 6% and 48 7% at 24.48 72 hrs. of 
incubation. Increased frequency at this 
dose showed the significant result compared 
to the normal control at P < 0.05. How-
ever at 50 n^g/ml of concentration some 
interesting observations were made. At 24 
hrs of incubation, the drug influenced the 
rate of chromosomal aberration significantly 
(33.0%) while at 24 and 48 hrs. of incuba-
tion the drug did not give any significant 
increase in the chromosomal abarration, 
4 5% and 4 3% respectively. The positive 
control (CP), being a potent mutagen, 
influences the rate of aberration at all 
exposure times. 
The effect of hydrocortisone on human 
lymphocytes in the presence of S9 mix has 
been summarised in Table-2. The mean 
percentage value at 10 /ug/ml was 9 0 in the 
presence of S9 mix which was significantly 
higher than the mean peicent of chromo-
somal aberration value of 2 3% observed 
in normal control (P < 0.05). At 25 /xg/ml 
of concentration, the drug enhanced the 
rate of aberrations (20 0%), which gave a 
statistically significant value at P < 0 05 
At 50 /Lig/ml of concentration no significant 
value were observed (4.0% & 3 5%). The 
decreased value may be attributed to the 
toxic effect at higher concentrations. 
b) Sister chromatid Exchange (SCE) — 
Table-3 Shows the effect of hydrocor-
tisone on the frequency of SCE in humsn 
lymphocytes. The mean SCE frequency 
at 10 /xg/ml did not enhance it significantly 
(2 46 L O . 1 9 ) when this is compared with 
normal control value (2 .32±1 7). The 
concentration with 25 (ug/ml had a mean 
SCE frequency of 3 66±0 .28 which was 
significantly higher than the mean SCE 
value observed in normal control (P<^0C5). 
No significant value was observed at higher 
concentration i.e. 50 /ug/ml The mean 
SCE value was 2.5 ^0.18, not found signi-
ficant at P < 0 05. The data of the 
mean SCE frequency value of the positive 
control d;ug (CP) was 4 6 0 : t 0 68 The 
value was highly significant compared to 
normal control. 
The data of SCE in human lymphocyte 
after hydrocortisone exposure in the pre-
sence of S 9 mix has been described in 
Table-4. There was not any significant 
increase in SCE value observed at 10 /ugml 
( 1 7 8 i 0 16). Both the doses at 25 and 50 
Table 3 
Sister Chromatid Exchange (SCE) in human lymphocytes after Hydrocortisone exposure 
in vitro. 
Treatment 
(ug/ml) 
Hydrocortisone 
10 
25 
50 
Control Normal 
DMSO (5 ug/ml) 
(—ve control) 
CP(IXIO-^M) 
( : ve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
No. of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
123 
183 
125 
116 
110 
225 
Range 
0 - 6 
1 -8 
0 - 6 
0 -4 
0 - 4 
2 - 1 0 
SCE8/Cell±SE 
2.46-fc 0.1 9 
3.66±0.36* 
2.5 ±0.28 
2.32±0.17 
2.20±0.14 
4.60 ±0.68* 
Table 4 
Sister Chromatid Exchange (SCE) in human lymphocytes after Hydrocortisone exposure 
with metabolic activation (S^ mix). 
Treatment 
(ug/ml) 
Hydrocortisone 
10 
25 
50 
Control Normal 
DMSO (5 ug/ml) 
(—ve control) 
GP( IXIO- 'M) 
( fve control) 
Duration 
(hr) 
48 
48 
48 
48 
48 
48 
No. of 
metaphases 
50 
50 
50 
50 
50 
50 
Total 
SCE 
89 
197 
144 
79 
70 
325 
Range 
0 - 4 
0 - 8 
0—6 
0 - 3 
0—3 
2 - 1 2 
SCEs/Cell±SE 
1.78±0.16 
3.94±0.37* 
2.88±0.24» 
1.58 ±0.18 
1.40 ±0,16 
6.50±1.30* 
CP : Cyclophosphamide ; DMSO : dimethyl sulphoxide ; SE : standard error 
* significant at P <^  0 05. 
jug/ml of concentration in the presence of 
S9 mix enhanced the frequency of SCE. 
At 25 jug/mt, the mear\ SCE frequency was 
3 94a_0.37 which was significant at 
P < 0.05 when compared with that of the 
normal control SCE ( 1 . 5 6 ± 0 . 1 8 ) . A 
slightly decreased SCE frequency was 
observed and found significant with 50 
^g /ml compared to normal control. The 
enhanced SCE at higher level of concentra-
t ion of the drug may be due to the meta-
bolic activation by liver enzyme (S9 mix). 
An increased mean SCE frequency was 
observed by CP (6 50 t 1 30). 
Discussions 
Chromosome aberration assessment 
serves as a good indicator of the clastogenic 
effects of any genotoxic agent (Gebhart^^ 
Buckton & Evans', Hsu'^). Present study 
very evidently established the clastogenic 
potential of hydrocortisone in human 
lymphocyte cultures. Its effect was mtixi-
mum at ^5 /xg/ml concentration. The 
highest concentration ( 5 0 f^g/ml ) also 
caused clastogenicity but with a lesbtr 
magnitude This may'be due to cell cycle 
delay and ceil killing effect caused by the 
drug at the highest concentration ( Ball 
etal.'^). The present findings are further 
supported by the reports of Loeb et al^\ 
Naumova™ and Rubin^'* ) indicating the 
suppression of DNA snythesis, prevention 
of protein binding of the drug at its higher 
doses, reduction in mitotic cell population 
and induction of genetic damage after the 
hydrocortisone and other glucocorticoid 
treatment in man. 
Hydrocortisone also enhanced the 
frequency of chromosomal aberration in the 
presence of metabolic activation. 
SCE arise from CNA breaks and the 
reunion of broken exchanged fragments ct 
almost homologous loci ( la t t et ai'^'^). We 
observed rise in the frequency of SCE with 
higher dose of hydrocortisone, but wi th 
lesser magnitude at the highest concentra-
t ion. The effect was same even in the 
presence of metabolic activation. The rise 
may be due to the hydrocortisone's intlu 
ence in increasing the number of DMA 
lesions. 
Because of the apparent relationship 
between chromosome abnormalities, muta-
genesis and carcinogenesis (Sandberg^'^), 
in vivo and in vitro, screening for chromo-
some aberrations is an established tool in 
the evaluation of potential hazatds to the 
genetic material due to environmental 
agents. The theoretical possibility of 
genetic damage during post-natal life wi l l 
apply directly to the health of the drug 
user. Any mutational effect on adult 
Somatic calls could lead to cancer (Weiss 
efa/.""). People should, therefore be 
careful and aware of the potential hazatds 
of such drugs, especially if they are conti-
nuously exposed to for such a long periods 
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CORRIGENDUM 
Due to typographical error, in the result, introduction 
and discussion section, the dose concentrations of steroids 
have been written as mg/ml^t should be read as ^g/ml. 
